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ABSTRACT
Comprehensive analysis of chromosome 14q32 deletions in chronic lymphocytic
leukemia
Rachel A. Harris, Ph.D.
University of Nebraska, 2020
Supervisor: Bhavana J. Dave, Ph.D.
Chronic lymphocytic leukemia (CLL) is a genetically heterogeneous disease
characterized in part by a combination of conventional cytogenetic and fluorescence in
situ hybridization (FISH) analyses. Previous studies have investigated the occurrence of
many cytogenetic abnormalities in CLL. However, few have focused on the frequency
and variation of deletions within chromosome 14 (14q32), including genes associated
with the IGH gene region and the possible related prognostic implications. We performed
a comprehensive analysis and examined the frequency of abnormalities, specifically,
deletions of the 14q32 region, categorized the size variation of these deletions using
microarray, and assessed the effect on time-to-first-treatment (TTFT) and overall
survival (OS). A retrospective analysis was performed on 698 CLL cases investigated
with conventional cytogenetics, FISH, or both assays in our laboratory. A 14q32
abnormality, including a deletion within this region, was detected in 35% (245/698) of
cases overall, with the majority of cases containing a 5’ partial telomeric 14q32 deletion.
To further define the size variation and decipher the minimum deleted region (MDR)
within the 14q32 deletions, a subset of 40 available bone marrow or unstimulated
peripheral blood specimens with FISH-confirmed 14q32 deletions of various types were
further analyzed utilizing single nucleotide polymorphism (SNP) microarray. Deletions
within 14q32 were most frequent at the 5’ telomeric end of the IGH variable region
(14q32) (35/40 cases) that varied from 236 to 1401 kb and commonly involved genes
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FAM30A, ADAM6, LINC00226, and LINC00221. The MDR among the majority included
a 213 kb region that encompassed LINC00221. We analyzed the effect of TTFT and OS
among a subset of consented CLL cases with and without deletions of 14q32 that had
available follow-up information. Cases with a 14q32 deletion had a median TTFT that
was shorter than cases with a sole instance of a deletion or nullisomy 13q, a known
good prognostic indicator, and longer than cases with a sole deletion of 11q or 17p, both
of which are associated with an unfavorable prognosis. This investigation facilitates our
understanding of the frequency and variability of 14q32 deletions in CLL and
underscores the need for comprehensive testing, including microarray, to better
comprehend clinical implications.
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CHAPTER 1: INTRODUCTION
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CHAPTER 1: INTRODUCTION
Chronic lymphocytic leukemia (CLL), a mature B-cell neoplasm, is the most
prevalent leukemia in the Western world and frequently occurs in older adults (Kipps et
al., 2017; Quintero-Rivera, Nooraie, & Rao, 2009). In the United States and Western
Europe, CLL accounts for the majority of all chronic leukemias (Aoun et al., 2004; Bosch
& Dalla-Favera, 2019; Siegel, Miller, & Jemal, 2019). Once considered a homogeneous
disease, CLL is now viewed as a heterogeneous disease with differences in cytogenetic
results, gene mutations, and proliferation (Bosch & Dalla-Favera, 2019; Chiorazzi, Hatzi,
& Albesiano, 2005; Urbankova et al., 2012).
History
The first cases of what we now know as CLL were recorded in 1845 by two
independent researchers, Rudolf C. Virchow, a German pathologist, and John H.
Bennett, an English physician and pathologist. Several investigators over the next few
decades also recorded similar cases with excessive white blood cells. In 1852, Bennett
chose to call this “leukocythemia” and Virchow coined the term “leukemia” in 1857
(Hamblin, 2000). In the 1890s, following the discovery of new staining techniques to
identify different types of blood cells, Paul Ehrlich, a German physician, enhanced
leukemia research by developing a tri-acid stain to identify cellular components that
included the nucleus, cytoplasm, and other cytoplasmic details (Ehrlich, 1891). The new
staining technique was successful and allowed researchers to further distinguish
between the different leukemias. In 1903, Türk published criteria for the diagnosis of CLL
(Turk, 1903). In 1924, Minot and Isaacs described clinical features and history of CLL in
a paper that remained a standard of reference for physicians over the next few decades
(Minot & Isaacs, 1924). After the clinical features had been described, many researchers
and physicians continued to study CLL. Still, it wasn’t until 1959 that Richard Doll
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determined that CLL occurred more frequently in men and that the average age of onset
was late middle age (Court Brown & Doll, 1959).
Clinical methods for the staging of CLL were developed in the 1970s and 1980s.
In 1975, Kanti R. Rai developed the Rai staging system in New York that is used
primarily in the United States (Rai et al., 1975). Meanwhile, in Paris, Jacques-Louis Binet
developed the Binet staging system in 1981 that is mainly used in Europe (Binet et al.,
1981; Rai & Keating, 2003). Both systems suggested that prognosis is associated with
disease burden. The designation of staging groups in CLL allowed numerous clinicians
and researchers to categorize their patients better and begin controlled case
experiments.
In 1979, Gösta Gahrton reported the first consistent chromosomal abnormality
observed by a karyotype in a small subset of CLL patients. The abnormality, trisomy 12,
had no known significance to the patients at that time (Gahrton, Robert, Friberg, Zech, &
Bird, 1980; Hamblin, 2000). Historically, culturing of B-lymphocytes has proven to be
difficult because of their quiescent nature, and thus detection of cytogenetic
abnormalities was difficult. Detection of cytogenetic abnormalities by karyotyping yielded
abnormal results 40 – 50% of the time in CLL patients (Döhner et al., 2000). In the
1990s, two separate groups studied the relevance of an additional prognostic marker for
CLL. The sequence of the CLL cells was compared to the sequence of germline cells to
assess the mutational status of the variable region of the immunoglobulin heavy chain
(IGHV). This allowed the patients to be classified into two groups: mutated CLL (M-CLL)
and unmutated CLL (U-CLL) (Rai & Jain, 2016).
The addition of interphase cytogenetics, known as fluorescence in situ
hybridization (FISH), improved the detection of chromosomal abnormalities in interphase
cells. In 2000, Hartmut Döhner and colleagues developed a panel of FISH probes used
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to evaluate the frequency and clinical significance of cytogenetic abnormalities detected
in CLL. This study determined that 80% of CLL patients had cytogenetic abnormalities,
which is more than double to what cytogenetics alone was able to detect. The most
frequent abnormality in this subset of patients was not trisomy 12 as initially observed by
Gahrton, but instead was a deletion of 13q14 (Döhner et al., 2000).
Pathogenesis
Normal B-cell lymphocytes are found in the bone marrow and progress from
stem cells to mature B-cells through a series of steps (Carter, 2006; Ten Hacken,
Gounari, Ghia, & Burger, 2019) [Figure 1]. The maturation of B-cells occurs in the bone
marrow and continues in the lymphoid tissue. Before maturation of the stem cell to a
mature B-cell, VDJ recombination occurs in the progenitor B-cells (pro-B) that leads to
the development of precursor B-cells (pre-B). This process generates two variable heavy
chains and two variable light chains to complete the B-cell receptor (BCR) but can result
in errors that cause the cells to undergo apoptosis (Ten Hacken et al., 2019). CLL, an
indolent, mature B-cell neoplasm, results from an accumulation of CD5+ and CD23+
neoplastic B-cells in the blood, bone marrow, or lymphoid tissues (Campo et al., 2017;
Naeim, Rao, & Grody, 2009; Speedy et al., 2016; Ten Hacken et al., 2019; Zhang &
Kipps, 2014). Spontaneous cell division does not occur in CLL cells because the cells
are arrested at the G0G1 phase of the cell cycle, and accumulation of these cells occurs
due to lack of apoptosis instead of rapid cell division (Caligaris-Cappio & Hamblin, 1999;
Heerema et al., 2010; Shanshal & Haddad, 2012). Clonal proliferation of B-lymphocytes
at various stages of differentiation results in mature B-cell neoplasms. Two types of CLL
may develop from mature B-cells, including unmutated CLL (U-CLL) that develops from
mature, naïve B-cells and mutated CLL (M-CLL) that develops from memory B-cells that

Figure 1. Maturation of B-cell lymphocytes. A) Maturation of B-cells occurring in the bone
marrow starting with the stem cell and progressing to mature B-cells. B) Continued
maturation of B-cells in the peripheral lymphoid tissue (liver/spleen). Unmutated-CLL (U-CLL)
develops from mature, naïve, B-cells and is associated with advanced disease. Mutated-CLL
(M-CLL) develops from memory B-cells that have undergone somatic hypermutation (SHM) in
the germinal center and is associated with an indolent disease course.
4
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have undergone somatic hypermutation in the germinal center, prior to the development
of a clonal abnormality. Mature B-cell neoplasms present with varying clinical, biological,
and morphological features and can range from indolent to aggressive forms of the
disease (Seifert et al., 2012).
Epidemiology and Etiology
Due to a longer survival rate, CLL is not only the most common form of adult
leukemia in the western world, but it is also the most prevalent among all leukemias with
an incidence rate of five cases per 100,000 persons per year (Campo et al., 2017; Rai &
Keating, 2003). In 2020, there will be an estimated 21,040 new cases of CLL diagnosed,
with 4,060 deaths expected (Siegel, Miller, & Jemal, 2020). The highest incidence of
CLL worldwide is found in the United States among adult Caucasian males with an
approximate 2:1 male-to-female ratio (Brown, 2013; Campo et al., 2017). The median
age at the time of CLL diagnosis is 70 years, but may also be seen in younger adults
(Campo et al., 2017). While CLL has been diagnosed in younger patients, less than 2%
of patients are aged 45 or less at the time of diagnosis. The incidence of CLL rapidly
escalates with increased age (Shanshal & Haddad, 2012).
The highest incidence of CLL occurs in Europe and European populations
around the world (Speedy et al., 2016). There is a stark disparity in the occurrence of
CLL among Caucasian and Asian populations (Kawamata et al., 2013; S. M. Yang, Li,
Gale, & Huang, 2015). The lowest incidence of CLL is found in Asian countries, including
China and Japan, even after migration to another geographic location, emphasizing the
genetic profile as a dominant explanation (Kawamata et al., 2013; Speedy et al., 2016).
The incidence of CLL is 5 - 10-fold lower among Asians than in Caucasians.
Considerable differences have been noted between Asian and Caucasian populations
regarding IGHV mutations and rearrangements (S. M. Yang et al., 2015). CLL is unique
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in that most other leukemias are observed in equal percentages among Eastern and
Western ethnic populations. The reasons for the low incidence of CLL in Asian countries
are still unknown but point towards heritable genetics instead of environmental factors
(Brown, 2013; Campo et al., 2017; Rai & Jain, 2016).
Environmental risk factors have been noted in various leukemias, but there has
been little association with environmental exposures contributing to the risk of
developing CLL. To date, occupations and chemicals associated with agriculture have
the strongest association with an environmental risk factor, but the specifics are
unknown. The possible link between genetics and immune system dysfunction regarding
the development of CLL has become particularly interesting because no substantial
environmental risk factor has been identified (Speedy et al., 2016). A family history of
CLL is currently the best-defined risk factor for acquiring CLL (Brown, 2013).
Monoclonal B-cell Lymphocytosis
Monoclonal B-cell lymphocytosis (MBL), a possible precursor to CLL and other
B-cell lymphoproliferative disorders, is now medically recognized in approximately 5% of
the population over 40 years of age (Parikh, Strati, Tsang, West, & Shanafelt, 2016).
These groups harbor populations of clonal B-cells with the phenotype of a B-cell
malignancy but are asymptomatic with no clinical evidence of disease (Shanshal &
Haddad, 2012). Patients with MBL have fewer than 5 x 109/L of circulating monoclonal
B-lymphocytes, and do not have other manifestations of a lymphoproliferative disorder
(Brown, 2013; Campo et al., 2017; Hallek, 2013). Monoclonal B-cell lymphocytosis is
classified into three distinct groups based on the immunophenotype, including CLL-type,
atypical CLL-type, and non-CLL –type (Campo et al., 2017; Kalpadakis et al., 2014). The
majority of cases of MBL show expression of CD5, CD19, CD23, and diminished
expression of CD20 and CD79b, with a phenotype that presents like CLL (CLL-type)
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(Campo et al., 2017; Kalpadakis et al., 2014; Kern et al., 2012). There are now two
recognized categories of MBL that are dependent on the absolute number of Blymphocytes present in the blood: low-count MBL (LC-MBL) and high-count MBL (HCMBL). Low-count monoclonal B-cell lymphocytosis has less than 0.5 x 10 9/L monoclonal
B-lymphocytes in the blood and most likely does not represent a malignant population
(Campo et al., 2017; Kalpadakis et al., 2014). High-count monoclonal B-cell
lymphocytosis contains greater than 0.5 x 109/L monoclonal B-lymphocytes and is
closely related to early-stage CLL (Brown, 2013; Campo et al., 2017; Kalpadakis et al.,
2014). The current expectation is that most cases of MBL will not progress to CLL,
especially for individuals with LC-MBL (Brown, 2013; Call et al., 2014).
Heritability
Not only is CLL the most commonly occurring leukemia in the US, but it is also
one of the most heritable leukemias, and it has the highest genetic predisposition of all
hematologic neoplasms (Campo et al., 2017; Slager, Caporaso, de Sanjose, & Goldin,
2013). Few studies have been conducted concerning the heritability of CLL. There is a
very low incidence of CLL in Asian populations, even after migration to a Western
geographic location. The low frequency of CLL in these populations provides reasoning
that genetic, rather than environmental, risk factors may be drivers of the disease
(Brown, 2013; S. M. Yang et al., 2015). Familial CLL has been defined as having two or
more first-degree relatives with CLL. A family history of CLL is currently the best-defined
risk factor for acquiring CLL. Approximately 12% of patients with CLL have reported a
family history of a known lymphoproliferative disorder (LPD), and 6 - 9% have a family
member with CLL (Brown, 2013). The overall risk of CLL increases 2 - 7 times in firstdegree relatives of patients with CLL (Campo et al., 2017). Family members of patients
with CLL show an increased incidence of monoclonal B-cell lymphocytosis (Brown,
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2013). Interestingly, there have been no familial studies of CLL in Asian populations (S.
M. Yang et al., 2015). Familial studies have suggested that there is evidence of inherited
genetic factors that contribute to disease development. In several studies, CLL was
shown to co-segregate with other B-cell lymphoproliferative disorders, suggesting that
these diseases operate under a similar mechanism of action. Familial cases have a
higher incidence in females and a younger age of onset than sporadic cases of CLL.
Although multiple germline mutations linked to CLL have not been readily identified, this
study highlights the role of genetic changes in the causation of the disease.
Diagnosis
Several tools have been developed to define the parameters for establishing a
diagnosis of CLL. They are constantly revised to accommodate changes in
recommendations for CLL diagnosis, treatment, and management including guidelines
from the World Health Organization (WHO), the NCCN Clinical Practice Guidelines for
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, and the International
Workshop on Chronic Lymphocytic Leukemia (iwCLL) (Campo et al., 2017; Hallek et al.,
2018; Wierda et al., 2020). Most patients in the early stages of CLL are asymptomatic
and discovered as an incidental finding during a routine complete blood count (CBC)
(Campo et al., 2017; Oscier et al., 2012). The increased sensitivity of diagnostic tools
allows CLL to be detected at an earlier stage, resulting in approximately 70% of patients
to be asymptomatic at presentation (Speedy et al., 2016). Signs and symptoms include
fatigue, splenomegaly, hepatomegaly, lymphadenopathy, infections, cytopenias, or
anemia (Campo et al., 2017; Wierda et al., 2020). A diagnosis of CLL requires blood
counts and blood smears to be evaluated and the circulating B-lymphocytes assessed
by flow cytometry and requires the presence of at least 5 x 109 monoclonal Blymphocytes/L (5000/µl) in the peripheral blood and persistent lymphocytosis for at least
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three months (Campo et al., 2017; Hallek, 2019; Hallek et al., 2018). Flow cytometry and
immunophenotyping via cell surface markers can be performed on a patient’s peripheral
blood and are generally adequate tests to establish a diagnosis of CLL (Hallek et al.,
2018). A patient’s bone marrow does not need to be assessed to diagnose CLL, but it is
required to determine complete response to therapy.
There are many sites of involvement for CLL, including the peripheral blood,
bone marrow, lymph nodes, liver, spleen, and other extranodal sites. The non-leukemic
cases referred to as small lymphocytic lymphoma (SLL). These cases have the
immunophenotype and tissue morphology of CLL (Campo et al., 2017). A diagnosis of
SLL requires lymphadenopathy, the absence of cytopenias, and peripheral blood that
contains no more than 5,000/µL of B-lymphocytes. It is preferred to confirm a diagnosis
of SLL with a lymph node biopsy when possible (Hallek, 2013).
Serum markers may be tested at the time of diagnosis. These serum markers
include CD23, thymidine kinase (TK), an intracellular DNA synthesis protein, and ß 2microglobulin (ß2M), a component of the HLA class I complex on nucleated cells (Parikh
& Shanafelt, 2016). Disease burden and clinical outcome seem to correlate with the
presence of ß2M and TK in CLL patients (Parikh & Shanafelt, 2016). The presence or
absence of these serum markers may predict survival or progression-free survival
(Hallek et al., 2018). Patients with levels of ß2M that are below 3.5 mg/L have a
substantially longer time to progression compared to those with levels higher than 3.5
mg/L (Parikh & Shanafelt, 2016). Lower rates of complete remission (CR) and overall
survival (OS) from chemoimmunotherapy are associated with elevated levels of ß 2M.
Rapid lymphocyte doubling time (LDT), or the time it takes for the absolute lymphocyte
count (ALC) to double, a shorter time to progression, and a lower rate of response to
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therapy has been associated with patients that have serum TK levels of greater than 8.5
U/L (Parikh & Shanafelt, 2016).
Immunophenotype
Flow cytometry is a valuable and efficient immunophenotyping tool that tests
multiple antibodies and identifies the expression of antigens on the surface of a cell.
Flow cytometry can test several parameters to diagnose CLL and identify prognostic
markers. In most CLL cases, the neoplastic cells express a moderate amount of the Bcell antigen CD19 (Speedy et al., 2016). CLL cells also co-express T-cell antigens CD5
and CD43, while the presence of CD23 helps differentiate CLL from mantle cell
lymphoma (Campo et al., 2017; Hallek et al., 2018; Shanshal & Haddad, 2012; Speedy
et al., 2016). In typical CLL, CD10 is negative, and FMC7 is usually negative or weakly
expressed (Campo et al., 2017). A unique characteristic of CLL is the low expression of
CD20, CD79b, and surface immunoglobulin (IgM/IgD), which helps to distinguish CLL
from other B-cell lymphoproliferative disorders (Campo et al., 2017; Hallek et al., 2018;
Speedy et al., 2016). Additional cell surface markers may be studied to help classify
borderline cases.
IGHV Mutation Status
During maturation of B-lymphocytes in the bone marrow, immunoglobulin
variable (IGHV) gene segments rearrange to create a code for an immunoglobulin
molecule that will serve as the B-cell receptor for antigen. The mutational status of the
IGHV genes shows significant variability in CLL patients and is strongly associated with
prognosis and outcome. Throughout the disease, the IGHV mutation status will not
change, unlike other markers used to establish prognosis (Montserrat, Bauman, &
Delgado, 2016). Two types of CLL correlate with the mutational status of the IGHV
genes, including unmutated (U-CLL) and mutated (M-CLL), which originate from different
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cells [Figure 1]. The expression of CD38, CD49d, and ZAP-70 has been correlated with
IGHV mutation status and are used as surrogate markers in distinguishing two subsets
of CLL (Wierda et al., 2020). In U-CLL, the B-cell receptor (BCR) on the surface of the
CLL cell has greater than 98% homology with the germline IGHV sequence and
originate from mature, naïve B-cells that express CD5 (Hallek et al., 2018; Ten Hacken
et al., 2019). Approximately 30 – 50% of the population of patients with CLL show U-CLL
and display early disease progression (Campo et al., 2017; Mehes, 2005; Montserrat et
al., 2016; Seifert et al., 2012; Ten Hacken et al., 2019). Patients with unmutated IGHV
tend to have more aggressive disease and shorter progression-free survival (PFS), with
a median overall survival (OS) of approximately eight years (Parikh, 2016; Montserrat
2016). A higher expression of CD38, CD49d, and ZAP-70, as well as association with
unfavorable-risk cytogenetics like deletions of 11q and 17p, are associated with U-CLL
(Campo et al., 2017; Chiorazzi, Rai, & Ferrarini, 2005; Montserrat et al., 2016).
Approximately 2 - 8% of patients with unmutated CLL will develop diffuse large B-cell
lymphoma (DLBCL), or Richter syndrome (RS), and generally have a median survival of
less than one year. Less than 1% of patients with CLL will develop classical Hodgkin
lymphoma (HL) and typically occur in cases of mutated CLL (Campo et al., 2017).
Mutated CLL (M-CLL) arises from memory B-cells with BCRs that have
undergone somatic hypermutation (SHM) in the germinal center of peripheral lymphoid
tissue (Ten Hacken et al., 2019). The BCRs in M-CLL have less than 98% homology
with the germline IGHV sequence (Hallek et al., 2018; Ten Hacken et al., 2019).
Approximately 50 - 70% of CLL patients have M-CLL and have an indolent disease with
a better prognosis than U-CLL (Campo et al., 2017; Mehes, 2005; Montserrat et al.,
2016). M-CLL is associated with favorable-risk cytogenetics like deletions of 13q and
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trisomy 12. Patients with M-CLL also experience longer PFS and have a median OS of
greater than 20 years (Parikh & Shanafelt, 2016).
Staging
There are currently two systems for staging CLL, the Rai system, and the Binet
system. The Rai (USA) and Binet (Europe) staging systems are based on the results of
physical examination and laboratory tests (Shanshal & Haddad, 2012). The Rai system
used in the United States previously defined prognosis using five different categories
ranging from least involvement at stage 0 to the most involvement at stage IV [Table 1].
The revised Rai system now includes just three groups: low-, intermediate-, and highrisk (Hallek et al., 2008). The Binet staging system used to stage CLL in Europe is also
separated into three different categories: stage A, stage B, and stage C (Binet et al.,
1981) [Table 2]. Both of these staging systems are inexpensive and rely on standard
laboratory tests. While the Rai and Binet systems remain a standard for CLL treatment
and follow-up care, they fail to predict disease course in patients with early-stage
disease (Chiorazzi, Rai, et al., 2005). Both staging systems are used to determine the
extent of the disease and are not used to differentiate between a favorable or
unfavorable prognosis but may help clinicians decide when to start patients on therapy
(Schnaiter, Mertens, & Stilgenbauer, 2011).
Prognosis and Progression
A vast majority of patients newly diagnosed with CLL are in the early stages of
the disease and do not require immediate treatment. The Rai and Binet systems fail to
determine overall disease progression since the majority of cases are diagnosed early at
Rai 0/Binet A stages and do not provide valuable information about prognosis (Haferlach
et al., 2010; Hallek et al., 2018; Parikh & Shanafelt, 2016; Pepper et al., 2012). The Rai
and Binet staging systems describe the extent of the disease and overall tumor burden,
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Table 1. Rai Staging System. The Rai Staging System is primarily used in the United
States and outlines three main prognostic groups, low-, intermediate-, and high-risk.
Rai Stage

Modified Rai Stage

Clinical Features
Lymphocytosis (< 15,000/mm3) in blood or bone
marrow

0

Low

I

Intermediate

Lymphocytosis and lymphadenopathy

II

Intermediate

Lymphocytosis and splenomegaly with/without
lymphadenopathy

III

High

Lymphocytosis, anemia (Hb < 11 g/dl)

IV

High

Lymphocytosis and thrombocytopenia (> 100 x
109/l)
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Table 2. Binet Staging System. The Binet Staging System, primarily used in Europe,
outlines three prognostic categories, A, B, and C.
Binet Stage

Clinical Features

A

Hb  10 g/dl, platelets  100 x 109/l and < 3 enlarged areas

B

Hb  10 g/dl, platelets  100 x 109/l, and  3 enlarged areas

C

Hb < 10 g/dl, platelets < 100 x 109/l, or both (independent of involved
areas)
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but other factors are significant in determining the prognosis and progression of earlystage CLL (Campo et al., 2017; Haferlach et al., 2010). Other parameters like
lymphocyte doubling time (LDT), the extent of bone marrow involvement, and absolute
lymphocyte count (ALC), were used to establish prognosis in the late 1900s, but no
longer retain prognostic importance with the newer parameters currently available
(Parikh & Shanafelt, 2016). The prognosis of patients with CLL is determined by some
disease and treatment-related factors, including age, gender, disease stage, serumbased markers, IGHV mutation status, types of treatment, cytogenetic abnormalities,
and the extent of minimal residual disease. Concurrent chromosome and FISH studies in
the diagnostic specimen can help determine the prognosis of a patient with CLL (Brejcha
et al., 2014). A favorable prognosis is associated with low-risk cytogenetics, such as an
isolated deletion of 13q14, mutated IGHV genes (M-CLL). An unfavorable prognosis is
associated with high-risk cytogenetics, including complex karyotypes and deletions of
11q and 17p, unmutated IGHV genes (U-CLL) (Campo et al., 2017; Wierda et al., 2020).
Mutations of TP53, ATM, NOTCH1, SF3B1, and BIRC3 have also been associated with
an unfavorable prognosis (Campo et al., 2017; Landau et al., 2015; Wierda et al., 2020).
Currently, the most relevant scoring system to determine the prognostic outcomes for
CLL is the CLL International Prognostic Index (CLL-IPI) scoring system that uses
weighted scores of different independent prognostic factors. These factors include age,
clinical stage, IGHV mutation status, TP53 deletion and/or mutation, and serum β2M
concentration [Table 3]. The results from the scoring categorize patients into low-risk
(score 0 – 1), intermediate-risk (score 2 – 3), high-risk (score 4 – 6), and very high-risk
(score 7 -10) categories. Patients that fall in the low-risk category and are asymptomatic
do not require therapeutic intervention (Group, 2016; Hallek, 2019).
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Table 3. Weighted scoring for CLL International Prognostic Index (CLL-IPI).The
CLL-IPI uses a weighted scoring system of five independent prognostic factors to
determine patient risk. Based on the weighted score, patients can be placed in one of
four risk categories: low-, intermediate-, high-, and very high-risk.
Weighted
Score

Prognostic Factors

Age

≤ 65 years
> 65 years

0
1

Clinical Stage

Rai 0 or Binet A
Rai I – IV or Binet B - C

0
1

Serum β2M
Concentration

≤ 3.5 mg/L
> 3.5 mg/L

0
2

IGHV Mutation Status

Mutated
Unmutated

0
2

TP53 Status

No abnormalities
Deletion 17p and/or TP53 mutation

0
4

Total Risk Score

0 - 10
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Treatment
Due to the heterogenic nature of CLL and various degrees of progression, no
single treatment will work for all patients. There are many factors that should be
considered when determining the appropriate treatment for CLL patients including, the
clinical staging, notable symptoms, comorbidities, age, disease extent, TP53 and IGHV
mutation status, chromosome karyotype and FISH results, and prior treatment history
(Haferlach et al., 2010; Hallek et al., 2018; Wierda et al., 2020). Management of CLL
with treatment options have been outlined in the NCCN guidelines and are continuously
updated (Wierda et al., 2020). Treatment for CLL should only be given to those
individuals with active, symptomatic disease. Some characteristics of active disease
according to the iwCLL guidelines include fever, weight-loss, and night sweats,
symptoms or complications from lymphadenopathy, splenomegaly, or hepatomegaly,
cytopenias not caused by autoimmune phenomena, and a lymphocyte doubling time of
fewer than six months (Eichhorst et al., 2011). If CLL presents as a lymph node-based
disease, called small lymphocytic lymphoma (SLL), the treatment is the same.
Standard treatment for patients without symptoms that fall in Rai low to
intermediate risk or Binet stages A and B is to use a “watch-and-wait” strategy and
monitor blood work every 3 - 12 months (Eichhorst et al., 2011; Haferlach et al., 2010;
Hallek et al., 2018; Shanshal & Haddad, 2012). However, delays of treatment may be
harder to administer, especially in high-risk CLL patients (Oscier et al., 2012).
Asymptomatic patients with an intermediate risk based on the clinical staging systems
may benefit from a watch-and-wait protocol until there is evidence of symptomatic or
progressive disease (Hallek, 2019). Patients with higher stages of CLL may benefit from
more aggressive treatment regimens. Other treatments used on patients with more
disease progression include cytotoxic drugs and monoclonal antibodies (Haferlach et al.,
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2010). Several main components can be involved in CLL treatment: single
chemotherapeutic agents, monoclonal antibodies, BCR, BCL-2, and phosphatidylinositol
3-kinase (PI3K) inhibitors, and drugs that are currently in clinical development (Hallek,
2013).
Cytostatic Agents, Purine Analogs, and Monoclonal Antibodies
Alkylating agents have served as the gold-standard for initial therapy for CLL for
several decades and included the use of chlorambucil, cyclophosphamide, and
bendamustine (Hallek, 2015). Several side effects may occur after the extended use of
these alkylating agents, including severe infections, as well as the risk of developing
secondary acute leukemia (Eichhorst et al., 2016; Hallek, 2015, 2019). Also, these
cytotoxic drugs cannot specifically target CLL cells and cause toxicity in some normal
cells, which limits the deliverable dose or intensity of the drug (Khan, Saif, Sandler, &
Mirrakhimov, 2014). Combination therapy, including the use of a purine nucleoside
analog like fludarabine, had generally been seen as the standard for initial front-line
treatment for physically fit CLL patients (Eichhorst et al., 2016; Speedy et al., 2016). The
introduction of purine nucleoside analogs improved patient response rates when
combined with cyclophosphamide to provide a more effective chemotherapy regimen
(Speedy et al., 2016), until the introduction of monoclonal antibodies and more recently,
targeted agents. The addition of a monoclonal, anti-CD20 antibody, like rituximab to a
traditional alkylating agent, has improved the outcome of most patients (Hallek, 2019).
Monoclonal antibodies can be used as a single-agent therapy in patients with relapsed
or refractory disease (Hallek, 2019; Speedy et al., 2016). One popular first-line therapy
option that has shown high response rates in physically fit patients is the combination of
fludarabine, cyclophosphamide, and rituximab (FCR), especially in patients who are
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previously untreated and have mutated IGHV; however, this therapy combination is not
suitable for all patients (Wierda et al., 2020).
BCR and BCL-2 Inhibitors
The signaling of the B-cell receptor in neoplastic cells is supported by tyrosine
kinases, including Bruton’s tyrosine kinase (BTK), ZAP-70, PI3K, Spleen tyrosine kinase
(Syk), and Src family kinases (Hallek, 2013). B-cell receptor kinase inhibitors, including
idelalisib and ibrutinib, induce apoptosis in CLL cells and not the normal cell population
(Hallek, 2015). Patients with deletions of ATM and TP53 and unmutated IGHV respond
to therapy with B-cell receptor kinase inhibitors (Khan et al., 2014). BCL-2 inhibitors are
also critical regulators in the apoptotic process and can target anti-apoptotic BCL-2
family proteins (Hallek, 2013). One useful BCL-2 inhibitor is venetoclax, a potential
monotherapy option for patients with relapsed or refractory CLL regardless of their age
or comorbidities (Wierda et al., 2020). In patients with deletions of TP53 that have
relapsed or refractory CLL, ventoclax as a monotherapy or with a monoclonal antibody
has proven to be particularly effective (Stilgenbauer et al., 2018; Wierda et al., 2020).
CAR-T Therapy
Patients who have failed first-line therapy or cannot tolerate traditional treatments
may benefit from the use of autologous chimeric antigen receptor T-cells (CAR-T).
Patient T-cells are collected in steady-state and then reprogramed to have chimeric
antigen receptors (CAR) on the surface and expanded in culture (Castro & Kipps, 2016;
Mato, Thompson, Nabhan, Svoboda, & Schuster, 2017). CD19 has been identified as
the ideal target for CLL because it is only expressed in B-cells. Once infused into the
host, the engineered T-cells target CLL-specific antigens like CD19 and initiate, in a
sense, a type of graft-versus-leukemia (GVL) effect in the malignant cells while
preserving the non-targeted cells (Mato et al., 2017). CAR-T therapy does not require
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the availability of an allogeneic donor (Byrd, Jones, Woyach, Johnson, & Flynn, 2014).
Initial studies with CAR-T therapy have proven to be promising in eradicating
relapsed/refractory CLL, but CAR-T therapy is not without complications. In the future,
CAR-T therapy may become part of another combination therapy strategy for improved
efficacy in CLL (Hallek, 2019; Mato et al., 2017).
Response and Residual Disease
In 2008, The International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
standardized the assessment of response in patients with CLL (Hallek et al., 2008).
Updated recommendations to the iwCLL criteria have been made based on advances in
the detection of prognostic markers, gene mutations, and the identification of novel
therapeutic targets (Hallek et al., 2018). A careful physical examination and a CBC must
evaluate the patient’s response to the chosen treatment. Parameters to determine
response to treatment are separated into two groups; group A assesses the lymphoid
tumor load, and group B assesses the hematopoietic system. Patient response to
treatment is grouped into the following categories: complete remission (CR), partial
remission (PR), partial disease (PD), and stable disease (SD) (Hallek et al., 2018)
[Table 4]. A bone marrow biopsy must be performed to determine complete remission,
and all response criteria have to be met (Eichhorst et al., 2011; Hallek et al., 2018).
Partial remission (PR) requires two parameters from group A, and one parameter from
group B to improve from baseline. Progressive disease (PD) is described when the
individual has one met one response criteria from group A or B. Patients are considered
to have stable disease (SD) when they have not achieved CR or PR and do not show
signs of PD; stable disease also indicates a nonresponse to treatment. A patient who
has previously achieved the criteria for CR or PR, but after six months demonstrates the
progression of the disease is in relapse (Hallek et al., 2008). The median survival of

Table 4. Response criteria. This table contains parameters for two groups that are used to assess patient response
to treatment. Patient reponse is grouped into the following categories: complete remission (CR), partial remission
(PR), partial disease (PD), and stable disease (SD).
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patients with indolent forms of CLL is greater than 25 years (Chiorazzi, Rai, et al., 2005).
However, recent advancements in CLL treatment, including the use of targeted
therapies, have increased the median survival of patients with aggressive forms of the
disease (Wierda et al., 2020). Refractory disease is defined as treatment failure or those
who have not achieved CR or PR, and show progression within six months from the last
therapeutic. Individuals who show CR or PR are the only ones who have demonstrated a
clinically beneficial response and all others are rated as treatment failure (Hallek et al.,
2018). Minimal residual disease (MRD) has also been introduced as an additional
category in response assessment and an independent predictor of progression-free
survival (PFS) and overall survival (OS), which is of particular importance for clinical
trials (Hallek, 2013; Montserrat et al., 2016). MRD is detected in the blood and/or bone
marrow by using multi-color flow cytometry, real-time quantitative PCR using allelespecific oligonucleotides or next-generation sequencing. Patients are considered to have
undetectable MRD remission if less than one CLL cell is detected per 10,000 leukocytes,
which is an important predictor of the efficacy of the chosen treatment (Hallek et al.,
2018).
Cytogenetics and FISH Testing in CLL
The gold-standard for detecting chromosomal abnormalities in CLL is to perform
concurrent conventional cytogenetic analysis using karyotypes as well as FISH studies
that utilize a panel of curated probes with prognostic significance in CLL (Amare et al.,
2013; Döhner et al., 2000; Mikhail et al., 2016; O'Malley et al., 2011; Puiggros, Blanco, &
Espinet, 2014; Urbankova et al., 2014; Wierda et al., 2020). Cytogenetic analysis
provides enhanced information on global genetic abnormalities, including balanced
translocations, and helps to define the prognosis and progression of the disease. Unlike
most leukemias, chromosome translocations are rare in CLL. Instead, numeric
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chromosome abnormalities, submicroscopic deletions, and gene mutations are
characteristic of the disease. Conventional cytogenetics and FISH are used together to
provide a more complete analysis than either assay can provide individually (Aoun et al.,
2004; Quintero-Rivera et al., 2009). Cultured cells are required to prepare Giemsabanded (G-banded) karyotypes from metaphases for conventional cytogenetic analysis.
However, mature B-cells demonstrate a low level of spontaneous mitotic activity with an
inadequate response to conventional mitogens, resulting in a low detection rate of
cytogenetic abnormalities by conventional karyotyping alone in many mature B-cell
malignancies, including CLL (O'Malley et al., 2011; Schnaiter et al., 2011; Seifert et al.,
2012). This observation led to the addition of IL-2 and synthetic CpG oligonucleotides to
cell culture media that would act as mitotic stimulants to generate metaphase cells for
analysis (Brejcha et al., 2014; Dun et al., 2018; Haferlach & Bacher, 2011; Heerema et
al., 2010; Muthusamy et al., 2011). The use of interleukin 2 (IL-2) in combination with
synthetic CpG oligonucleotides (TCGTCGCTGTCTCCGCTTCTTCTTGCC) known as
DSP30 has proven to be an effective mitotic stimulant of the target cells in mature B-cell
malignancies (Brejcha et al., 2014; Dun et al., 2018; Haferlach & Bacher, 2011).
Together, these additives work synergistically to stimulate cells arrested in the G 0G1
phase of the cell cycle to progress through mitosis. The addition of DSP30 and IL-2 has
increased the abnormality detection rate in the conventional cytogenetic analysis by
stimulating these cells to divide, even in low-level disease (Dun et al., 2018; Shi et al.,
2013). Cytogenetic abnormalities detected by karyotype are observed approximately 40
– 50% of the time by conventional cytogenetics. However, cytogenetic lesions are rarely
seen in early-stage disease but tend to appear as the disease progresses (Chiorazzi,
Rai, et al., 2005). Analysis of Giemsa-banded karyotypes allows for the discovery of
additional genetic aberrations that would have otherwise gone undetected in the
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traditional FISH panel and detects clonal evolution. Clonal evolution, defined as the
acquisition of a new cytogenetic aberration, occurs in 17 – 26% of patients during the
disease course and is associated with shorter OS (Brejcha et al., 2014). Clonal evolution
seems to be more prevalent among those patients with overexpression of ZAP-70, which
is associated with an unfavorable prognosis (Brejcha et al., 2014; Cavazzini, Ciccone,
Negrini, Rigolin, & Cuneo, 2009; Shanafelt, Geyer, & Kay, 2004). However, a clonal
association has been noted in those with overexpression of CD38 and ZAP-70, and
unmutated IGHV (Brejcha et al., 2014). Complex karyotypes, defined as three or more
cytogenetic abnormalities observed in a karyotype, can also be characterized by
conventional cytogenetic studies. Karyotypic complexity is associated with an adverse
prognosis in several leukemias, including CLL (Cavallari et al., 2018; Puiggros et al.,
2017).
Approximately 80 - 90% of CLL cases show cytogenetic abnormalities detected
by FISH studies (Campo et al., 2017; Döhner et al., 2000; Haferlach, Dicker, Schnittger,
Kern, & Haferlach, 2007). Interphase FISH testing is currently a standard practice to
provide prognostic information in CLL cases and follow the disease’s progression. FISH
is the most recommended test for the follow-up of a CLL diagnosis due to the ability of
the FISH panel to analyze a large number of cells and quantify the results (Mehes,
2005). There are several advantages for the use of FISH studies for determining
prognosis in CLL, including the analysis of dividing (metaphase) and non-dividing
(interphase) cells simultaneously and increased sensitivity to detect low-level clones.
FISH is also one of the best methods for detecting cytogenetic abnormalities that fall
within the curated CLL FISH panel, including cryptic abnormalities that cannot be
appreciated by conventional cytogenetics (Brejcha et al., 2014; Dave, Nelson, & Sanger,
2011; Mehes, 2005). FISH testing employs a panel of probes at specific genes or gene
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regions to detect the most common abnormalities in CLL. These include deletions of 6q
frequently involving loss of MYB, trisomy 12 identified by using a centromeric probe for
chromosome 12, deletions of 11q22.3 (ATM), deletion or nullisomy of 13q14 and
monosomy or nullisomy 13 (identified with combined use of locus-specific probes for
13q14 and 13q34), abnormalities of 14q32 (IGH gene locus), and deletions of 17p13.1
(TP53).
Common Cytogenetic Abnormalities Observed in CLL
Numerous studies have focused on the prognostic implications for each of the
recurrent chromosomal abnormalities detected in CLL (Döhner et al., 2000; Haferlach et
al., 2007; Hallek; Mehes, 2005; Puiggros et al., 2014; Schnaiter et al., 2011). Although a
majority of CLL cases exhibit cytogenetic abnormalities, approximately 20 - 40% of
cases exhibit a normal karyotype. These cases are expected to have a favorable to
intermediate prognosis (Mehes, 2005; Parikh & Shanafelt, 2016). Cytogenetic
abnormalities associated with CLL may be seen as single abnormalities, or with other
characteristic aberrations of CLL. The most common genetic abnormalities in CLL
include deletions of 6q, deletions of 11q, trisomy 12, deletions of 13q, abnormalities of
IGH on 14q32, and deletions of 17p. The frequencies of each of these abnormalities are
observed in similar percentages among all ethnic groups, although there is geographic
variation in the occurrence of CLL (S. M. Yang et al., 2015). The abnormalities based on
their reported frequencies are as follows:
Deletions of 13q
Deletions of the long arm of chromosome 13 at 13q14 are the most frequently
observed aberration seen in CLL patients and occur in approximately 50 - 60% of all
cases of CLL (Grygalewicz et al., 2016; Hallek, 2013, 2019; Shahjahani et al., 2015).
Deletions of 13q14 represent early clonal aberrations and suggest the presence of a
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tumor suppressor gene that, when deleted or inactivated, may be crucial to CLL
development (Eid et al., 2014). These deletions of 13q can occur at a single locus, or
result in a larger interstitial deletion that can be differentiated by FISH by using probes at
13q14 and 13q34. Deletions of 13q14 are undetectable in approximately 90% of cases
by traditional karyotyping due to the sub-microscopic size of the deletion (Grygalewicz et
al., 2016). In some cases, deletions of 13q14 can be biallelic that results when both
copies of 13q14 are deleted, also known as nullisomy 13q14 (Mehes, 2005; Puiggros,
Delgado, et al., 2013). Monoallelic deletions of 13q14 occur more frequently than
biallelic deletions of 13q14 (Döhner et al., 2000), and biallelic deletions of 13q14 are
routinely smaller in size (Grygalewicz et al., 2016; Ouillette, Collins, Shakhan, Li, Li, et
al., 2011). In most cases, the commonly deleted region of 13q14 includes the microRNA
cluster containing MIR-15A/MIR16-1 that is downregulated or deleted in most CLL cases
(Puiggros, Delgado, et al., 2013; Speedy et al., 2016). Loss of these microRNAs can
result in the resistance of apoptosis of the tumor cells by upregulating BCL-2 (Speedy et
al., 2016). Several studies have shown that larger deletions of 13q that include the RB1
gene may be linked with a poorer prognosis than the smaller 13q14 deletions (Ouillette,
Collins, Shakhan, Li, Li, et al., 2011; Yi et al., 2017). RB1 regulates the progression of
the cell cycle and controls genomic stability, so the loss of this gene could result in a
more adverse prognosis than the small deletion of 13q (Yi et al., 2017). As a sole
cytogenetic abnormality, deletions of 13q14 are linked with the most favorable
prognosis; however, it is not currently known if biallelic deletions of 13q14 confer a
worse prognosis than a monoallelic deletion of 13q14 (Grygalewicz et al., 2016;
Puiggros, Delgado, et al., 2013). Cases that have sole deletions of 13q14 have the
longest median treatment-free interval and survival time, at approximately 133 months
(Eid et al., 2014; Mehes, 2005; Quintero-Rivera et al., 2009). However, cytogenetic
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abnormalities observed with a deletion of 13q14 tend to negate this effect (Eid et al.,
2014). Deletions of 13q are most often associated with mutated IGHV genes (M-CLL),
which is also considered a favorable prognostic marker, but have also been noted in
cases with unmutated IGHV genes (U-CLL) (Campo et al., 2017).
Trisomy 12
Trisomy 12, resulting in three copies of chromosome 12, is the second most
common abnormality detected in CLL and results in a favorable to intermediate
prognosis (Hallek, 2013; Mehes, 2005). Before the use of FISH for clinical testing,
trisomy 12 was the most common abnormality observed by a conventional karyotype
(Speedy et al., 2016). Even with poor metaphase morphology, it was still possible to
recognize three copies of chromosome 12. Due to the advancement of cytogenetic
culturing methods and FISH studies, it is now known that trisomy 12 is not the most
frequent genetic abnormality. The overall incidence of trisomy 12 in CLL is
approximately 10 – 20% (Campo et al., 2017; Döhner et al., 2000; Eid et al., 2014;
Hallek, 2019; Mehes, 2005; Puiggros et al., 2014). Often, trisomy 12 is accompanied by
other cytogenetic aberrations, including deletions of 6q23 and 13q14 and trisomy 18 and
19, among others (Eid et al., 2014; Mehes, 2005). A duplication of 12q22, which includes
the CLLU1 gene, can serve as a prognostic marker in patients under the age of 70
(Shahjahani et al., 2015).
Deletions of 11q
Deletions of the long arm of chromosome 11 at 11q22-23 most often contain the
ataxia-telangiectasia mutated gene, ATM. The ATM gene has various functions,
including checkpoint control of the cell cycle, DNA repair, and codes for a protein that
acts upstream of TP53 in the damage response pathway (Eid et al., 2014; Shahjahani et
al., 2015). Deletions of 11q occur in CLL in approximately 25% of patients with advanced
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disease who have not undergone treatment, and 10% of patients with early-stage
disease (Hallek, 2013). These deletions have been associated with disease progression,
adverse prognosis, and reduced OS (Chiorazzi, Rai, et al., 2005; Shahjahani et al.,
2015; Urbankova et al., 2012).
Deletions of 17p
Deletions in the short arm of chromosome 17 at 17p13.1 result in the loss of the
tumor suppressor gene locus, TP53, and can be detected by conventional karyotyping
and FISH analysis. These deletions are usually reported with other cytogenetic
abnormalities and have been linked with an adverse prognosis and frequently occur in
U-CLL cases (Chiorazzi, Rai, et al., 2005). TP53 is an essential gene in the regulation of
apoptosis, and when deleted, may allow cells to survive and accumulate further genetic
defects (Mehes, 2005). TP53, like ATM, is an integral component of the TP53 DNA
damage response pathway (Greipp et al., 2013). At the time of initial diagnosis, a de
novo 17p deletion is observed in only 5 – 8% of chemotherapy-naïve patients. These
patients may have a longer OS than patients who have acquired a 17p deletion after
initial treatment (Hallek, 2019; Tam et al., 2009). Loss of the TP53 gene locus occurs
more frequently in patients who have been previously treated and have refractory
disease than at the time of initial diagnosis (Hallek, 2019; Oscier et al., 2012). Often,
patients with 17p deletions resulting in the loss of TP53 have an inadequate response to
traditional chemotherapy (Döhner et al., 2000; Mehes, 2005; Shahjahani et al., 2015).
Greater than 80% of patients with a deletion of 17p have a mutation of the remaining
TP53 allele. Mutations of TP53 are associated with a poor prognosis, and these patients
have a significantly lower response rate and short progression-free survival (PFS) and
overall survival (OS) (Hallek, 2019; Oscier et al., 2012; Puiggros et al., 2014).
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Deletions of 6q
Deletions of 6q occur at a much lower frequency than other abnormalities in
approximately 3 – 10% of CLL cases and are rarely seen as a sole abnormality (Dalsass
et al., 2013; Döhner et al., 2000; Shahjahani et al., 2015). Both deletions of 6q21 and
6q23 (MYB) have been reported in CLL, and most often, these deletions are observed
as a secondary abnormality or with a complex karyotype (Finn, Kay, Kroft, Church, &
Peterson, 1998). These deletions have been associated with lymphocytosis,
splenomegaly, CD38 over-expression, and unmutated IGHV (Shahjahani et al., 2015).
Currently, 6q deletions are thought to have an intermediate prognosis (Gerrie et al.,
2014).
Abnormalities of 14q32
Chromosomal abnormalities like deletions and rearrangements involving the IGH
gene region at 14q32 have been reported in mature B-cell malignancies, including CLL.
The IGH region is a large region on chromosome 14 that is composed of many genes,
and abnormalities of IGH typically involve the variable region (Amare et al., 2013).
Although both deletions and translocations of the IGH gene region occur in CLL, there is
limited data on the frequency of these abnormalities. Many early studies that utilized
FISH testing to determine the frequency of chromosomal abnormalities associated with
prognostic significance in CLL did not study the IGH gene region. Other studies targeted
the region with a less informative FISH probe that was not able to detect smaller
deletions in this region. Consequently, it has been traditionally reported that 14q32
deletions do not occur in a significant percentage of CLL patients. However, more recent
studies have suggested that abnormalities of 14q32 occur more frequently than
previously thought. Deletions within the IGH gene region are not readily visualized
cytogenetically but are detectable by FISH studies. The reported incidence of deletions
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of 14q32 varies greatly in the literature, with an incidence of 2 – 24%, and were
assessed in relatively low study populations; however, not all studies utilized a universal
FISH probe to characterize these deletions, so the incidence of each type of 14q32
deletion observed in CLL may be skewed (Amare et al., 2013; Berkova et al., 2008;
Quintero-Rivera et al., 2009; Reindl et al., 2010). The use of some types of dual-color
break-apart FISH probes can distinguish between 5’ partial and complete telomeric
deletions of 14q32, as well as 3’ centromeric deletions of the same region. Although
several studies have mentioned the use of a dual-color break-apart probe for this region,
they still fail to separate the difference between unique probe signal patterns
representing each type of deletion. In a study by Amare and colleagues, deletions of the
IGH gene region were commonly associated with additional cytogenetic abnormalities,
including deletions of 13q, and trisomy 12 (Amare et al., 2013). Large, interstitial
deletions of 14q that do not involve the variable portion of the IGH gene region have also
been observed in CLL, and are frequently associated with trisomy 12 and unmutated
IGHV (Cosson et al., 2014; Pospisilova et al., 2007; Reindl et al., 2010). These large
deletions have also been observed as a sole abnormality by karyotype (Cosson et al.,
2014; Reindl et al., 2010). To date, there is no focused research regarding the impact of
telomeric IGH deletions in the prognosis of CLL.
Translocations involving 14q32 region are observed in many B-cell malignancies,
but are rare in CLL and occur in approximately 4 - 9% of CLL cases (Baliakas et al.,
2015; Berkova et al., 2008; Cavazzini et al., 2008; Cavazzini et al., 2012). The
prognostic implications of IGH translocations have been described in other
malignancies, but the effects of these translocations in CLL are largely unknown (Gerrie
et al., 2012). The most common translocations associated with IGH include
translocations with 2p (BCL11A), 6p (CCND3), 8q (MYC), 11q (CCDN1), 18q (BCL2),
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and 19q (BCL3) (Cavazzini et al., 2008; De Braekeleer et al., 2016). The presence of
small deletions and duplications that result from the translocations cannot be ruled out
without a more specific assay like microarray following the initial detection of a
translocation by cytogenetics or FISH. The occurrence of translocations is thought to be
associated with higher Binet stages and more advanced disease (Mayr et al., 2006).
The Utility of Microarray Studies in CLL
The recent addition of copy-number microarray studies to detect genetic
abnormalities has allowed for a whole-genome assessment to identify aberrations
associated with prognostic significance in CLL. The microarray technique can identify
copy-number alterations in regions of the genome that provide important prognostic
information for CLL, including the increased detection of submicroscopic deletions and
duplications that would have otherwise gone unnoticed by traditional cytogenetics and
predefined FISH panels, and delineate a complex karyotype (Kolquist et al., 2011). CLL
is an ideal neoplasm to study with genomic microarray because it is primarily a disease
that is genetically characterized by chromosomal gains and losses, which are easily
detected by microarray (Chun et al., 2018). Copy-number microarray cannot detect
translocations involving a balanced exchange of chromosomal material; however, these
translocations are rare in CLL, supporting the use of microarray studies for this
leukemia. The first genome-wide copy-number analyses of CLL was performed in the
1990s (Improgo & Brown, 2013). Since then, advances in microarray technology,
including BAC arrays, oligonucleotide arrays, and single nucleotide polymorphism (SNP)
arrays, have improved the density and sensitivity of microarray studies (Chun et al.,
2018; Gunnarsson, Mansouri, & Rosenquist, 2013; Improgo & Brown, 2013). In addition
to identifying copy number changes, SNP microarray studies can also detect copyneutral loss-of-heterozygosity (CN-LOH) and genome-wide genomic instability missed
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by conventional karyotyping and FISH analysis (Pei et al., 2014; Shahjahani et al.,
2015). Instances of acquired CN-LOH have been reported in CLL, with a relatively low
overall incidence. The most common areas with noted CN-LOH include 13q, 17p, and
11q (Edelmann et al., 2012). The use of copy-number microarray studies to complement
current conventional cytogenetics and FISH studies in CLL has been suggested by
several researchers with the intent of detecting known genetic abnormalities with
prognostic significance in CLL and to determine if microarray studies were sufficient for
use in a clinical setting (Houldsworth et al., 2014; Kolquist et al., 2011; Ouillette, Collins,
Shakhan, Li, Peres, et al., 2011; Puiggros, Puigdecanet, et al., 2013; Stevens-Kroef et
al., 2014). Microarray is also advantageous in a situation of culture failure, or instances
where there are a limited number of interphase and metaphase cells that would yield
inadequate results for cytogenetic and FISH studies. Since microarray uses extracted
DNA, it still possible to yield results if the cells fail to proliferate in culture, which can
often be the case in CLL (Kolquist et al., 2011).
Specific Objectives
Previous studies have shown that IGH deletions occur in CLL, with an extensive
range in the reported incidence of deletions of 14q32 (Amare et al., 2013; Berkova et al.,
2008; Quintero-Rivera et al., 2009; Reindl et al., 2010). However, to the best of our
knowledge, no studies have specifically focused on the possible size variation that exists
among 5’ telomeric 14q32 deletions and the genes involved in the deleted region. The
prognostic implications of these deletions are also hitherto unknown. More recently,
microarray studies have been used as a powerful tool to determine the genetic variation
in CLL (Chun et al., 2018; Gunnarsson et al., 2013; O'Malley et al., 2011). Microarray
studies can detect genomic imbalances that may not be visible by conventional
cytogenetics and accurately pinpoint the breakpoints and genes involved in the deleted
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or duplicated regions. It is a useful adjunct to cytogenetics and FISH because it helps in
detecting the submicroscopic genetic changes that are not included, and hence go
undetected by using the traditional FISH panel (Gunn et al., 2008; Kolquist et al., 2011;
O'Malley et al., 2011; Urbankova et al., 2012). Cytogenetic and FISH studies facilitate
the detection of genetic abnormalities that determine prognosis and help determine
treatment strategies (Döhner et al., 2000; Reindl et al., 2010). If we combine these tests
with microarray and perform a more comprehensive analysis, small duplications and
deletions, loss of heterozygosity, and gene amplification may be detected that are not
seen by conventional cytogenetics and traditional FISH panels.
While numerous studies have focused on the biology and prognostic implications
of other common abnormalities of CLL, there is a paucity of investigations regarding the
frequency, diversity, and clinical impact of 14q deletions. Our project is composed of the
following aims:
(1) Determine the frequency and variation in IGH deletions in CLL
(2) Perform complete characterization of IGH deletions in cases utilizing
additional techniques
(3) Delineate the possible variation in size of IGH deletions using microarray
(4) Analyze the frequency of additional abnormalities associated with 14q32
deletions in CLL
(5) Decipher other hitherto unknown abnormalities in CLL, specifically, with the
help of microarray studies
(6) Investigate the potential impact that IGH deletions have on time-to-firsttreatment (TTFT) and overall survival (OS).
By combining the various cytogenetics and molecular cytogenetic applications,
we will comprehensively identify the variation in partial deletions of IGH and other
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secondary abnormalities in CLL. We will then be able to focus on the candidate gene(s)
that may play a role in disease causation or progression. Comparisons and clinical
correlation may help determine the implications of a partial IGH deletion and risk
categorization for CLL.
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CHAPTER 2: METHODS
An initial retrospective analysis of conventional cytogenetics and fluorescence in
situ hybridization (FISH) studies on bone marrow or peripheral blood specimens were
performed using cases that were confirmed by flow cytometry and/or a histologic
diagnosis on tissue biopsies to have a diagnosis of CLL or SLL, with a few cases having
an associated diagnosis of lymphoproliferative disorder (LPD) by flow cytometry
analysis. These cases were referred for chromosome analysis and/or the CLL FISH
panel at the University of Nebraska Medical Center Human Genetics Laboratory
between 2010 and 2019. Each case was included only once in this retrospective
analysis. The methods described involve culturing techniques and analysis standards for
conventional cytogenetics and FISH studies that were followed for the cases in the
retrospective portion of the study.
Next, after determining that deletions of 14q32 (IGH) frequently occur in cases
with CLL, a microarray study on select cases to determine the variation in size of the
14q32 deletions. The Affymetrix® CytoScan™ HD array SNP microarray platform. The
cases included in the microarray studies were confirmed to have an IGH deletion by a
FISH panel for CLL, as analyzed by the Human Genetics Laboratory. Each case had an
appropriate amount of excess specimen available for DNA extraction. Peripheral blood
or bone marrow aspirates were used for the microarray studies.
The potential clinical significance of the deletion of 14q32 was assessed by
comparing cases that contained a deletion of 14q32 with cases that had sole FISH
abnormalities of known prognostic significance. A total of 115 confirmed CLL cases had
clinical data available to assess time-to-first-treatment (TTFT) and overall survival (OS).
The Institutional Review Board at the University of Nebraska Medical Center approved
this study.
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Conventional Cytogenetics
Culturing Methods
Bone marrow and peripheral blood samples were collected in sterile vacutainers
containing sodium heparin or EDTA and transported to the Human Genetics Laboratory.
Chromosome preparations were obtained by processing the bone marrow and
peripheral blood according to conventional cytogenetic protocols to achieve mitosing
cells (Aoun et al., 2004). At least two cultures were initiated for each specimen with an
incubation period of 24 – 48 hours [Figure 2]. A direct over-night culture (DirON) was
established by using 10 ml of CHANG Medium® BMC (FUJIFILM Irvine Scientific, Santa
Ana, CA) without mitogens and 0.5 ml of the specimen and was incubated overnight at
37°C. The DirON cultures also contained 10 µl of Colcemid® Solution -10 µg/ml
(FUJIFILM Irvine Scientific, Santa Ana, CA), for a continuous, slow arrest of the cells in
metaphase. In this study, a stimulated media that is effective in increasing the mitotic
index in CLL cases (Brejcha et al., 2014; Dun et al.), called DSP, was prepared and
utilized for culture initiation. This media contained CHANG Medium ® BMC, recombinant
Human Interleukin-2 (IL-2) (PeproTech, Rocky Hill, NJ), and 2 µM DSP-30
oligonucleotides (TCGTCGCTGTCTCCGCTTCTTCTTGCC) (Integrated DNA
Technologies, Coralville, IA). DSP-Stimulated cultures were incubated for 48-hours for
both bone marrow and peripheral blood specimen types.
Harvesting Methods
A cytogenetic harvesting protocol was used to harvest all cultures following 24 –
48-hours of incubation. First, 10 ml of a hypotonic solution (referred to as THC) was
added to each culture, and each culture was then incubated for 20 minutes at 37˚C. The

Figure 2. Initiation of cultures for conventional cytogenetic analysis and FISH. This drawing represents the initiation of
two cultures for each patient sample. The first culture, a direct overnight (DirON) culture contained 0.5 ml of specimen, 10 µl
of Colcemid  Solution, and 10 ml of CHANG Medium BMC. The second culture, a 48DSP culture, contained 0.5 ml of
specimen, 20 µl of IL-2, 100 µl of reconstituted DSP30 oligonucleotides, and 10 ml of CHANG Medium BMC.
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hypotonic solution (THC) contained trypsin, 0.4% KCL, and 0.08 µg/ml Colcemid ®
Solution (FUJIFILM Irvine Scientific, Santa Ana, CA) (Aoun et al., 2004). Following
incubation with THC, all specimen types were processed through four fixation steps.
First, 2 ml of 3:1 methanol (Macron Fine Chemicals/Avantor Performance Materials,
Center Valley, PA)/glacial acetic acid (Macron Fine Chemicals/Avantor Performance
Materials, Center Valley, PA) (Carnoy’s Fixative) was added to the hypotonic to prefix
the specimen. After a 6-minute spin at 1500 RPM, the supernatant was aspirated, and 6
ml of fixative was added to the culture. This process was repeated two additional times
by adding 4 ml of fixative to the culture [Figure 3].
Slide Preparation and Staining
After the harvest was complete, slides were prepared from the harvested cell
pellet as needed for conventional cytogenetics and FISH [Figure 4]. For the CLL FISH
panel, the 48-DSP culture was preferred for FISH analysis. For conventional cytogenetic
slide preparations, 100 µl of the cell pellet was dropped onto a pre-cleaned glass slide
using a micropipette. A Thermotron Drying Chamber CDS-5® (Venturedyne, Ltd.,
Holland, MI) provided ideal slide drying conditions for optimal chromosome spreading
and morphology by maintaining optimal temperature and humidity in the chamber. A
temperature of 25.5 - 26.5°C and 35 - 37% humidity was ideal for preparing metaphase
slides for each specimen type in this study. Slides were allowed to dry completely inside
the Thermotron Drying Chamber CDS-5® (Venturedyne, Ltd., Holland, MI). They were
then aged in a hot oven (100°C) for 25 minutes to enhance the absorption of stain and
produce a more consistent banding pattern. A conventional Giemsa-banding protocol
using Wright stain (GTW-banding) was followed (Dave et al., 2011). Prepared slides
from harvested cultures were placed in Trypsin-EDTA (1X) (FUJIFILM Irvine Scientific,
Santa Ana, CA) with Hanks’ Balanced Salt Solution (HBSS) (FUJIFILM Irvine Scientific,

Figure 3. Harvesting method for cytogenetic cultures. This drawing outlines the harvesting procedure for all
cytogenetic cultures following a set incubation period. After inoculation and incubation of the specimen in medium,
hypotonic (THC) is added followed by a 20 minute incubation period at 37°C. After the hypotonic incubation, 2 ml of
fixative is added to the culture, followed by three more fixation steps that results in a cell pellet.
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Figure 4. Slide preparation for FISH and GTW-banding. After the cells were harvested, slides
were prepared for both FISH hybridization and GTW-banding for chromosome analysis.
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Santa Ana, CA) for 6 seconds and then stained for approximately 50 seconds with
Wright working stain, prepared by adding 1 part Wright Stain Stock Solution (SigmaAldrich, St. Louis, MO) to 2 parts of pH 6.8 Gurr’s Buffer (BDH Laboratory, Poole,
England).
Analysis
Cytogenetic analysis was performed on at least twenty metaphase cells when
available using a bright-field microscope (Olympus BX models) or a Leica Biosystems
GSL metaphase scanner (Leica Biosystems, Buffalo Grove, IL). Image capture was
performed with the Leica Biosystems capture software and analyzed with the
CytoVision® Image Analysis System (Leica Biosystems, Buffalo Grove, IL). When
available, 20 cells were analyzed, and at least three karyotypes were prepared for each
study. Karyotypes of GTW-banded metaphase chromosomes using Wright stain were
described according to the International System of Cytogenetic Nomenclature 2016
(ISCN) (An International System for Human Cytogenomic Nomenclature (ISCN)).
According to ISCN guidelines, abnormal clones were defined as having two or more
cells with the same structural abnormality or the same chromosome gain, or the
presence of three or more cells with the same chromosome loss. A normal karyotype
was defined as having no identifiable clonal aberrations in the analyzed metaphase
cells. A total of three cytogenetic technologists and a director of the Human Genetics
Laboratory analyzed or reviewed each clinical case. Results from the cytogenetic studies
were obtained from the archived SOFT ® Computer database and archived images in
CytoVision® Image Analysis Software (Leica Biosystems, Buffalo Grove, IL) in the
Human Genetics Laboratory at the University of Nebraska Medical Center.
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Fluorescence in situ Hybridization (FISH)
Slide Preparation
Fluorescence in situ hybridization (FISH) studies provided a platform for the rapid
detection of translocations, loss, and gain of whole chromosomes, and deletions and
duplications identified in precise nucleic acid sequences. FISH was performed on
interphase and metaphase preparations utilizing commercially available probes. A panel
of probes used to detect cytogenetic abnormalities associated with CLL was prevalidated and applied for clinical use and was comprised of locus-specific, centromeric,
dual-fusion, and dual-color break-apart probes. This panel included the Poseidon ATM
(11q22.3)/p53 (17p13.1) DNA Probe set (Abbott Molecular, Abbott Park, IL), the LSI
D13S319 (13q14) and the LSI 13q34 probes (Abbott Molecular, Abbott Park, IL) with the
CymoGen Dx Copy Control probe for chromosome 12 (Biocare Medical, Pacheco, CA),
the LSI IGH (14q32) Dual Color Break Apart Probe with LSI MYB (6q23) (Abbott
Molecular, Abbott Park, IL) and the LSI IGH/CCND1 XT t(11;14) Dual Fusion
Translocation Probe (Abbott Molecular, Abbott Park, IL) [Figure 5]. Slides were
prepared for FISH studies in a Thermotron Drying Chamber CDS-5® (Venturedyne, Ltd.,
Holland, MI) with a consistent temperature of 25°C and 47% relative humidity. Fixed
cells were dropped on two hybridization areas per slide using 10 µl of resuspended cell
pellet in each area. The slides were allowed to dry in the Thermotron Drying Chamber
CDS-5® (Venturedyne, Ltd., Holland, MI). A phase microscope was then used to ensure
the presence of an appropriate number of nuclei necessary for analysis in each
hybridization area. Slides were aged at 100°C in an incubator for 2 minutes and placed
on a HyBrite® Instrument (Abbott Molecular, Abbott Park, IL).

Figure 5. Panel of commercially-available FISH probes for CLL. These idiograms represent the probe sets utilized to
detect FISH abnormalities associated with CLL. A) Vysis LSI MYB (6q23) (aqua), Vysis LSI IGH (14q32) Dual Color
Break Apart Probe (red/green) B) CymoGen Dx Copy Control 12 probe for 12 centromere (aqua), Vysis LSI D13S319
(13q14.3) (red), Vysis LSI 13q34 (13q34) (green) C) Vysis LSI IGH/CCND1 XT Dual-Color Dual-Fusion Probes
(14q32/11q13) (red/green) D) Repeat-Free™ Poseidon™ p53 (17p13.1) (green) and ATM (11q22.3) (red) Probes.
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Probes were mixed in a ratio of 7 µl of LSI or CEP buffer to 2 µl of the probe (1 µl
each of two different probes) to 1 µl of sterile, deionized water. The probe mixture
containing the appropriate amount of probe, buffer, and water was added on the prewarmed slide. Each hybridization area received 3 µl of probe mixture, and a 12-mm
round coverslip was applied to the slide and sealed with rubber cement. Co-denaturation
of the probe and target DNA was performed at 75 - 78°C for 1 minute with a subsequent
hybridization at 37 - 39°C for 12 - 18 hours. Following hybridization, the rubber cement
was removed along with the coverslips. The slides were then washed with 0.4% sodium
chloride and sodium citrate (SSC) (Sigma-Aldrich, St. Louis, MO) containing 0.3%
Nonidet P-40 (NP-40) (Abbott Molecular, Abbott Park, IL) at 72°C for 2 minutes and
again with 2X SSC with 0.1% NP-40 for 1 minute at room temperature. The slides were
then removed and allowed to air dry. The cells were counter-stained with 4’, 6-Diamino2-phenylindole solution (DAPI/Antifade II) (Abbott Molecular, Abbott Park, IL) [Figure 6].
Analysis
In addition to the abnormalities detected by karyotype, FISH studies are a
beneficial and reliable tool in detecting abnormalities of prognostic significance in
oncology studies. FISH studies can characterize aneuploidy, amplification,
microdeletions and duplications, derivative chromosomes, and unidentifiable
chromosome material that cannot be visualized by conventional cytogenetics when the
appropriate probe set is applied. Cryptic abnormalities, like deletions or partial deletions
of the IGH gene region, are also detectable by these assays. FISH testing is also
informative when metaphase cells are insufficient for analysis in conventional
cytogenetic preparations because of the ability to analyze interphase cells. When
available, 200 interphase cells were scored by two experienced technologists (100 cells
each). Both interphase and metaphase cells, when available,
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Figure 6. Slide preparation, hybridization, post-hybridization wash, and DAPI
counterstain for FISH. Harvested cells were used to prepare slides for FISH in a
Thermotron® Drying Chamber CDS-5®. Co-denaturation of the probe and target DNA
was performed, followed by hybridization overnight. After hybridization, the slides were
washed and counterstained with DAPI and analyzed.
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were viewed on a Leica DM6000B (Leica Biosystems, Buffalo Grove, IL) using the
appropriate filter set to visualize individual colors: red, green, aqua, and DAPI (blue), as
well as dual-color red/green and DAPI/red/green filters that allow for excitation at
different wavelengths. Image capture and analysis were performed with the Leica
Biosystems capture software, CytoVision® (Leica Biosystems, Buffalo Grove, IL).
Hybridization signals were assessed, and the final percentage of abnormal cells was
calculated per probe set. The false-positive and negative cutoff values used for this
study were deemed appropriate for clinical studies and established by the Human
Genetics Laboratory at the University of Nebraska Medical Center for clinical studies.
For reference, the abnormal range for trisomy 12 is 5 - 100%, for deletions of 6q23,
11q22.3, 13q14, 13q34, 14q32 or 17p13.1 is 10 - 100%, for IGH rearrangement is 7 100%, and for IGH/CCND1 fusion is 2 - 100%.
DNA Extraction and Quantitation
After conventional cytogenetic cultures were established, the remaining
specimen from select cases was used for DNA extraction. Genomic DNA was extracted
using a fully automated DNA extraction instrument called a QIAcube® and the QIAamp
DNA Blood Mini Kit (QIAGEN, Redwood City, CA). The QIAcube® protocol programmed
in the machine provides all necessary steps for cell lysis and purification using QIAprep
Spin Miniprep Columns (QIAGEN, Redwood City, CA). This procedure yielded between
40 to 630 µg/ml of DNA per specimen. Manual extraction of blood or bone marrow
specimens was utilized in several cases utilizing QIAGEN Puregene reagents (QIAGEN,
Redwood City, CA) [Figure 7]. For the manual extraction, approximately 300 µl of the
specimen was added to 900 µl of Red Blood Cell (RBC) Lysis solution in a 1.5 ml snapcap microcentrifuge tube and was left to incubate at room temperature for 10 minutes.
After centrifugation, the supernatant was removed, and the pellet was vortexed. Then,

48

Figure 7. Manual extraction of DNA from peripheral blood and bone marrow
specimens. Approximately 300 µl of the specimen was used for the manual extraction
of DNA. After a series of lysis and protein precipitation steps, the DNA was precipitated
using 100% isopropanol and rinsed with 70% ethanol (EtOH). A volume of 20 – 100 µl of
DNA hydration solution was used to rehydrate the DNA pellet.
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450 µl Cell Lysis Solution (QIAGEN, Redwood City, CA) was added. A 4.5 µl aliquot of
Proteinase K (20 mg/ml) (Sigma-Aldrich, St. Louis, MO) was added to the
microcentrifuge tube, and the specimen was incubated at 55°C for 30 minutes. The
specimen was cooled, and then 150 µl of Protein Precipitation Solution (QIAGEN,
Redwood City, CA) was added. After mixing, the specimen was centrifuged to pellet the
proteins, and the supernatant was transferred to a new microcentrifuge tube containing
450 µl of 100% isopropanol. The tube was inverted to precipitate the DNA. After
centrifugation, the isopropanol was removed, and the pellet was rinsed with 200 µl of
70% ethanol. Following another centrifugation step, the 70% ethanol was removed and
the DNA pellet was allowed to dry at 37°C for approximately two minutes. The DNA was
then resuspended in 20 – 100 µl of DNA Hydration Solution (QIAGEN, Redwood City,
CA).
The DNA concentration and quantitation were determined by using the
NanoDrop One™ ND-ONE spectrophotometer (Thermo Fisher Scientific, Waltham, MA),
and the Qubit® 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA). The NanoDrop
One™ ND-ONE spectrophotometer (Thermo Fisher Scientific, Waltham, MA) used 1.5 µl
of DNA and measured the concentration of the DNA, as well as A260, A280, A260/280,
and A260/230. The Qubit® 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA)
utilized the Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific, Waltham, MA) that
included Qubit® dsDNA BR Reagent 200X concentrate in DMSO, Qubit® dsDNA BR
Buffer, Qubit® dsDNA BR Standard #1, and Qubit® dsDNA BR Standard #2. A master
mix was prepared by diluting the Qubit® dsDNA BR Reagent 200X Concentrate in
DMSO in Qubit® dsDNA BR Buffer to achieve a total ratio of 1:200. Two sample
standards were used that were included in the Qubit dsDNA BR Assay Kit (Thermo
Fisher Scientific, Waltham, MA), Standard #1 and Standard #2. Thin-walled Qubit
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assay tubes (Thermo Fisher Scientific, Waltham, MA) were labeled for each DNA
specimen and standard. An aliquot of 1 µl of DNA from each specimen was added to
199 µl of the prepared master mix. For Standard #1 and Standard #2, 10 µl of each
Standard and 190 µl of the prepared master mix were used. This analytical assay
determined the DNA quantity of 40 to 850 ng/µl for the bone marrow and peripheral
blood specimens that were used in the microarray studies.
Affymetrix® CytoScan™ HD Array
The Affymetrix® CytoScan™ HD Array (Affymetrix®, Santa Clara, CA) platform
was used to detect copy number changes across the genome. Application of the
Affymetrix® CytoScan™ HD Array (Affymetrix®, Santa Clara, CA) allows for breakpoint
estimation, loss of heterozygosity (LOH) determination, and detection of low-level
mosaicism. The CytoScan™ HD Assay protocol used in this study was optimized for
processing 8 to 24 samples at a time to obtain whole-genome copy number results and
SNP information. This protocol does not utilize genome-wide association studies. For
our study, seven samples were processed at a time. The processing for this assay was
spread over the course of four days for each set of seven specimens and contained
several quality control steps to verify each product was of sufficient quality to continue
the assay [Figure 8].
Restriction Enzyme Digestion
Each sample was digested by the restriction enzyme Nsp 1. This digestion was
completed in the Pre-PCR clean area. First, the thermal cycler was turned on to allow
the lid to preheat. The setup for Nsp 1 digestion was performed on ice. The genomic
DNA and controls were vortexed three times and were spun down at 2000 RPM for 1
minute. An Nsp 1 digestion master mix was prepared in a 1.5 ml Eppendorf tube and
contained nuclease-free water, 10X Nsp 1 buffer, 100X BSA, and the Nsp 1 enzyme
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Figure 8. Overview of the Affymetrix® CytoScan™ HD Array protocol. This protocol
consisted of nine steps and three quality-control assessments performed over the
course of four days.
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[Figure 9A]. In eight different wells, 14.75 µl of the digestion master mix was added
along with 5 µl of genomic DNA. The last well contained no genomic DNA and contained
5 µl of the negative control. The plate was then sealed and placed on a preheated
Veriti™ 96-Well Thermal Cycler (Thermo Fisher Scientific, Waltham, MA) and was run
on a pre-set digestion protocol [Figure 9B]. Following the digestion, the plate was spun
down at 2000 RPM for 1 minute.
Ligation
In this step, a ligation master mix was prepared and contained 10X T4 DNA
Ligase Buffer, 50 uM adaptor Nsp 1, and T4 DNA ligase [Figure 10A]. An aliquot of 5.25
µl of ligation master mix was added to each well, bringing the total volume in each well to
25 µl. The plate was then sealed, vortexed, and spun down and loaded on to a
preheated Veriti™ 96-Well Thermal Cycler (Thermo Fisher Scientific, Waltham, MA) and
was run on a pre-set ligation protocol [Figure 10B]. After the ligation protocol was
completed, the plate was spun down at 2000 RPM for 1 minute.
PCR
After ligation, PCR of the digested and ligated product was performed. A 25 µl
aliquot of each ligated sample was diluted with 75 µl of chilled Affymetrix® nuclease-free
water bringing the total volume in each well to 100 µl. The diluted samples were kept on
ice. The PCR reaction utilized a Titanium DNA amplification kit (Clontech Laboratories,
Takara Bio Company, Mountain View, CA), and water. A volume of 10 µl of each sample
was transferred to a new PCR plate using a multi-channel pipette. A negative control
must also be used to assess the presence of contamination. A PCR Master Mix was
prepared [Figure 11A], and a multi-channel pipette was used to aliquot 90 µl of master
mix to each sample. The PCR plate was the sealed, vortexed, and spun down, and
loaded on a preheated Veriti™ 96-Well Thermal Cycler (Thermo Fisher Scientific,
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Figure 9. CytoScan™ Digestion protocol. DNA digestion using a restriction enzyme,
Nsp I, was the first step in the Affymetrix® CytoScan™ HD Array protocol. This figure
outlines the reagents and Thermal Cycler program for DNA digestion. A) The digestion
master mix included nuclease-free water, 10X Nsp I Buffer, 100X BSA, and the
restriction enzyme, Nsp I. B) The thermal cycler program used and performed on a
Veriti™ 96-Well Thermal Cycler (Thermo Fisher Scientific, Waltham, MA).
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Figure 10. CytoScan™ Ligation protocol. This figure outlines the reagents and
Thermal Cycler program for the ligation step. A) Reagents and volumes used for the
ligation master mix. B) The thermal cycler program used and performed on a Veriti™ 96Well Thermal Cycler (Thermo Fisher Scientific, Waltham, MA).
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Figure 11. CytoScan™ PCR protocol. This figure outlines the reagents and Thermal
Cycler program for PCR. A) Reagents and volumes used for the PCR master mix. B)
The thermal cycler program used and performed on a Veriti™ 96-Well Thermal Cycler
(Thermo Fisher Scientific, Waltham, MA).
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Waltham, MA) and was run on a pre-set PCR Program [Figure 11B]. A 3 µl aliquot of
PCR product from each well was pulled from the 96-well plate, and diluted with 17 µl of
nuclease-free water for a total of 20 µl. The diluted PCR reaction was loaded in a precast 2% E-Gel® (Thermo Fisher Scientific, Waltham, MA), and run with an E-Gel®
PowerBase™ Electrophoresis System (Thermo Fisher Scientific, Waltham, MA). A USB
PCR marker 50 – 2000 bp ladder (Affymetrix®, Santa Clara, CA) was used as the
control. The 2% E-Gel® was imaged using the Gel Doc™ EZ Gel Documentation System
(Bio-Rad, Hercules, CA). The average PCR product distribution was determined to be of
sufficient quality when the average product distribution was between 150 - 2000 bp
[Figure 12].
PCR Purification
After confirming the PCR product on the 2% E-gel®, the PCR product was
purified [Figure 13]. First, the PCR plate was vortexed and spun down for 1 minute.
Next, 1.5 ml Eppendorf tubes were labeled according to each sample in the PCR plate.
All four aliquots of each sample were pooled and transferred to the Eppendorf tube. The
negative control was discarded. Next, 720 µl of purification beads were added to each
pooled sample and then capped and inverted 10 times. After inverting the tubes, each
tube incubated at room temperature for 10 minutes, which allowed the DNA to bind to
the purification beads. After the incubation period, the tubes were spun in a
microcentrifuge for three minutes at 1600 RPM. The Eppendorf tubes were placed on a
MagnaRack (Life Technologies, Carlsbad, CA) until all of the pellets moved to the
magnet. After this, the supernatant was aspirated and discarded without disturbing the
bead pellet. Then, 1 µl of purification wash buffer was added to each tube, vortexed for
two minutes, and centrifuged at 1600 RPM for three minutes. The tubes were then
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Figure 12. Quality check of the PCR product using a 2% E-Gel ®. After PCR was
completed, a 3 µl aliquot of each PCR product was pulled from the 96-well plate and
diluted with 17 µl of nuclease-free water, which was then loaded on a pre-cast 2% EGel® (Thermo Fisher Scientific, Waltham, MA). A USB PCR marker 50 – 2000 bp ladder
(Affymetrix®, Santa Clara, CA) was used. The PCR was determined to be successful if
the average product distribution was between 150 – 2000 bp.
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Figure 13. PCR purification. After confirming the quality of the PCR product with a 2%
E-gel®, each PCR product was purified using Purification Beads (Affymetrix®, Santa
Clara, CA) and a MagnaRack (Life Technologies, Carlsbad, CA). A) After washing, the
tubes were removed from the rack, and Elution Buffer (Affymetrix®, Santa Clara, CA)
was added to each tube. The eluted product was then used for quantitation. B) A
MagnaRack (Life Technologies, Carlsbad, CA) was utilized during the magnetic
separation and wash steps, and to separate the magnetic beads from the eluted, purified
DNA for seven samples at a time.
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placed back on the MagnaRack (Life Technologies, Carlsbad, CA) until all of the pellets
moved to the magnet. The supernatant was pipetted off, and the tubes were centrifuged
at 1600 PRM for 30 seconds and placed back on the MagnaRack (Life Technologies,
Carlsbad, CA) to remove any remaining drops of the purification wash buffer. The tubes
were then removed from the MagnaRack (Life Technologies, Carlsbad, CA), and any
remaining purification wash buffer evaporated at room temperature for 10 minutes.
Then, 52 µl of elution buffer was added to each tube directly onto the beads. The tubes
were vortexed for 10 minutes to resuspend the purification beads and elution buffer and
then centrifuged at 1600 RPM for three minutes and placed on the MagnaRack (Life
Technologies, Carlsbad, CA) for 10 minutes. Once all of the beads moved to the side of
the tube, a volume of 47 µl of the eluted sample was transferred to the appropriate well
on a new 96-well plate.
Quantitation
A NanoDrop™ ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham,
MA) was used to verify the yield of each purified PCR product before fragmentation. A 2
µl aliquot of each purified PCR product was pulled from the fragmentation plate and was
added to 18 µl of nuclease-free water, and this dilution was used for quantitation. The
NanoDrop™ ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA) used
2 µl of diluted and purified PCR product and measured the concentration of the DNA as
well as optical densities at 260, 280, and 320. The average acceptable yield of DNA that
was used for fragmentation was ≥ 3 µg/µl. The A260/A280 ratio, used to assess the
purity of the nucleic acids, was acceptable between 1.8 and 2.0.
Fragmentation
Fragmentation of the purified PCR product was performed after determining that
the yield of each purified product was of sufficient quality. A fragmentation master mix
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was prepared [Figure 14A], and 10 µl of the master mix was added to 45 µl the purified
DNA product to make a total of 55 µl in each well. The plate was sealed, vortexed, spun
down, and loaded on a preheated Veriti™ 96-Well Thermal Cycler (Thermo Fisher
Scientific, Waltham, MA) and was run on a pre-set fragmentation program [Figure 14B].
Following fragmentation, 4 µl of each fragmented product was removed from the 96-well
plate and diluted with 28 µl of nuclease-free water to make a 1:8 dilution. After
thoroughly mixing and spinning down the 1:8 dilution, an aliquot of 8 µl of each 1:8
dilution of the fragmented product was added to 12 µl of nuclease-free water to make a
1:1000 dilution. This dilution was used to run a pre-cast 4% E-Gel® (Thermo Fisher
Scientific, Waltham, MA) and run with an E-Gel® PowerBase™ (Thermo Fisher Scientific,
Waltham, MA) Electrophoresis System (Thermo Fisher Scientific, Waltham, MA) to verify
the quality of the fragmented product. A dilution of the TrackIt 25 bp DNA ladder (Life
Technologies, Carlsbad, CA) was prepared using 2 µl of the ladder and 28 µl of
nuclease-free water. A volume of 20 µl of each 1:1000 dilution of the fragmented product
was loaded onto the 4% E-Gel®, with 15 µl of the diluted TrackIt 25 bp DNA ladder
(Life Technologies, Carlsbad, CA) in lanes 1 and 12 to determine the product
distribution. The 4% E-Gel® was imaged using the Gel Doc™ EZ Gel Documentation
System (Bio-Rad, Hercules, CA). The fragmented PCR products were considered to be
of sufficient quality when the majority of the product was between 25 – 125 bp [Figure
15].
Labeling
Next, the fragmented samples were labeled using terminal deoxynucleotidyl
transferase enzyme (TdT). A labeling master mix was prepared with 5X TdT buffer, 30
mM DNA labeling reagent, and TdT [Figure 16A]. An aliquot of 19.6 µl of
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Figure 14. CytoScan™ Fragmentation protocol. This figure outlines the reagents and
Thermal Cycler program for the fragmentation step. A) The fragmentation master mix
reagents and volumes used. B) The thermal cycler program used and performed on a
Veriti™ 96-Well Thermal Cycler (Thermo Fisher Scientific, Waltham, MA).
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Figure 15. Quality check of fragmentation product using a 4% E-Gel ®. After
fragmentation, a dilution of each fragmented product was used to run a pre-cast 4% EGel® (Thermo Fisher Scientific, Waltham, MA). A dilution of the TrackIt 25 bp DNA
ladder (Life Technologies, Carlsbad, CA) was used. The fragmentation product was of
sufficient quality when the majority of the product was between 25 – 125 bp.
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Labeling Master Mix was added to 51.0 µl of each sample in the 96-well plate for a total
volume of 70.5 µl. The plate was then sealed, vortexed, spun down, and loaded on a
preheated Veriti™ 96-Well Thermal Cycler (Thermo Fisher Scientific, Waltham, MA) and
was run on a pre-set labeling program [Figure 16B].
Hybridization
Following the labeling protocol, a hybridization master mix was prepared [Figure
17A]. Next, 190 µl of hybridization master mix was added to each well in the 96-well
plate that contained the labeled product, and the plate was sealed, vortexed, and spun
down. The plate was loaded on a preheated Veriti™ 96-Well Thermal Cycler (Thermo
Fisher Scientific, Waltham, MA) and was run on a pre-set hybridization program [Figure
17B]. During the hybridization program, the CytoScan™ HD arrays were labeled and
prepared to receive the hybridized product. A 200 µl pipette tip was placed in the upper
right septa of each CytoScan™ HD array for venting. When the Thermal Cycler program
was finished, the plate was held at 49°C for at least one minute, and the lid was opened
on the Veriti™ 96-Well Thermal Cycler (Thermo Fisher Scientific, Waltham, MA). An
aliquot of 200 µl from each hybridized sample in the 96-well plate was injected into each
corresponding array and immediately sealed with ½” Tough-Spots® (Diversified Biotech,
Boston, MA). The arrays were then loaded into trays in the hybridization and rotated at
50°C and 60 RPM for 16 - 18 hours.
Washing and Staining
The GeneChip® Fluidics Station 450 (Affymetrix®, Santa Clara, CA), controlled by
the Affymetrix® GeneChip® Command Center (Affymetrix®, Santa Clara, CA), was used
to wash and stain the arrays. The GeneChip® Fluidics Station 450 (Affymetrix®, Santa
Clara, CA) was primed before washing to ensure the lines of the station were filled with
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Figure 16. CytoScan™ Labeling protocol. This figure outlines the reagents and
Thermal Cycler program for labeling. A) The labeling master mix reagents and volumes
used. B) The thermal cycler program used and performed on a Veriti™ 96-Well Thermal
Cycler (Thermo Fisher Scientific, Waltham, MA).
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Figure 17. CytoScan™ Hybridization protocol. This figure outlines the reagents and
Thermal Cycler program for hybridization. A) The hybridization master mix reagents and
volumes used. B) The thermal cycler program used and performed on a Veriti™ 96-Well
Thermal Cycler (Thermo Fisher Scientific, Waltham, MA). Biotech, Boston, MA) were
then removed from each array, and the reagent remaining inside the array was removed
and returned to the corresponding wells in the 96-well plate in case of a failed
hybridization. Then the arrays were loaded into the GeneChip® Fluidics Station 450
(Affymetrix®, Santa Clara, CA).
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the appropriate buffers and were ready to run the designated protocol. Three types of
buffer were used for each array. An aliquot of 500 µl of Stain Buffer 1, 500 µl of Stain
Buffer 2, and 1000 µl of Array Holding Buffer were each put in 1.5 ml centrifuge tubes
and loaded on the fluidics station. The hybridized arrays were removed from the
hybridization oven between 16- and 18-hours from the time of incubation. The ToughSpots® (Diversified Biotech, Boston, MA) were then removed from each array, and the
reagent remaining inside the array was removed and returned to the corresponding wells
in the 96-well plate in case of a failed hybridization. Then the arrays were loaded into the
GeneChip® Fluidics Station 450 (Affymetrix®, Santa Clara, CA).
Scanning
After the wash and stain protocol is complete, the arrays were removed, checked
for air bubbles, and loaded into the Affymetrix® GeneChip® Scanner 3000 7G
(Affymetrix®, Santa Clara, CA). After air bubble removal, the septa on the arrays were
closed using Tough-Spots® (Diversified Biotech, Boston, MA). The Affymetrix®
GeneChip® Scanner 3000 7G (Affymetrix®, Santa Clara, CA), controlled by the
Affymetrix® GeneChip® Command Center (Affymetrix®, Santa Clara, CA), was used to
scan each array. The .CEL files generated by the scanner were processed to CYCHP
files for analysis in the Chromosome Analysis Suite (ChAS) software (Applied
Biosystems, Thermo Fisher Scientific, Waltham, MA).
Affymetrix® CytoScan™ HD Array Analysis Using Chromosome Analysis Suite
Software (ChAS)
Chromosome Analysis Suite (ChAS) software (Applied Biosystems, Thermo
Fisher Scientific, Waltham, MA) was used to analyze and export patient array results
from the Affymetrix GeneChip® Scanner 3000 7G (Affymetrix®, Santa Clara, CA). A filter
was created for uniform analysis of gains, losses, and LOH, and was applied to each
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case. A gain was defined as a marker count of 25 with a size of 10 kbp. A loss was
defined as a maker count of 20, with a size of 5 kbp. LOH was defined as having a
marker count of 50, and a size of at least 3000 kbp. The analysis was performed using
the ChAS software, which flagged aberrations identified in each chromosome. Manual
inspection of the Allele Peaks and Smooth Signal tracks were performed on each
chromosome to determine gains and losses that were not flagged by the analysis
software automatically or to confirm the size of the aberration that was recognized by the
ChAS software [Figure 18]. The Allele Peaks track was also useful in detecting
instances of LOH and copy-neutral LOH (CN-LOH) [Figure 19]. In addition to the
standard analysis tracks, several tracks were loaded into the ChAS software to aid in
determining if variations were of benign or pathogenic origin. The Database of Genomic
Variants (DGV), the HCBI Database for Genomic Structural Variants (dbVAR), Fullerton
Common AOH Blocks, and Common AOH Hispanics, and the Fullerton and Cooper
overlap map for recurring deletion/duplication regions were used to assess the
significance of the genomic imbalance. Copy-number alterations (CNAs) were
determined to be benign if there were no genes in the region of interest, if they
overlapped with common constitutional deletion and duplication regions, or if they
overlapped with the DGV or dbVAR tracks. Variants of clinical significance were noted in
accordance with the ACMG
technical standard for reporting acquired copy-number abnormalities (Mikhail et al.,
2019). CN-LOH was also assessed and classified as an area greater than 10 Mb of
segmental loss of heterozygosity with a diploid copy-number state. The UCSC Genome
Browser (University of California Santa Cruz), human assembly build GRCh37/hg19,
was also used to visualize gains and losses.
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Figure 18. Detecting chromosomal gains and losses in ChAS. Tracks that were
used to manually assess gains and losses in the Chromosome Analysis Suite (ChAS)
software (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA) are shown. This
figure shows a telomeric deletion of chromosome 1 from band q41 – q44. A) The Copy
Number State track highlights areas of chromosomal gain or loss as indicated by blue
regions for gain and red regions for loss. However, this track that is flagged
automatically by the ChAS software is not reliable in assessing breakpoints in every
aberration. B) The Allele Peaks track should have a 1:1 ratio when the copy number
state is 2. In the red box, the copy number state is less than 2, which can be appreciated
by the “pinched” track. C) The Smooth Signal track can also be used to assess copy
number state. In the blue box, the copy number state is less than 2, which indicates a
chromosomal loss.
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Figure 19. Assessing regions of copy-neutral LOH (CN-LOH). Tracks that were used
to manually determine instances of loss of heterozygosity in the Chromosome Analysis
Suite (ChAS) software (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA) are
shown. This figure shows the profile of chromosome 11. A) The outside tracks of the
Allele Peaks track are in a 1:1 ratio, which indicates no chromosomal loss. However,
loss of the middle track over the long arm of chromosome 11 (highlighted by a blue box)
indicates an area of copy-neutral LOH. B) The Smooth Signal track notes no
chromosomal loss but is not able to appreciate areas of CN-LOH.
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Clinical Comparisons and Statistical Methods
To determine the impact of 14q32 abnormalities on clinical outcomes, we
compared cases that had a 14q deletion as a sole abnormality and also those with
additional abnormalities with cases that contained a sole abnormality with known
prognostic effects or cases that did not have any abnormalities as determined by FISH
studies. A subset of 115 CLL cases with available clinical follow-up history was utilized
for this analysis. We compared different groups to determine and compare the
distribution for time-to-first-treatment (TTFT) and also analyzed overall survival (OS). All
cases included in the clinical comparisons had FISH studies performed that included the
analysis of the IGH dual-color break-apart probe. Two groups were created based on the
type of 14q32 deletions present in each study. In group 1, only cases with a 5’ telomeric
14q32 deletion and no instances of a 3’ centromeric 14q32 deletion were included in the
analysis of 14q32 deletions and in group 2, cases that contained either a 5’ telomeric or
3’ centromeric 14q32 deletion or cases that contained both a 5’ telomeric and 3’
centromeric 14q32 deletion were included in the analysis. In each of these two groups,
cases that contained a 14q32 deletion were categorized into three subsets, 1) those that
had a 14q32 deletion as the sole cytogenetic alteration, 2) those that had a 14q32
deletion and one additional change with known prognostic impact (trisomy 12 or
deletion/nullisomy 13q14), and 3) those that had a 14q32 deletion with two or more
additional FISH abnormalities. These subsets from each group were compared with
cases that have sole abnormalities with known prognostic significance including 1) cases
with a deletion or nullisomy of 13q14 that is known to confer a good prognosis for CLL
cases, 2) cases that had trisomy 12 as a sole abnormality 3) cases with normal FISH
results with no detectable FISH abnormality, and 4) cases that contained either a
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11q22.3 (ATM) or 17p13.1 (TP53) deletion as a sole abnormality, which are known to
confer an inferior prognosis among CLL cases.
The Kaplan-Meier method was used for comparisons and assessment of
statistical significance. We assessed TTFT and OS for each group that was
distinguishable by the 14q32 deletions present. For these clinical comparisons, TTFT
was defined as the time from diagnosis to the start of therapy. Some cases in this cohort
were initially following a watch-and-wait protocol and eventually progressed to needing
treatment. For these cases, TTFT was defined as the time from diagnosis to the time of
the first indication for therapy, which is when these patients started treatment. Those
cases that were still following a watch-and-wait protocol at the last follow-up were
censored. OS was defined as the time from diagnosis to death or last follow-up, with
cases censored if they were alive at the time of the last follow-up. The log-rank test was
used to compare survival distributions with regard to cytogenetic findings. P-values
≤0.05 were considered statistically significant. Statistical analyses were performed with
the SAS software version 9.4 (SAS Institute Inc., Cary, NC).
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CHAPTER 3: RESULTS
Retrospective Analysis
A retrospective analysis of cytogenetics and FISH studies was performed to
determine the incidences of various genetic abnormalities associated with CLL. These
aberrations were observed as sole occurrences, as well as in combination with other
abnormalities. From 2010 to 2019, a total of 698 bone marrow or peripheral blood
specimens were submitted for cytogenetic and/or FISH studies at the Human Genetics
Laboratory at the University of Nebraska Medical Center. A diagnosis of CLL or SLL was
confirmed as appropriate by flow cytometry or histologic examination of bone marrow or
nodal biopsies. Conventional cytogenetics and/or FISH studies were performed in each
case, as indicated by the oncologist, to identify cytogenetic abnormalities. Of the 698
cases, 268 were from women with a mean age of 69.2 years, and 430 cases were from
men with a mean age of 68.5 years at the time of specimen collection [Figure 20].
Abnormalities Detected by Conventional Cytogenetics and FISH
Conventional cytogenetic studies were performed on 90% (625/698) of cases.
Abnormal karyotypes were observed in 44% (274/625) of these cases, with no
abnormalities detected in the remaining 351 (56%; 351/625) cases. The loss of a sex
chromosome was observed in 8% (23/274) of the abnormal cases and was observed as
a sole abnormality in these cases [Table 5]. Loss of the Y chromosome has been
associated with advanced age but is considered disease-related when the loss is
observed in greater than 75% of cells that were analyzed (Wiktor et al., 2000). The age
range of the 23 males with Y chromosome loss as a sole abnormality was 60 – 88 years
with a mean
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Figure 20. Age range and sex distribution among 698 cases. In the retrospective
analysis, 430 males with an average age of 68.5 years and 268 females with an average
age of 69.2 years were studied. The age range was from 29 – 96 years, with the highest
prevalence occurring in the 6th and 7th decades of life.
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Table 5. Results of conventional cytogenetics by G-banded karyotyping.
Conventional cytogenetic studies were performed in 90% (625/698) cases. A normal
karyotype was observed in 351 cases (56%). An abnormal karyotype was observed in
274 cases (44%), with 23 of these cases having a sex chromosome abnormality as the
only cytogenetic alteration.
Karyotype Results

Number of Cases (%)

Normal Karyotype

351 (56)

Abnormal Karyotype

274 (44)

45,X,-Y

23

Total with Conventional
Cytogenetics

625
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age of 77 years. The loss of the Y chromosome was identified with normal FISH results
in 61% (14/23) of these cases. Of the 23 cases with sole Y chromosome loss, only four
of these cases (17%; 4/23) had lost the Y chromosome in greater than 75% of cells by
conventional cytogenetics. Two of the four cases with Y chromosome loss in greater
than 75% of cells were found to otherwise be normal by FISH studies. A total of 146
cases were found to have a sole abnormality by karyotype (53%; 146/274), which
included 23 cases with loss of the Y chromosome. The most common sole abnormality
identified by a karyotype was trisomy 12, which occurred in 45 cases (31%; 45/146).
Conventional cytogenetics also identified deletions of 6q, 11q, 13q, 14q, and 17p,
among other abnormalities. Two abnormalities in a single karyotype were observed in
19% (53/274) of cases, and three or more abnormalities, indicating a complex karyotype,
were observed in 27% (75/274) of cases with an abnormal karyotype [Figure 21]. FISH
studies were performed on 99% (696/698) of cases in this cohort. Abnormal FISH results
were observed in 77% of cases (536/696), with no abnormalities detected by FISH in the
remaining 160 cases [Table 6]. Of the 536 cases that were determined to be abnormal
by FISH, 46% (247/536) of the cases exhibited a sole abnormality by FISH, 35%
(188/536) of abnormal cases had two abnormalities, and three or more abnormalities
were in the remaining 19% (101/536) of cases [Figure 22].
Conventional cytogenetics and FISH were performed in combination in 89%
(623/698) of cases. A normal karyotype and normal FISH studies were observed in 131
cases (21%; 131/623). Abnormal results were detected by one or both assays in 492
cases (492/623). An abnormal karyotype was observed in 4% (22/492) of cases with
normal FISH studies (with 14 (64%; 14/22) of these cytogenetically abnormal cases
involving a sex chromosome abnormality). A normal karyotype and abnormal FISH
results were observed in 45% (219/492) of cases. An abnormal result was detected by
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Figure 21. Number of detected cytogenetic abnormalities by karyotype. A total of
274 cases had an abnormal karyotype. The majority of cases had a sole cytogenetic
abnormality (53%; 146/274), and 23 of these cases exhibited loss of a sex chromosome
by karyotype. Two cytogenetic abnormalities were identified in 53 cases (19%; 53/274),
and 75 cases (27%; 75/274) had three or more cytogenetic abnormalities by karyotype.
A normal karyotype was observed in 351 cases.
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Table 6. Results of FISH studies. FISH studies were performed in 696 cases. Normal
FISH studies were observed in 160 (23%; 160/696) cases, while the majority of cases
had abnormal FISH results (77%; 536/696).

FISH Results

Number of Cases (%)

Normal

160 (23)

Abnormal

536 (77)

Total with FISH

696
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Figure 22. Number of detected FISH abnormalities. A total of 536 cases had
abnormal FISH results, 247 (46%; 247/536) of the cases exhibited a sole abnormality by
FISH, 188 (35%; 188/536) of the abnormal cases had two abnormalities, and three or
more abnormalities were in the remaining 101 (19%; 101/536) cases. FISH studies were
normal in 160 cases.
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both of these assays in 251 cases (51%; 251/492) [Table 7]. The abnormality rate for
karyotype detection was 44% (22+251 = 273/623), while the abnormality rate for FISH
studies was 75% (219+251 = 470/623). The combined use of both techniques increased
the abnormality detection rate to 79% (492/623). However, in the majority of cases with
an abnormal karyotype and normal FISH studies, the only abnormality detected by
karyotype was the loss of the Y chromosome.
Known Recurrent CLL Abnormalities
FISH studies for a selection of probes specific to recurrent abnormalities
observed in CLL were utilized to assess each case [Table 8]. Sole abnormalities were
detected by FISH in 46% (247/536) of cases [Figure 23]; however, the majority of cases
(54%; 289/536) had more than one abnormality detected by FISH studies. Deletion of
13q14 was detected as a sole FISH abnormality in 35% (86/247) of cases and was the
most common sole abnormality detected by FISH studies. Nullisomy 13q14, involving
deletion of 13q14 in both chromosome 13 homologs, was observed in significantly fewer
cases as a sole abnormality [Figure 23]. Overall, the deletion of 13q14 or nullisomy
13q14 was the most common FISH abnormality observed and was detected in 307
cases (58%; 307/536) [Figure 24]. Trisomy 12 was observed by FISH in 151 abnormal
cases (28%; 151/536) [Figure 25]. As a sole abnormality, Trisomy 12 was the second
most frequent sole FISH abnormality and was observed in 23% (57/247) of cases.
However, trisomy 12 was the most common abnormality observed by karyotype in the
cases with sole FISH abnormalities because it is easily detected by karyotype [Figure
23]. In contrast, many of the other CLL abnormalities are submicroscopic and are
manifested only by FISH studies. Conventional cytogenetics was studied in 91% (52/57)
of the cases with a sole trisomy 12 abnormality by FISH and was detected by karyotype
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Table 7. Abnormal cases detected from 623 cases that were studied by both
conventional cytogenetics and FISH studies. Cytogenetics and FISH were studied in
combination in 623 cases, and 79% (492/623) of these cases were determined to be
abnormal by one or both assays. Both cytogenetics and FISH were abnormal in 40%
(251/623) cases. An abnormal karyotype was observed in 44% (22+251 = 273/623;
44%) of cases and abnormal FISH was observed in 77% (219+251 = 480/623; 77%).
The combined use of both techniques increased the abnormality detection rate to 79%.
Number of
Abnormal Cases

Percentage of
Abnormal Cases (%)

Abnormal Karyotype and Normal FISH

22

4

Normal Karyotype and Abnormal FISH

219

35

Abnormal Karyotype and FISH

251

40

Total Number of Abnormal Cases by
One or Both Assays

492

79

Type of Study
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Table 8. Incidence of abnormalities in 696 cases studied with FISH. This table
shows the overall detection rate of abnormalities associated with CLL in 536 cases with
abnormal FISH results. Cases were characterized by a sole FISH abnormality, or by
multiple abnormalities. A deletion or nullisomy 13q14 was seen in nearly 60% of
abnormal cases. Normal FISH results were observed in 160 cases.

FISH Results

Number of Cases (%)
n = 696*

Deletion or Nullisomy 13q14

307 (44)

14q32 Abnormality

245 (35)

Trisomy 12

149 (21)

Deletion 11q22.3 (ATM)

53 (8)

Deletion 17p13.1 (TP53)

49 (7)

Deletion 6q21 or 6q23 (MYB)

15+ (2)

Normal FISH

160 (23)

*Multiple abnormalities could be detected in a single case.
+
Although the 6q23 (MYB) FISH probe was not utilized in 215 cases, the percentage
is based on 696 cases with FISH results.

Figure 23. Sole abnormalities identified by FISH analysis. Sole abnormalities were detected by FISH in 247
cases. The three most commonly occurring sole abnormalities were (1) a deletion of 13q14 in 35% (86/247) case,
(2) trisomy 12 in 23% (57/247) of cases, and (3) abnormalities of 14q32 in 21% (53/247) of cases, with the majority
having a 14q32 deletion.
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Figure 24. Cytogenetics and FISH images of deletion/nullisomy 13q14. A)
Conventional cytogenetics image illustrating an interstitial deletion of 13q14. B)
Idiograms of the Copy Control 12 Clear-View TM FISH probe (12 centromere), and the
Vysis LSI D13S319 (13q14.3) and Vysis LSI 13q34 (13q14) probes. C) An interphase
cell with loss of one red signal, indicating a 13q14 deletion. D) An interphase cell with
loss of both red signals, indicating nullisomy 13q14.
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Figure 25. Cytogenetics and FISH images of trisomy 12. A) Conventional
cytogenetics image illustrating three copies of chromosome 12. B) Idiograms of the
CymoGen Dx Copy Control 12 probe for 12 centromere and the Vysis LSI D13S319
(13q14.3) and Vysis LSI 13q34 (13q14) probes. C) An interphase cell with three aqua
signals (white arrows), indicating trisomy 12, as well as two normal copies of 13q
(red/green signals).
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as a sole abnormality or with additional chromosomal aberrations in 79% (41/52) of
these cases. Deletions of 11q22.3 (10%; 53/536) [Figure 26] and 17p13.1 (9%; 49/536)
[Figure 27] were observed at a similar frequency in cases with abnormal FISH results.
Deletions of 11q22.3 (4%; 10/247) and 17p13.1 (2%; 5/247) were observed as a sole
abnormality by FISH in very few cases [Figure 23], highlighting the rare occurrence of
these deletions without other chromosomal abnormalities. Complex karyotypes, which
associated with advanced disease stages, were observed with a sole deletion of 11q or
17p by FISH in 27% of cases (4/15). This further implies that neither of these
abnormalities are primary genetic changes in CLL. Deletions of 6q23 were detected by
FISH in 15 cases; however, the introduction of the LSI MYB (6q23) FISH probe to the
CLL FISH panel did not occur until late 2012 and was not studied by FISH in 215 cases
[Figure 28]. Only three cases had a sole deletion of 6q that was detected by FISH
[Figure 23].
Abnormalities of 14q32 (IGH Gene Region)
An abnormality of the IGH gene region at chromosome 14q32 was the second
most common type of abnormality observed overall in this study cohort. Various
aberrations involving 14q32 were detected either as a sole abnormality or in combination
with other genetic alterations in 46% (245/536) of cases with abnormal FISH studies. Of
the 245 cases with 14q32 abnormalities, 81% (199/245) had a deletion of 14q32, 10%
(25/245) had a 14q32 rearrangement, 3% (8/245) had multiple partial deletions of 14q32
involving the same or different chromosome 14 homologs, 3% (7/245) had a loss of one
copy of 14q32, and less than 1% (1/245) had a gain of one copy of 14q32 by FISH
analysis. Deletion of 14q32 and a rearrangement of 14q32 occurring on one or both
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Figure 26. Cytogenetics and FISH images of deletion of 11q22.3 (ATM). A)
Conventional cytogenetics image illustrating an interstitial deletion of 11q. B) Idiograms
of the Repeat-Free™ Poseidon™ p53 (17p13) and ATM (11q22.3) probes. C) An
interphase cell with one red signal, indicating the loss of 11q22.3 (ATM), and two normal
copies of 17p (green signals).
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Figure 27. Cytogenetics and FISH images of deletion of 17p13 (TP53). A)
Conventional cytogenetics image illustrating an isochromosome 17q resulting in the loss
of one copy of 17p. B) Idiograms of the Repeat-Free™ Poseidon™ p53 (17p13) and
ATM (11q22.3) probes. C) An interphase cell with one green signal, indicating the loss of
17p13 (TP53), and two normal copies of 11q (red signals).
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Figure 28. Cytogenetics and FISH images of deletion of 6q23 (MYB). A)
Conventional cytogenetics image illustrating an interstitial deletion of 6q. B) Idiograms of
the LSI MYB (6q23) probe hybridizes and the LSI IGH Dual-Color Break-Apart Probe
(14q32). C) An interphase cell with one aqua signal, indicating the loss of 6q23 (MYB),
and two normal copies of 14q (red and green signals).

90

homologs were detected in 2% of cases (5/245) [Table 9]. Conventional cytogenetic
analysis was performed on 218 (89%; 218/245) cases, but only detected an abnormality
or loss of chromosome 14 in 39 of these cases (18%; 39/218), which highlights the
importance of FISH studies in detecting a 14q32 abnormality, and most often a 14q32
deletion, in these cases. Sole abnormalities of 14q32 were identified by FISH in 53
cases (22%; 53/245), with the majority of cases having a deletion of 14q32 (83%; 44/53)
[Figure 23]. However, if we include three cases that had multiple partial deletions of
14q32 as the only abnormalities, the number of cases with a sole 14q32 abnormality
increases to 56 cases.
FISH distinguished between deletions of the 3’ (centromeric) and 5’ partial or
complete deletions (telomeric) of 14q32 with the use of a dual-color break-apart probe
[Figure 29A]. Although the two 3’ centromeric and 5’ telomeric 14q32 FISH probes
fluoresce red and green respectively, when both signals are intact and juxtaposed
together, a yellow fusion signal is apparent for a normal copy of 14q32 when using the
LSI IGH Dual-Color Break-Apart probe (Abbott Molecular). The LSI MYB (6q23) probe is
used in combination with the dual-color break-apart 14q32 probe and fluoresces in aqua
in this hybridization area. An interphase cell with two normal copies of 14q32 (IGH gene
region) is shown in Figure 29B. FISH distinguished 5’ telomeric 14q32 deletions as
either having partial or complete loss by analyzing the presence or absence of a
diminished green probe signal corresponding to the probe spanning the length of the 5’
variable region of IGH. The presence of a diminished green signal on the telomeric
portion of the 14q32 FISH probe suggests that there is still a portion of the variable
region that remains. A 5’ partial deletion of 14q32 was called by FISH when there was
one red signal and one green signal (or yellow fusion), which represents the normal copy
of 14q32, and one normal red signal with a diminished green signal, which represents
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Table 9. Types of 14q32 (IGH) abnormalities observed by FISH.Various
abnormalities of 14q32 were detected either as a sole abnormality or in combination with
other genetic alterations in 46% (245/536) of cases with abnormal FISH studies. The
most frequently occurring IGH abnormalities was a deletion of 14q32 in 199 cases, with
eight additional cases having multiple 14q32 deletions.
14q32 (IGH) Abnormalities
14q32 Deletion
5’ Telomeric Partial 14q32 Deletion
5’ Telomeric Complete 14q32 Deletion
3’ Centromeric 14q32 Deletion

Number of Cases (n = 245)
199
163
19
17

Multiple Partial 14q32 Deletions

8

14q32 Rearrangement

25

14q32 Deletion and Rearrangement

5

Loss of One Copy of 14q32

7

Gain of One Copy of 14q32

1
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the abnormal copy of 14q32 [Figure 29C]. This signal pattern indicating a 5’ partial
14q32 deletion of one copy of 14q32 was observed in 82% (163/199) of cases with
14q32 deletions. Conventional cytogenetic analysis was utilized in 139 (85%; 139/163)
of the cases with a 5’ partial deletion of 14q32, but the 14q32 deletion was only identified
by a karyotype in four cases. A 14q32 deletion was determined to be the sole
abnormality in 18% (44/245) of cases with a 14q32 abnormality, with a partial deletion of
the 5’ (telomeric) portion of the IGH gene region occurring in 73% (32/44) of cases with a
sole deletion of 14q32 [Figure 23]. A complete deletion of the 5’ telomeric portion of
14q32 was called by FISH when there was one red and one green signal (or yellow
fusion) to represent the normal copy of 14q32, and one normal red signal with no green
signal, which represents the abnormal copy of 14q32 [Figure 29D]. Complete 5’
telomeric deletions were observed in 19 cases (10%; 19/199) with a 14q32 deletion. A
karyotype was studied in a majority of these cases (95%; 18/19) cases with 5’ complete
deletions of 14q32, but a 14q32 abnormality was only identified by karyotype in one
case. A 5’ complete 14q32 deletion was only observed as a sole FISH abnormality in
four cases. For both types of 5’ 14q32 deletions, analysis of a karyotype identified
identify large deletions of 14q32, additional material of unknown origin on 14q32, or loss
of a whole copy of 14, which could all result in 5’ partial or complete loss of 14q32
detected by FISH.
Deletion of the 3’ centromeric region of 14q32, was called by FISH when there
was one red and one green signal (or yellow fusion) to represent the normal copy of
14q32, and one normal green signal with no red signal, which represents the abnormal
copy of 14q32 [Figure 29E]. The 3’ centromeric deletion was observed by FISH in 9%
(17/199) of cases with an IGH deletion. A karyotype was studied in 16 of these 17 cases.
A large deletion of chromosome 14 was observed by conventional cytogenetics in ten
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Figure 29. Interphase nuclei hybridized with the LSI IGH Dual-Color Break-Apart
Probe and LSI MYB (6q23) Probe. Two probes are used in this hybridization area. The
LSI MYB (6q23) probe hybridizes to chromosome 6 at band q23 and fluoresces in aqua.
The LSI IGH Dual-Color Break-Apart Probe (14q32). This probe hybridizes to
chromosome 14 at band q32 and includes the IGH gene region. A) The LSI IGH DualColor Break-apart probe maps for 14q32 are shown. The red signal flanks the 3’ end of
the constant region (C) of the IGH gene region, and the green signal is located in the 5’
variable region (V) of IGH. B) A normal interphase cell hybridized with the LSI IGH DualColor Break-Apart probe. Two intact green signals (5’ end) and two intact red signals (3’
end) are observed. C) An abnormal interphase cell with a white arrow showing a
diminished 5’ (green) signal on one chromosome 14 homolog, which represents a 5’
partial deletion of 14q32. D) An abnormal interphase cell with a white arrow showing the
loss of one complete 5’ (green) signal. E) An abnormal interphase cell hybridized with a
white arrow pointing to the green signal representing the intact 5’ IGH region and
deletion of the 3’ signal (no red signal).
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cases with a 3’ centromeric IGH deletion either as a sole abnormality or in combination
with other chromosomal abnormalities. A 3’ centromeric 14q32 deletion was observed as
a sole FISH abnormality in eight cases [Figure 23]. Although a karyotype was studied in
all of these, a 14q32 deletion was visible by conventional cytogenetics in only five cases.
Eight cases (3%; 8/245) involved more than one partial 14q32 deletion on one or
both chromosome 14 homologs. Although some of these cases were also characterized
by recurrent CLL FISH abnormalities, three of these cases had more than one 14q32
deletion as the only abnormalities detected by FISH. Deletion of both the 3’ centromeric
and 5’ partial telomeric region of 14q32 was observed on the same homolog in two
cases [Figure 30B]. Conventional cytogenetics was also able to visualize this large
deletion involving the IGH gene region in both of these cases. A 5’ partial deletion of
14q32 was observed in both chromosome 14 homologs in two cases [Figure 30C]. A
karyotype was studied in both of these cases, but there were no visible aberrations of
14q32 by this method. Three cases had a 3’ centromeric 14q32 deletion on one
homolog, and a 5’ partial 14q32 deletion on the other homolog [Figure 30D]. These
cases were also studied by conventional cytogenetics with no visible 14q32
abnormalities. One case had a loss of one copy of the IGH gene region, with a 5’
complete deletion on the other 14q32 homolog [Figure 30E]. The loss of one copy of the
IGH gene region was represented by additional material of unknown origin on one copy
of 14q32 by conventional cytogenetic karyotyping. Less than 1% of cases had gain or
loss of one copy of 14q32 as a sole FISH abnormality (2/247).
A rearrangement of the IGH gene region is detectable by using the IGH dualcolor break-apart probe, but this probe is not able to identify the translocation partner
involved in the rearrangement. The use of the IGH/CCND1 dual-fusion probe in the CLL
FISH panel was performed by pathologist request in 2010 – 2011 and was permanently

Figure 30. Cases with complex 14q32 FISH results involving one or both 14q32 homologs. A) Idiograms of the LSI
MYB (6q23) probe hybridizes and the LSI IGH Dual-Color Break-Apart Probe (14q32). The red signal flanks the 3’ end of
the constant region (C) of the IGH gene region and the green signal is located in the 5’ variable region (V) of IGH. All
images show two normal copies of 6q23 (aqua). B) An abnormal interphase cell illustrating a 3’ centromeric (red) deletion
and a 5’ partial telomeric (green) deletion as appreciated by a diminished green signal on occurring on the same
homolog. The white arrow points to the diminished green signal indicating a partial deletion and loss of one red signal.
This finding was observed in three cases. C) An abnormal interphase cell showing two diminished green signals which
indicates a 5’ partial telomeric deletion occurring on both homologs of 14q. There are two normal red signals
(centromeric). This finding was observed in three cases. D) An abnormal interphase cell with a 3’ centromeric (red)
deletion on one homolog, and a 5’ partial telomeric deletion illustrated by the diminished green signal occurring on the
other homolog. The white arrow points to one green signal with no red signal (3’ centromeric deletion), and a partial
green signal (5’ partial telomeric deletion) with a normal red signal. This finding was observed in three cases. E) An
abnormal interphase cell with a 5’ complete telomeric deletion of 14q32, resulting in only one red signal, with loss of one
complete copy of the other chromosome 14 homolog. This finding was observed in one case.

95

96

introduced to the CLL FISH panel at the Human Genetics Laboratory in 2012 [Figure
31]. Cases that exhibited an IGH/CCND1 fusion detected by FISH studies excluded from
this study. Additional fusion probes to detect IGH/MYC or IGH/BCL2 fusion were
performed at the request of the clinician, or to confirm cytogenetic findings. In our study,
a rearrangement of the IGH gene region was observed in 10% (25/245) of cases with an
IGH abnormality and without deletion of 14q32, and in 5% (25/536) of cases with
abnormal FISH results. The most frequently occurring rearrangement observed by FISH
was the fusion of IGH/BCL2, or a variant signal pattern (32%, 8/25). A variant IGH/MYC
fusion was observed in one case. In the remaining 16 cases, an unidentified
chromosome segment was involved in the rearrangement with IGH; however, these
cases were negative for the fusion of IGH/CCND1. The IGH/CCND1 dual-fusion probe
was analyzed in 87% (173/199) of cases with a deletion, or multiple deletions of 14q32
and was found to be negative in these cases [Table 10]. There were 26 (13%, 26/199)
cases with a 14q32 deletion that did not have an analysis of the IGH/CCND1 FISH probe
at the time of the study. All eight cases with more than one IGH deletion affecting one or
both 14q homologs were also studied with the IGH/CCND1 dual-fusion probe and were
negative for IGH/CCND1 fusion in these cases. Rearrangements of the IGH gene region
were the sole FISH abnormality in 3% (7/247) of cases.
Deletion of 14q32 and a rearrangement of 14q32 occurring on one or both
homologs was detected in 2% of cases with an IGH abnormality (5/245) [Table 11]. All
of the cases with deletion and rearrangement of 14q32 were studied with the Vysis LSI
IGH/CCND1 XT Dual-Color Dual-Fusion Probes (14q32/11q13). There were five cases
with a 5’ partial 14q32 deletion and a rearrangement of 14q32. One case had a 5’ partial
14q32 deletion and an unidentified IGH rearrangement occurring on the same (or
translocated) homolog. Two cases had a 5’ partial deletion of 14q32 occurring on the
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Figure 31. Cytogenetics and FISH images of an IGH/CCND1 fusion. The most
frequently occurring rearrangement observed by FISH studies in 43% of the cases with
an IGH rearrangement was the fusion of IGH/CCND1 or a variant signal pattern. A)
Conventional cytogenetics image illustrating a balanced translocation involving 11q13
and 14q32. B) Idiograms of the Vysis LSI IGH/CCND1 XT Dual-Color Dual-Fusion
Probes (14q32/11q13). When an IGH/CCND1 fusion is present, the red and green
signals will be very close together, resulting in a yellow signal. C) An interphase cell
hybridized with the LSI IGH Dual-Color Break-Apart probe (red/green) and the LSI MYB
probe (aqua). The split red and green signals indicate a rearrangement of 14q32. D) An
interphase cell hybridized with the LSI IGH/CCND1 Dual-Fusion probe showing two
fusion signals (yellow), one normal copy of 11 (red), and one normal copy of 14 (green).
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Table 10. Results of IGH/CCND1 fusion in cases with deletions of 14q32. A deletion
of 14q32 was detected in 199 cases. A majority of these cases (87%; 173/199) were
also studied with the Vysis LSI IGH/CCND1 XT Dual-Color Dual-Fusion Probes
(14q32/11q13) and were negative for IGH/CCND1 fusion.

5’ Partial
14q32 Deletion

5’ Complete
14q32 Deletion

3’ Centromeric
14q32 Deletion

Negative
IGH/CCND1 Fusion

140

18

15

Positive
IGH/CCND1 Fusion

0

0

0

IGH/CCND1 Fusion
Not Studied

23

1

2

Total

163

19

17
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Table 11. Cases with a 14q32 deletion and rearrangement. There were five cases
that were characterized by both a deletion of 14q32 and a rearrangement of 14q32
involving one or both chromosome 14 homologs. All five cases were negative for
IGH/CCND1 fusion. A deletion and rearrangement of IGH were detected in different
cellular populations in two cases. All cases were further characterized by additional
cytogenetic abnormalities detected by FISH studies.
5’ Partial
IGH Deletion

5’ Complete
IGH Deletion

Unidentified IGH
Rearrangement

IGH/BCL2 Fusion

Translocated Homolog

1

0

Non-Translocated Homolog

2

0

Different Cellular Populations

1

1

Total

4

1
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chromosome 14 homolog without the translocation. The translocation partner involved in
the IGH rearrangement could not be identified in these two cases. One case showed a 5’
partial deletion and a rearrangement of IGH in different cellular populations, which was
distinguishable by the percentage of cells that each abnormality was observed in by
FISH. The 5’ partial telomeric deletion occurred in 43.5% of cells, while the IGH
rearrangement occurred in 10% of cells. There was one case with a 5’ complete 14q32
deletion as well as an IGH/BCL2 rearrangement of 14q32, but these abnormalities also
occurred in different cellular populations. In this study, many different types of IGH
abnormalities were detected by FISH analysis including IGH rearrangements and
gain or loss of one copy of 14q32; however, the majority of cases involved a
deletion of the IGH gene region that resulted in either 3’ centromeric or 5’
complete and partial telomeric deletions.
Frequency of Additional Cytogenetic Changes with 14q32 Abnormalities
Conventional cytogenetics and FISH detected other abnormalities with
prognostic implications in cases with 14q32 deletions [Figure 32]. One additional
abnormality was observed in 49% (94/199) of cases with various deletions of the IGH
gene region [Figure 33]. A karyotype was studied in 90% (85/94) of these cases and
was found to be abnormal in over half of them (53%; 50/94). A 5’ partial deletion of
14q32 was observed in 77 (82%; 77/94) cases, a 5’ complete deletion of 14q32 was
seen in 10 (11%; 10/94) cases, and a 3’ centromeric 14q32 deletion was identified in
seven cases (7%; 7/94). Deletion of 13q14 was the most common additional
abnormality observed in cases with a 5’ partial 14q32 deletion (45%; 35/77) and
with a 5’ complete 14q32 deletion (60%; 6/10). A 3’ centromeric 14q32 deletion was
not observed with a deletion of 13q14 in this group of cases. Nullisomy 13q14 occurred
in a much smaller number of cases for both types of 5’ 14q32 deletion, and wasn’t
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Figure 32. Additional FISH abnormalities observed with 14q32 deletions. Deletions
of 14q32 occurred as a sole abnormality by FISH in 44 cases. One additional
abnormality was detected by FISH in 94 cases with a 5’ partial, 5’ complete, or 3’
centromeric 14q32 deletion. Two additional FISH abnormalities were detected in 51
cases, and three or more additional FISH abnormalities occurred in 11 cases.
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Figure 33. Distribution of additional abnormalities in combination with an IGH
deletion. One additional abnormality was detected by FISH in 94 cases with a 14q32
deletion. A deletion of one homolog of 13q14 was the most common abnormality
associated with deletions of the IGH gene region and occurred in 41 cases. The second
most common abnormality associated with an IGH deletion was trisomy 12, and it
occurred in 33 of these cases.
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observed in any cases with a 3’ 14q32 deletion. Trisomy 12 was the most commonly
observed additional abnormality in cases with a 3’ centromeric deletion (86%; 6/7).
It was also observed in cases with 5’ partial (34%; 26/77) and 5’ complete (10%; 1/10)
14q32 deletions. Deletions of 11q22.3 (ATM) were observed in six cases that had a 5’
partial 14q32 deletion, and deletion of 17p (TP53) was observed in one case with a 5’
partial 14q32 deletion.
A total of 51 (26%, 51/199) cases were observed to have two additional FISH
abnormalities in combination with a 3’ centromeric, 5’ partial, or 5’ complete deletion of
14q32 [Figure 32]. The most frequent combination of abnormalities in this group with
two abnormalities in addition to deletion of 14q32 included a deletion of 13q14 and
nullisomy 13q14 that occurred in 17 cases with 5’ partial and complete 14q32 deletions.
The second most frequent combination of abnormalities in addition to a 5’ partial or 5’
complete deletion of 14q32 included deletion of 11q22.3 and deletion of 13q14. Further,
there were 10 (5%, 10/199) cases that had three or more FISH abnormalities in addition
to a deletion of the IGH gene region [Figure 32]. A karyotype was studied in nine of
these cases and had a complex karyotype (three or more abnormalities) in 56% (5/9) of
these cases.
From this retrospective study, we were able to determine that abnormalities
of 14q32 frequently occur in this cohort of cases, and were the third-most frequent
sole abnormality that was detected by FISH studies. In our study, nearly half of all
cases with abnormal FISH results had an abnormality of 14q32, the majority of
these cases having a deletion of 14q32. Although a single deletion of 14q32
involving the 5’ telomeric or 3’ centromeric portion was the most common 14q32
abnormality, we also observed cases with multiple 14q32 deletions and 14q32
rearrangements with various chromosomal partners. We determined that
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deletions of 13q14 were the most common additional abnormality observed in
cases with a 5’ telomeric 14q32 deletion. Overall, these results from this
retrospective study suggest that FISH studies are the most specific tool that is
used to detect prognostically-relevant cytogenetic abnormalities associated with
CLL. However, both cytogenetics and FISH studies together can impact the
characterization of chromosome abnormalities observed in these cases.
Microarray
The retrospective analysis confirmed that abnormalities involving 14q32 occur
frequently within the population of cytogenetically abnormal cases in this cohort, most
often resulting in a deletion detected by FISH analysis. However, there have been rare
studies that have utilized enhanced detection methodologies to further define the
breakpoints involved in each type of 14q32 deletion and the size of the deletion within
the 14q32 region. To determine the deletion dimensions and the genes located therein,
we investigated 40 cases with available specimen that had a FISH-confirmed deletion of
14q32 by utilizing the Affymetrix® CytoScan™ HD SNP microarray.
Cytogenetics and FISH Results of Cases Studied by Microarray
A subset of 40 bone marrow or unstimulated peripheral blood specimens with
FISH-confirmed 14q32 deletions of various types were further studied with an
Affymetrix® CytoScan™ HD array. The majority of these cases were studied by both
conventional cytogenetics and FISH (73%; 29/40), and 11 of these cases were studied
by FISH only. FISH studies noted a range of hallmark abnormalities associated with
CLL, including deletions of 11q, 13q, and 17p, and trisomy 12. These abnormalities are
considered Tier 1A variants with strong clinical significance as defined by the most
recent American College of Medical Genetics (ACMG) guidelines for technical standards
for acquired copy-number testing (Mikhail et al., 2019). The most common FISH
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abnormalities observed in this subset of cases included deletions of 13q and trisomy 12.
Several types of 14q32 deletions were observed by FISH, including complete deletions
of the 5’ telomeric or 3’ centromeric portions of 14q32, a 5’ partial deletion of 14q32, and
deletions involving both the centromeric and telomeric portions 14q32. A sole deletion of
14q32 was observed by FISH in 11 of the 40 cases. The remaining 31 cases had
additional abnormalities observed by FISH. The most common abnormalities observed
by FISH in addition to deletion of 14q32 were deletions of 13q14 and trisomy 12, but
deletions of 11q and 17p were also observed. A karyotype was studied in 31 cases, with
normal karyotypes observed in 17 cases (55%; 17/31) with a deletion of the IGH gene
region [Table 12]. An abnormal karyotype was observed in 14 cases (45%; 14/31), with
only two of these cases having a visible deletion of 14q32 by karyotype. In several cases
with abnormal karyotypes, complex abnormalities and multiple abnormal clones were
observed.
Variation in Deletions of 14q32 Detected by Microarray
A total of 37 of the 40 cases studied by microarray were found to have a 3’ or 5’
14q32 deletion by FISH studies. These deletions identified by FISH were confirmed by
microarray in 35 cases (95%; 35/37). Low-level mosaicism of abnormalities present in
each case may hinder the call of abnormalities in microarray studies, which has been
demonstrated in this group of cases. Microarray studies identified a large variation in the
size of the 14q32 deletion detected in each case by utilizing the ChAS software for
analysis [Figure 34]. Deletions of 14q32 were the most frequent at the 5’ telomeric end
of the variable region by FISH studies (88%, 35/40 cases) [Table 13]. Overall, the 5’
telomeric 14q32 deletions varied in size from 236 to 1401 kb and commonly
involved genes FAM30A (formerly KIAA0125), ADAM6, LINC00226 and LINC00221,
all located at the 5’ telomeric end of 14q32. An identical 123 kb minimum deleted

Table 12. FISH and conventional cytogenetics results for cases further studied by microarray. A total of 40 cases
with confirmed 14q32 deletions by FISH were further studied with a SNP microarray. A 5’ partial 14q32 deletion was
observed in a majority of cases (31/40). Both abnormal and normal karyotypes were observed in addition to the abnormal
FISH results.
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Figure 34. Size variation in 5’ partial IGH (14q32) deletions detected by SNP
microarray. This figure shows an example of two cases with a 5’ partial telomeric 14q32
deletion. Case 35 had a 5’ partial 14q32 deletion that was detected by FISH studies in
45.5% of cells and confirmed by SNP microarray. The area highlighted by the red box
shows a change from a copy-number state of 2. The deletion spans part of chromosome
band 14q32.33 and is 455 kb in size. Case 12 also had a 5’ partial 14q32 deletion
detected by FISH studies in 83.5% of cells and was confirmed by SNP microarray. The
area highlighted by the red box shows a deletion that spans part of chromosome band
14q32.33 and is 790 kb in size.
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Table 13. MDR detected by microarray for 3’ and 5’ IGH deletions (includes partial
and complete). Microarray studies confirmed a 14q32 deletion detected by FISH
studies in 35 cases. Deletions of the 5’ telomeric portion of 14q32, including partial and
complete deletions, were the most frequent. These 33 cases had an MDR that was 123
kb in size. Only two cases had a 3’ centromeric deletion detected by both FISH and
microarray studies, with a much larger MDR.

FISH Results

Number of
Cases

MDR Size

MDR Linear Location
(GRCh37/hg19)

5’ IGH
Deletions

33*

123 kb

chr14:106777329 – 106900751 bp

3’ IGH
Deletions

2

37224 kb

chr14:69264347 – 106488194 bp

*A total of 35 cases had a 5’ IGH deletion detected by FISH, but only 33 were
detected by microarray.
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region (MDR) was found by microarray in 33 cases with 5’ telomeric 14q32
deletions and encompassed linear location chr14:106777329 – 106900751 bp
(GRCh37/hg19) that did not include any genes. However, 32 of these cases had an
identical 214 kb MDR that included LINC00221 [Figure 35]. With the use of the
Abbott dual-color break-apart probe for the IGH gene region, FISH distinguished
between a 5’ partial deletion of 14q32 and a 5’ complete deletion of 14q32. A 5’ partial
deletion was observed in 29 cases and a 5’ complete deletion of 14q32 was observed in
four cases by FISH. Microarray further defined the deleted regions for both types of 5’
IGH deletion [Table 14]. The cases with a 5’ partial deletion of 14q32 ranged in size
from 236 to 1,363 kb, and 97% (28/29) of these cases overlapped LINC00221, a
long intergenic non-protein coding RNA [Figure 36]. The MDR for these 28 cases
encompassed linear location chr14:106777329 – 106991032 bp (GRCh37/hg19) and
was 213 kb in size. Cases with a 5’ complete deletion of 14q32 ranged in size from 569
– 1,401 kb and had an MDR that was 569 kb in size from chr14:106716050 –
107285437 bp (GRCh37/hg19). The MDR for the four cases with 5’ complete
deletions of 14q32 included LINC00226 and LINC00221 [Figure 37]. A total of 32
cases that had 5’ partial or complete 14q32 deletions overlapped LINC00221 and
28/33 cases overlapped LINC00226.
A sole 5’ telomeric 14q32 deletion was observed by FISH in eight cases and was
identified by microarray in six cases. Four of these cases had a 5’ partial 14q32 deletion,
and two cases had a 5’ complete 14q32 deletion by FISH. Two of the cases with a 5’
partial deletion were not able to be visualized by microarray due to low-level mosaicism
present in the tumor and were only identified by FISH in 12% of cells. The MDR
detected by microarray for the four cases with a sole 5’ partial 14q32 deletion by
FISH was 366 kb, and encompassed linear location chr14:106727416 –

Figure 35. Thirty three cases with 5’ IGH deletions detected by microarray. Microarray further outlined the
breakpoints of 5’ IGH deletions observed in 33 cases. Cases with 5’ partial deletions detected by FISH are
designated by black bars, and cases with 5’ complete deletions by FISH are designated with grey bars. The overall
MDR (designated by a red box in the figure) for these 33 cases was 123 kb that overlapped linear locations
chr14:106777329 – 106900751 bp (GRCh37/hg19), but there were no genes included in this region. An identical
214 kb MDR (highlighted by yellow boxes in the figure) was detected in 32 cases that overlapped LINC00221.
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Table 14. Types of 5’ IGH deletions further defined by Affymetrix® CytoScan™ HD
array. This table highlights the MDR size, linear location, and genes involved for both 5’
partial and 5’ complete IGH deletions.

Number of
Cases

MDR Size

MDR Linear Location
(GRCh37/hg19)

Genes
Included

5’ Partial IGH
Deletion

29

123 kb

chr14:106777329 –
106900751 bp

No genes

5’ Complete
IGH Deletion

4

569 kb

chr14:106716050 –
107285436 bp

LINC00226,
LINC00221

Figure 36. Cases with 5’ partial IGH deletions detected by microarray. Microarray analysis further
defined the regions involved in the 5’ partial 14q32 deletion in 29 cases. Again, the MDR (highlighted by a
red box in the figure) for these 29 cases was consistent with the overall MDR for all cases with a 5’ IGH
deletion and was 123 kb in size and did not include any genes of interest. However, the majority of cases
had an MDR (highlighted by yellow boxes in the figure) that was 213 kb in size and overlapped LINC00221.
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Figure 37. Cases with 5’ complete IGH deletions detected by microarray. Microarray was able to further define the
regions involved in four cases with a 5’ complete telomeric 14q32 deletion. Commonly deleted genes include FAM30A,
ADAM6, LINC00226, and LINC00221. The MDR (highlighted by a red box in the figure) was 569 kb, and encompassed linear
locations chr14:106716050 – 107285437 (GRCh37/hg19) that included LINC00226 and LINC00221.
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107093267 bp (GRCh37/hg19), which included LINC00226 and LINC00221 [Figure
38]. The two cases with sole 5’ complete 14q32 deletions by FISH had an MDR that
was 971 kb and was from chr14:106313767 – 107285436 bp (GRCh37/hg19) that
included FAM30A, ADAM6, LINC00226 and LINC00221 [Figure 39]. These results
emphasize that the deletion of regions, including these two intergenic sequences,
may play a role in the initial pathogenesis of CLL.
Only two cases in this subset studied by microarray presented with a 3’
centromeric deletion flanking the IGH gene region on 14q32 by FISH [Figure 40]. One of
these cases was identified as a sole abnormality by FISH and microarray studies. These
deletions ranged in size from 37,626 kb – 37,910 kb [Figure 41]. Both of these cases
had a deletion that was distal to, or involving the ZFP36L1 gene at band 14q24.1. The
MDR for the two cases with 3’ centromeric IGH deletions ranged from
chr14:9264347 – 106890795 bp (GRCh37/hg19) and was 37,626 kb in size. The MDR
for the cases with 3’ centromeric deletions of 14q32 notably included the DICER1,
TCL1A, TCL1B, and TCL6 genes, which have been implicated in mature B-cell
neoplasms.
Two cases exhibited complete loss of both the 3’ centromeric and 5’ telomeric
portions of the IGH gene region on the same homolog, resulting in loss of one copy of
14q32 by FISH. In one case, this was the sole abnormality identified by FISH studies,
but this case did not have conventional cytogenetic analysis. By microarray, this area
was represented by a large deletion from 14q12 – 14q32.33 that was 81,972 kb in size.
The second case had a low mitotic index with only five normal cells analyzed by
kartoype. By microarray, it was determined that the loss detected by the FISH probe for
this case actually resulted in two separate deletions [Figure 42]. One of the deletions

Figure 38. Four cases with sole 5’ partial IGH deletions. Four cases with 5’ partial IGH deletions were further
characterized by microarray. The MDR (highlighted by a red box in the figure) for these four cases was 366 kb, and
encompassed linear locations chr14:106727416 – 107093267 bp (GRCh37/hg19) that included LINC00226 and
LINC00221.
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Figure 39. Two cases with sole 5’ complete IGH deletions. A 5’ complete 14q32 deletion was observed as a sole
abnormality in two cases. The MDR (highlighted by a red box in the figure) for these two cases was 971 kb, and
encompassed linear locations chr14:106313767 – 107285436 bp (GRCh37/hg19) that included FAM30A, ADAM6,
LINC00226 and LINC00221.
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Figure 40. Two cases with 3’ centromeric 14q32 deletions. A 3’ centromeric IGH
deletion was detected by microarray in two cases. Both cases had a deletion
(highlighted by the red boxes) that spanned chromosome band 14q24.1 - q32.33 and
were nearly identical in size.
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Figure 41. Cases with 3’ centromeric IGH deletions detected by microarray.
Microarray defined the deleted regions in two cases with 3’ centromeric IGH deletions.
The MDR (highlighted by a red box in the figure) was 37,224 kb and encompassed linear
locations chr14:69264347 – 106849677 bp (GRCh37/hg19). Both of these cases are
either distal to, or involving the deletion of the ZFP36L1 gene, which has previously been
reported to be involved in large 14q deletions and may serve a tumor-suppressor role.
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Figure 42. Case with loss of one copy of the IGH gene region further defined by
microarray. Microarray detected two distinct deletions. One deletion, at 14q32.13, was
1066 kb in size and spanned linear locations chr14:94965685 – 96032052 bp
(GRCh37/hg19). The other deletion, at 14q32.33, was 2232 kb in size and included
linear locations 14:105053471 - 107285437 bp (GRCh37/hg19). The first deletion
overlapped the MDR for the 3’ centromeric IGH deletion observed in two additional
cases, and the second deletion overlapped the MDR for cases with 5’ complete 14q32
deletions.
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was at 14q32.13 and was 1066 kb in size, with a linear location of chr14:94965685 –
96032052 bp (GRCh37/hg19). This deletion overlapped the MDR for the two cases with
a 3’ centromeric IGH deletion. The other deletion was at 14q32.33 and was 2232 kb in
size, with a linear location of chr14:105053471 – 107285437 bp (GRCh37/hg19), which
overlaps the MDR for the cases with 5’ complete deletions of 14q32.
One case showed a deletion of the 3' (centromeric) IGH (14q32) locus with
partial deletion of the 5' (telomeric) IGH locus by FISH, which resulted in a large deletion
of 14q32. Conventional cytogenetics was also able to visualize this deletion, which
resulted in a large deletion of the long arm of chromosome 14 from bands q22 – q23. By
microarray, the linear location of this deletion was determined to be from
chr14:69,241,896 – 107,213,468 bp (GRCh37/hg19) and was 37,971 kb in size. Of note,
this case overlapped the established MDR for the 3’ centromeric deletions and the MDR
for the 5’ partial telomeric deletions of 14q32 in this subset of cases.
Various deletions of 14q32 were assessed by microarray studies in this
subset of cases. The majority of cases studied had a 5’ partial telomeric 14q32
deletion that was observed in the FISH study. Out of the 33 cases studied that had
an identifiable 14q32 telomeric deletion by microarray, all of these had a deletion
that overlapped either LINC00226, LINC00221, or both segments. Four cases in
this study had a 5’ partial telomeric 14q32 deletion that was detected as a sole
abnormality by both microarray and FISH studies. The MDR for these four cases
with sole 5’ partial deletions was 366 kb in size and included LINC00221 and
LINC00226. These results emphasize that the deletion of the telomeric portion of
14q32 that includes these two intergenic sequences may play a role in the initial
pathogenesis of CLL. The combination of FISH and microarray studies helped to
highlight the genes involved in each deletion. The deletions of the 3’ centromeric
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portion of 14q32 were observed in a much smaller subset of cases in this study;
however, the deletion included a large region of the long arm of chromosome 14
encompassing a large number of genes that are deleted, thus, having a greater
impact in the pathogenesis of CLL.
Prognostically Relevant CLL FISH Abnormalities Detected by Microarray
In this subset, the majority of additional abnormalities detected by FISH studies
were also visualized by microarray. A 13q14 deletion or nullisomy 13q14 was the most
common additional abnormality detected by FISH studies in this subset (53%, 21/40). In
most instances, microarray detected the loss of 13q14 in these cases. Deletion of 13q14
was detected by FISH in 16 of these cases (76%; 16/21), with one of these cases having
concurrent deletions of 13q14 and 13q34 [Figure 43]. Nullisomy of 13q14 (or biallelic
deletions of 13q14), resulting in the loss of 13q14 on each homolog of chromosome 13,
was observed in two cases (10%, 2/21) [Figure 44]. Clones with a deletion of 13q14 and
nullisomy 13q14 were observed in three cases (14%, 3/21). Microarray analysis further
defined the linear location and the MDR of the various 13q deletions in 18 cases (86%;
18/21) [Table 15] and was not able to detect a 13q14 deletion in three cases due to lowlevel mosaicism of the abnormal clone. The deletion of 13q for these three cases was
observed in 12 – 14.5% of cells by FISH. Deletion of 13q14 was identified by both FISH
and microarray in 13 cases, with one of these cases having concurrent deletions of
13q14 and 13q34 by FISH. The detectable 13q14 deletions by microarray ranged in size
from 928 kb to 66,010 kb. The MDR for these 13 cases with a deletion of 13q14 and
a 5’ IGH deletion spanned 928 kb and had a linear location of chr13:50481211 –
51409043 bp (GRCh37/hg19) [Figure 45]. This MDR included the SPRYD7, TRIM13,
KCNRG, ST13P4, BCMS, and DLEU7 genes. Six of the 13 cases had a 13q14 deletion
that overlapped RB1, which is outside the detection area of the FISH probe for 13q.
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Figure 43. Three cases with loss of 13q14.2-14.3 detected by microarray. A deletion
of 13q14 was detected by microarray in 13 cases. This image highlights the variation in
the linear location of the 13q14 deletions in three cases. Each deleted region is
highlighted by a red box in the figure on the Smooth Signal track.
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Figure 44. Nullisomy 13q14 observed by FISH and microarray in two cases.
Nullisomy 13q14 was identified by FISH in two cases and was confirmed by microarray.
The MDR (highlighted with a yellow box in the figure) for these deletions was 928 kb in
size and encompassed linear locations chr13:50481211 – 51409043 bp (GRCh37/hg19).
This MDR included the SPRYD7, TRIM13, KCNRG, ST13P4, BCMS, and DLEU7
genes.

Table 15. Types of 13q deletions further defined by Affymetrix® CytoScan™ HD array. This table highlights each type of
13q deletion or combination of deletions that was observed in 21 cases, with the MDR and linear location for each deletion.
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Figure 45. Deletion of 13q14 observed by FISH and microarray in 13 cases. A deletion of 13q14 was
identified by FISH in 16 cases, with one case having concurrent deletions of 13q14 and 13q34, and was
confirmed by microarray in 13/16 cases (82%). The MDR (highlighted with a red box in the figure) for
these deletions was 928 kb in size and encompassed linear locations chr13:50481211 – 51409043 bp
(GRCh37/hg19). This MDR included the SPRYD7, DLEU1, DLEU2, TRIM13, KCNRG, ST13P4, BCMS,
and DLEU7 genes.
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There were three cases with both a deletion of 13q14 and nullisomy 13q14 observed by
FISH in different percentages of cells. These deletions also ranged in size; however,
both types of deletions were not always detectable by microarray due to low-level
mosaicism. We isolated seven cases with only a 5’ partial 14q32 deletion and
deletion of 13q14 by FISH to calculate the MDR of the 5’ partial 14q32 deletions
characterized by microarray. The 14q32 MDR for these seven cases was 368 kb in
size and spanned linear location chr14:106777329 – 107145068 bp (GRCh37/hg19),
including LINC00221 [Figure 46].
Trisomy 12 occurred in eight cases with various IGH deletions (20%, 8/40). Six of
the cases with trisomy 12 were associated with a 5’ partial deletion of 14q32 by FISH.
Since two of these six also had a 13q deletion, we calculated the MDR in 14q32 for the
four cases with a 5’ partial 14q32 deletion and trisomy 12. The MDR for these cases was
236 kb in size and spanned linear location chr14:106777329 – 107013827 bp
(GRCh37/hg19). The 14q32 deletion observed in these cases also included LINC00221
in the minimally deleted region, as was observed with cases that had a deletion of 13q
as an additional abnormality [Figure 47].
Deletion of 11q22.3 was observed by FISH in four cases from this subset with
14q32 deletions and confirmed by microarray studies (10%; 4/40). Microarray analysis
further delineated the size of the 11q deletions, which involved a large portion of 11q in
all four cases. The 11q MDR detected by microarray for these four cases was 16,058 kb
[Figure 48]. All four of the cases with 11q deletions were associated with a 5’ partial
deletion of 14q32 that was detected by FISH. Only one of the four cases was
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Figure 46. Range in size of 5’ partial IGH deletion in seven cases with a 13q14
deletion. Deletion of 13q14 and a 5’ partial IGH deletion were detected in seven cases
by both FISH and microarray. The MDR (highlighted with a red box in the figure) for the
5’ partial IGH deletion associated with a deletion of 13q14 in these seven cases was 368
kb from linear location chr14:106777329 – 107145068 bp (GRCh37/hg19) and included
LINC00221.
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Figure 47. Range in size of 5’ partial IGH deletion in four cases with trisomy 12.
Trisomy 12 and a 5’ partial IGH deletion were detected in four cases by both FISH and
microarray. The MDR (highlighted with a red box in the figure) for the 5’ partial IGH
deletion associated with trisomy 12 in these four cases was 236 kb from linear location
chr14:106777329 – 107013827 bp (GRCh37/hg19) and included LINC00221.
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Figure 48. Range in size of 11q deletions identified by microarray. A deletion of 11q
was observed by both FISH and microarray in four cases. The deletions identified by
microarray ranged in size from and a 5’ partial IGH deletion were detected in four cases
by both FISH and microarray. The MDR (highlighted with a red box in the figure) for the
11q deletions for these four cases was 16,058 kb from linear location chr11:100948408
– 117006778 bp (GRCh37/hg19) and included many genes in addition to ATM.
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characterized by a deletion of 11q22.3 and a 5’ partial IGH deletion as the only
abnormalities detected by FISH; however, the deleted region on 14q32 did not include
the LINC00221 non-coding region that was observed in cases with deletions of 13q and
trisomy 12.
FISH noted a deletion of 17p13 in six cases with an IGH deletion (15%, 6/40),
and all of these cases had 17p deletions confirmed by microarray. A 5’ partial or
complete loss of IGH, or loss of one copy of 14q32 was observed in conjunction with the
17p deletions, and the majority of these cases were associated with more than two FISH
abnormalities and complex karyotypes. The MDR of the 17p deletions observed in these
six cases was 18,921 kb and spanned linear location chr17:525 – 18922212 bp
(GRCh37/hg19). This region notably included the loss of TP53, a tumor-suppressor
gene. Only one case had a deletion of 17p and a 5’ complete IGH deletion as the only
additional abnormality. The 5’ complete deletion of 14q32 was 456 kb in size and
included LINC00226 and LINC00221. The initial 14q32 deletion combined with the
loss of TP53 suggests that the region encompassing LINC00226 and LINC0021
plays a role in CLL pathogenesis.
Novel Abnormalities Detected by Microarray
In this subset of CLL cases with confirmed 14q32 deletions, the microarray
studies detected novel cryptic aberrations that were not identified by conventional
cytogenetics or FISH in 16 cases (40%; 16/40). These additional aberrations were not
visualized by conventional methods due to probe limitations in FISH, and limited banding
resolution by karyotype. Chromosome aberrations identified by microarray were
considered novel when they were not identified by conventional cytogenetics or FISH.
This group of 16 cases contained five cases that were not studied with a karyotype. In
these five cases, an abnormality was considered novel by microarray when it was not
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also identified by FISH. Partial and whole chromosome loss and gain were observed by
microarray [Figure 49] in addition to copy-neutral LOH (CN-LOH). It is worth noting
that five out of the six cases with a sole 5’ telomeric 14q32 deletion by FISH and
confirmed by microarray did not have any novel abnormalities detected by
microarray.
Novel chromosome loss was identified in 11 cases by microarray, including
partial or complete loss of chromosomes 1, 2, 3, 7, 9, 11, 13, 14, 15, 18, 19, and 22.
Four cases exhibited a deletion of 22q11.22 [Figure 50]. The 22q11.22 deletion ranged
in size from 70 – 877 kb in these four cases with an MDR that included mir650. A nearly
identical deletion of chromosome 3 from p25.3p26.3 was detected by microarray only in
two cases. The MDR for this deletion was 8,685 kb in size and range from chr3:61891 –
8746451 bp (GRCh37/hg19). Both of these cases also had a 5’ partial telomeric deletion
of 14q32 and a deletion or nullisomy 13q14. Several cases had novel abnormalities on
chromosomes that are targeted by the CLL FISH panel. Still, these abnormalities fell
outside of the probe coverage area and were therefore not detected by FISH studies.
One case had an 11q deletion detected by microarray that was outside of the coverage
area for the Poseidon ATM (11q22.3)/p53 (17p13.1) DNA FISH Probe and two cases
had visible deletions of 13q by microarray. One case with a novel 13q deletion detected
by microarray was accompanied by several FISH abnormalities and novel microarray
changes. Of note, four cases (36%; 4/11) contained three or more novel chromosome
losses by microarray. In one case, conventional cytogenetics was able to identify a ring
chromosome 16 in a karyotype but did not provide any breakpoints. Microarray identified
two distinct deletions on chromosome 16. We can infer that the deletions on either end
of the chromosome represent the breakpoints involved in the ring chromosome 16 and
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Figure 49. Novel gains and losses detected by Affymetrix ® CytoScan™ HD array.
This figure shows the number of novel gains and losses detected by microarray that
were not observed by conventional cytogenetics and FISH studies. Gains are
represented by blue bars, and losses are represented by orange bars.

133

Figure 50. Examples of deletion of 22q11.22 identified by Affymetrix ® CytoScan™
HD array. Four cases were characterized by a novel deletion of 22q11.22 identified by
microarray only. The deletion of these four cases ranged in size, but all deletions
overlapped MIR650. This figure shows an example of two cases with a deletion of
22q11.22 by microarray. This deletion was associated with 5’ partial and complete
14q32 deletions, as well as a case with a 3’ and 5’ partial deletion on the same homolog.
Tracks for Copy Number State, Allele Difference, and Smooth Signal were used to
evaluate the deletion in ChAS.

134

with the use of microarray can give the ring chromosome nomenclature of
r(16)(p13.3q24.3) [Figure 51]. Microarray allowed for the clarification of breakpoints that
were involved in this ring chromosome. Novel chromosome gain was identified in seven
cases and included a whole-chromosome gain of 18, and partial gain of chromosomes 1,
3, 5, 6, 7, 9, 12, 17, and 19, detected in one case each. Four cases had a gain of 8q that
varied in size and included the MYC oncogene as well as several other genes [Figure
52]. Of note, three (43%; 3/7) cases with complex cytogenetics and FISH results with
deletion of 17p13.1 (TP53) each contained 2 - 4 instances of novel chromosome gain
detected solely by microarray studies.
Loss of Heterozygosity (LOH)
Two types of loss of heterozygosity were observed, LOH that resulted from a
copy-number loss in a chromosomal region and copy-neutral LOH (CN-LOH) [Figure
53]. LOH occurred when one copy of a region was lost in the instance of a deletion of a
chromosome and showed mosaic profiles in some of these deletions. Several cases with
chromosome loss showed LOH over the entire deleted region. CN-LOH was exclusively
identified by microarray studies, as it results in a normal diploid copy number state.
Acquired homozygosity through CN-LOH can support tumorigenesis by triggering
oncogenes or revealing mutated tumor suppressor genes. Copy-neutral LOH was
observed in seven cases (18%; 7/40) [Table 16]. Three of the seven cases had CN-LOH
spanning the entire long arm of chromosome 9 [Figure 54], and one case had mosaic
CN-LOH spanning the same region on 9q [Figure 55]. One case had CN-LOH of 11q
from q12.1 - q25, and another case had CN-LOH on chromosome 1 from p31.1 – p36.3.
Each of these cases had additional copy-number changes on other chromosomes. Two
cases had mosaic CN-LOH in chromosome 13. Both of these cases also had nullisomy
and/or deletion of 13q14 in a percentage of cells [Figure 56].
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Figure 51. Breakpoints for a ring chromosome 16 identified by cytogenetics
defined by microarray. In this case, a ring chromosome 16 was identified by
conventional cytogenetics, but no breakpoints were provided. From the smooth signal
track, we are able to see that there are two distinct deletions on the p arm and q arm of
chromosome 16 (highlighted in red boxes), suggesting nomenclature for the ring
chromosome as r(16)(p13.3q24.3).

Figure 52. Novel gains of 8q detected by Affymetrix® CytoScan™ HD array in four cases. This figure
shows two examples of gain of 8q that were detected by microarray. Gain of 8q is represented by a blue box in
each case, and shows that different-sized 8q gains were detected.
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Figure 53. ChAS examples of LOH and CN-LOH as detected by Affymetrix® CytoScan™ HD array. Three
examples of genetic alterations identified on chromosome 11 in ChAS. A) The blue track represents a deletion of
11q22.1q25 (copy number 1) with LOH over the deleted region. B) The green track represents a mosaic deletion
of 11q22.1q25 with mosaic LOH over the deleted region. C) The orange track represents CN-LOH spanning the
length of the q arm on chromosome 11, with no deletion of 11q in this region.
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Table 16. Seven cases with CN-LOH detected by Affymetrix® CytoScan™ HD array. This table highlights whole-arm
CN-LOH observed in chromosome 1, 9, 11, 13 with linear locations. Two of the seven cases exhibited mosaic CN-LOH.
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Figure 54. Three cases with CN-LOH of 9q, as detected by Affymetrix® CytoScan™ HD array. This
figure shows three cases (3, 7, and 9) with copy-neutral LOH (CN-LOH) over the entire q arm of
chromosome 9 that was able to be identified by the absence of probes in the center of the Allele Difference
tracks.
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Figure 55. Mosaic CN-LOH of 9q detected by Affymetrix® CytoScan™ HD array. This figure shows one case with mosaic
copy-neutral LOH over the entire q arm that was able to be identified by a separation of probes in Allele Difference track, with
no change in copy number over this area.
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Figure 56. Mosaic CN-LOH of 13q and nullisomy 13q14, as detected by Affymetrix ®
CytoScan™ HD array. This figure shows one case with mosaic copy-neutral LOH 13q
with a 13q14.2 biallelic deletion that was able to be identified by a separation of probes
in Allele Difference track, with no change in copy number over the areas with CN-LOH.
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Microarray studies on this subset of 40 cases allowed us to observe the size
variation that occurs in deletions of 14q32 that could not be distinguished by
conventional cytogenetics and FISH alone. The majority of cases had 5’ partial deletions
of 14q32 detected by FISH with variations in deletion size further delineated by
microarray. The 5’ partial 14q32 deletions ranged in size from 236 to 1363 kb with
various combinations of gene loss depending on the size of the deletion. The MDR for
these 5’ partial IGH deletions did not include any genes in this region; however, the MDR
for the majority of 5’ partial IGH deletions included LINC00221, a long-intergenic nonprotein-coding RNA. Sole deletions of 14q32, including five cases with 5’ partial
telomeric deletions and one case with a 3’ centromeric deletion, were found in six cases
with no additional abnormalities detected by FISH or microarray. However, novel
chromosome gains, losses, and CN-LOH were identified in 40% (16/40) of cases. Of
note, loss of 3p and 22q, and gain of 8q were observed in multiple cases. The detection
of CN-LOH in seven cases was detected by microarray studies alone and was observed
in cases with and without complex cytogenetic and FISH results. The combined
conventional cytogenetics, FISH, and microarray results allowed for a more
comprehensive view of the abnormalities contained in each case [Table 17]. However,
microarray was not always able to identify low-level mosaicism that was identified in the
FISH study. There were five cases with abnormalities detected by FISH that were not
able to be visualized by microarray. Abnormalities with low-level mosaicism by FISH that
were not detected by microarray included one case with a deletion of 6q23, two cases
with a deletion of 13q14, and one case with a 5’ partial IGH deletion. One case had both
a deletion of 13q14 and a 5’ partial 14q32 deletion that were not detected by microarray.
Each of these abnormalities ranged from 11 – 14.5% detection by FISH.
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Table 17. Overview of abnormalities observed by cytogenetics, FISH, and
microarray. This table illustrates the type of 14q32 deletion observed by FISH studies,
and additional abnormalities detected by FISH and microarray.
Case
#

Type of 14q
Deletion by
FISH

Karyotype

Additional FISH
Abnormalities

14q32
Microarray
Studies

Number of Novel
Array Abnormalities

6

5’ partial

N/A

0

Not Informative

0

10

5’ partial

Normal

0

Informative

0

20

5’ partial

Normal

0

Informative

0

26

3’ centromeric

Normal

0

Informative

0

28

5’ partial

Abnormal

0

Not Informative

0

29

5’ complete

Normal

0

Informative

0

30

5’ partial

Normal

0

Informative

0

31

5’ partial

Abnormal

0

Informative

0

16

Loss of 1 copy

Normal

0

Informative

Loss 14q32.13
Loss 13q14.2 – q14q.3

38

5’ complete

Normal

0

Informative

Loss 11q22.3 – q23.3

8

5’ partial

N/A

Deletion 13q14

Informative

0

14

5’ partial

Normal

Deletion 13q14

Informative

Loss 15q13.1

15

5’ partial

N/A

Deletion 13q14

Informative

0

12

5’ partial

N/A

Deletion 13q14

Informative

0

17

5’ partial

Normal

Deletion 13q14

Informative

CN-LOH 11q

19

5’ partial

Normal

Deletion 13q14

Informative

0

25

5’ complete

Normal

Deletion 13q14

Informative

0

27

5’ partial

Normal

Deletion 13q14

Informative

0

40

5’ partial

N/A

Nullisomy 13q14

Informative

Loss 3p26.3
Gain 8q24.12 – q24.3
Loss 22q11.22

4

5’ partial

N/A

Trisomy 12

Informative

0

7

5’ partial

N/A

Trisomy 12

Informative

CN-LOH 9q

18

5’ partial

Abnormal

Trisomy 12

Informative

0

21

3’ centromeric
and 5’ partial

Abnormal

Trisomy 12

Informative

CN-LOH 1p
Loss 15q12 – q21.1
Loss 22q11.22

33

5’ partial

Abnormal

Trisomy 12

Informative

Gain 6q25.3
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Table 17. (Continued) Overview of abnormalities observed by cytogenetics, FISH,
and microarray. This table illustrates the type of 14q32 deletion observed by FISH
studies, and additional abnormalities detected by FISH and microarray.
Case
#

Type of 14q
Deletion

Karyotyp
e

Additional FISH
Abnormalities

14q32
Microarray
Studies

Number of Novel
Array Abnormalities

36

3’
centromeric

Abnormal

Trisomy 12

Informative

0

22

5’ partial

Abnormal

Informative

0

1

5’ partial

Abnormal

Informative

Gain 9q21.2 – q34.3

37

5’ complete

Normal

Deletion
17p13.1

Informative

Loss 9p21.1 – p21.2
Loss 9q21.11 – q21.31
Loss 22q11.22

23

5’ partial

Normal

Deletion 13q14
Nullisomy 13q14

Informative

0

24

5’ partial

Normal

Deletion 13q14
Nullisomy 13q14

Informative

Mosaic CN-LOH 9q
Mosaic CN-LOH 13q
Loss 22q11.22

35

5’ partial

Normal

Deletion 13q14
Nullisomy 13q14

Informative

0

2

5’ partial

N/A

Deletion 13q14
Trisomy 12

Informative

0

13

5’ partial

Abnormal

Deletion 13q14
Trisomy 12

Informative

Loss 3p25.3 – p26.3
Gain 3q24 – q26.1
2 additional CNAs

5

5’ partial

N/A

Informative

0

32

5’ partial

Abnormal

Informative

0

3

Loss of 1
copy

N/A

Informative

Gain 8q13.1 – q24.3
CN-LOH 9q
4 additional CNAs

39

5’ partial

Abnormal

Informative

0

34

5’ partial

Abnormal

Deletion 6q23
Deletion 13q14

Informative

0

Abnormal

Deletion 13q14
Deletion
11q22.3
Deletion
17p13.1

Informative

Gain 8q23.1 – q24.3
CN-LOH 9q
Loss 14q24.2 – q24.3
5 additional CNAs

N/A

Deletion 6q23
Nullisomy 13q14
Deletion
17p13.1

Informative

Gain 8q22.1 – q24.3
Gain 18
Mosaic CN-LOH 13q
4 additional CNAs

9

11

5’ partial

5’ partial

Deletion
11q22.3
Deletion
17p13.1

Deletion 13q14
Deletion
11q22.3
Deletion 13q14
and 13q34
Deletion
11q22.3
Deletion 13q14
Deletion
17p13.1
Deletion 13q14
Deletion
17p13.1
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CLL is an ideal neoplasm to utilize copy-number microarray to assess genetic
abnormalities because a balanced translocation that leads to fusion gene formations or
gene disruptions that may play a primary role in disease pathogenesis are rare in this
disease. Copy-number microarray studies have allowed for a whole-genome
assessment of abnormalities in CLL. In our study, microarray delineated the
deletions of 14q32 in this cohort of cases by determining if there was variation in
the size of detectable 14q32 deletions. We identified a significant range in size of
the 5’ partial and complete deletions, as well as detected deletions involving the 3’
centromeric portion of IGH. Further, the studies confirmed that 14q32 deletions
existed as sole abnormalities and, therefore, could be an important initial event in
CLL pathogenesis. Additionally, microarray was able to detect novel cryptic gains
and losses that were not able to be visualized by conventional cytogenetics and
were not targeted by the panel of FISH probes used in these cases. A subset of
cases were also further characterized by CN-LOH that would have gone
undetected without microarray studies, which may have potential prognostic
implications.
Clinical Correlation
A prognostic hierarchy has been established for the presence or absence of
recurrent FISH abnormalities detected in CLL (Döhner et al., 2000). However, the effect
that 14q32 deletions have on patient prognosis and outcomes has been rarely studied.
After determining that deletions of 14q frequently occur within the population of CLL
cases and differ in size and linear location, we sought to determine the potential impact
that 14q deletions have on clinical outcomes. We assessed overall survival (OS) and
time-to-first-treatment (TTFT), on a subset of cases with confirmed CLL or SLL and with
available clinical data.
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A total of 115 cases had available clinical follow-up information and were used to
assess the prognostic significance of 14q deletions in CLL. All cases were studied by
FISH that defined the complete and partial deletions of 14q with the use of a dual-color
break-apart probe to assess the 14q32 gene region. We assessed both time-to-firsttreatment (TTFT) and overall survival (OS). The age range for these cases was from 31
to 87 years of age at diagnosis, and the majority of cases were male. Cases were
divided into subgroups based on the FISH abnormalities that were present in each
diagnostic study. Based on our retrospective data, we have identified that 5’ telomeric
14q32 deletions occur more frequently than 3’ centromeric 14q32 deletions in CLL
cases. Because of this, it was important for us to assess 14q deletions in two ways to
see if there was a difference in clinical impact: 1) only assess cases with a 5’ telomeric
14q32 deletion and 2) group all cases with a 14q32 deletion together including cases
with a 5’ telomeric or a 3’ centromeric 14q32 deletion. Only cases with a 5’ telomeric
14q32 deletion and no instances of a 3’ centromeric 14q32 deletion were included in the
analysis in group 1. In group 2, cases that contained either a 5’ telomeric or 3’
centromeric 14q32 or cases that contained both a 5’ telomeric and 3’ centromeric 14q32
deletion were included in the analysis. The cases included in group 1 and group 2 were
further subdivided into three categories in each group (i) cases with sole 14q32
deletions; (ii) cases with a 14q32 deletion and one additional abnormality, and (iii) cases
with a 14q32 deletion and multiple abnormalities (more than one additional). Table 18
describes the details of FISH abnormalities and clinical characteristics included in each
group and subgroup. Because it is important to precisely know the impact of 14q32
deletions without the modifying effect of an additional abnormality, we have compared
various sole abnormalities to determine the prognostic effect of a 14q deletion. The
prognostic consequences of deletions of 13q, trisomy 12, normal FISH results, deletions

Table 18. FISH abnormalities and clinical characteristics for CLL cases that contained a 14q32
deletion. In group 1, cases with only 5’ telomeric 14q32 deletions were included. In group 2, cases
with 5’ telomeric and 3’ centromeric deletions were included. These also included those cases that
had more than one partial 14q32 deletion.
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of 11q, and deletions of 17p have been previously published. Table 19 describes the
details and clinical characteristics of cases with sole FISH abnormalities or those with
normal FISH results. We compared the cases with sole 14q32 deletions with cases that
contained these genetic changes as sole abnormalities. Those cases that contained a
sole deletion or nullisomy of 13q, sole trisomy 12, a sole 11q/17p deletion, or normal
FISH results were included in both groups. Cases with multiple abnormalities that did not
include a 14q32 deletion were not included in the analysis.
Time-To-First-Treatment (TTFT)
Time-to-first-treatment (TTFT) was defined as the time from diagnosis to the time
of the first indication for therapy. Some cases in our group were following a watch-andwait protocol and eventually progressed to needing treatment. For these cases, time-totreatment was defined as the time from diagnosis to the first progression, which is when
these cases started treatment. Those cases that were still following a watch-and-wait
protocol at last follow-up were censored. For comparison, the cases that had sole
abnormalities of 13q, trisomy 12, normal FISH results, or deletion of 11q or 17p
remained the same in both group comparisons. In group 1, 91 cases were included in
the TTFT analysis. In this group, a total of 27 cases exhibited a 5’ telomeric 14q32
deletion as a sole abnormality or with additional FISH abnormalities. A total of 21 (78%;
21/27) cases with a 5’ telomeric deletion progressed to needing treatment including (i)
five (83%; 5/6) cases with a sole 5’ telomeric 14q32 deletion, (ii) five (5/8) cases with a 5’
telomeric 14q32 deletion and one additional abnormality, and (iii) 11 cases with a 5’
telomeric 14q32 deletion and multiple additional FISH abnormalities. Cases with a sole
5’ telomeric 14q32 deletion had a shorter median TTFT (2.98 years) than cases
with a sole deletion or nullisomy of 13q14 (6.27 years) [Figure 57A]. We also

Table 19. FISH abnormalities and clinical characteristics for CLL cases containing other sole
abnormalities or normal FISH results. This table includes three categories of FISH abnormalities with
known prognostic significance that were observed as a sole abnormality and cases that had no abnormalities
detected by FISH.
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isolated eight cases that had a 5’ telomeric 14q32 deletion with one additional genetic
abnormality that is known to impart a favorable (13q deletion) or intermediate (trisomy
12) prognosis in CLL and the median TTFT was similar to cases with a sole 5’ telomeric
14q32 deletion (3.7 years). Eleven cases had multiple abnormalities in addition to a 5’
telomeric 14q32 deletion, and seven of these cases (64%; 7/11) contained a deletion of
11q and/or 17p that is known to confer a poorer prognosis. These cases also had a
shorter median TTFT (1.13 years). The p-value for this assessment was considered
statistically significant (p = 0.014). We also compared TTFT for the three groups of 14q
deletions with cases that had a sole instance of trisomy 12 [Figure 57B], normal FISH
results [Figure 57C], and a sole deletion of either 11q or 17p [Figure 57D]. Although the
p-values for these three distributions were not statistically significant, we can infer that
cases with a sole 5’ telomeric deletion have a longer median TTFT (2.98 years) than
those cases with a sole deletion of 11q or 17p (0.7 years) [Figure 57D]. Overall, these
distributions suggest that cases with a 5’ telomeric 14q32 deletion (sole or with
other abnormalities) have an intermediate prognosis that was better when
compared to 11q and 17p deletions (longer TTFT); however, it was inferior when
compared to cases with 13q deletions (shorter TTFT) [Figure 58]. Although the pvalue for this Kaplan-Meier distribution that included all categories of FISH
abnormalities was not statistically significant, it outlined a trend that suggests
that 5’ telomeric 14q32 deletions likely have intermediate prognostic implications
in cases of CLL.
In our retrospective study, we determined that deletions involving the 5’ telomeric
end of 14q32 occur more frequently in CLL. To evaluate whether grouping all types of
14q deletions affect TTFT, we combined all cases that had a sole deletion of 14q

Figure 57. Kaplan-Meier plots depicting TTFT for group 1. Cases that contained a 5’ telomeric 14q32 deletion
(group 1) were further categorized into three subgroups, including (i) those that contained a 5’ 14q32 deletion as a
sole abnormality, (ii) cases with a 14q deletion and an additional abnormality, and (iii) cases with a 14q32 deletion
and multiple other abnormalities. These were then compared against cases with A) a sole deletion or nullisomy of
13q B) a sole instance of trisomy 12 C) normal FISH results D) a sole deletion of 11q or 17p.
151

Figure 58. Kaplan-Meier distributions showing time-to-first-treatment (TTFT) for all
abnormalities in group 1. The TTFT for cases had a sole 5’ telomeric deletion had a shorter
median TTFT (2.98 years) than patients with a sole deletion or nullisomy of 13q14 (6.27 years)
and a longer TTFT than patients with a sole deletion of 11q or 17p (0.7 years).
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together in group 2 to assess whether the inclusion of cases with 3’ centromeric 14q32
deletions, which generally result in a large deletion on the long arm of chromosome 14,
had an impact in the overall TTFT results. In group 2, 33 cases had any type of 14q
deletion, and 27 of these cases (81%; 27/33) progressed to needing treatment, which is
a slightly higher percentage of cases than in group 1. When group 2 was
subcategorized, there were (i) 12 cases that were considered to have a sole 14q32
deletion (sole 3’ centromeric 14q32 deletion (n = 2), sole 5’ telomeric 14q32 deletion (n =
6), and cases with both a 3’ centromeric and 5’ telomeric 14q32 deletion either occurring
on the same or different homologs) (n = 4), (ii) The addition of cases that contained a 3’
centromeric 14q32 deletion added two cases to the subset that contained a 14q deletion
with one additional FISH abnormality (n = 10). (iii) There were no new cases added to
the subset that contained a 14q deletion with multiple additional FISH abnormalities (n =
11). All three subsets of group 2 cases with 14q deletions were compared to the other
categories of FISH results without a 14q deletion, including sole abnormalities of 13q, a
sole instance of trisomy 12, a sole deletion of either 11q or 17p, and those cases with
normal FISH results. Nine cases in group 2 with a sole 14q deletion progressed to
needing treatment, suggesting that the majority of cases with either a 3’
centromeric 14q32 deletion or loss of both segments of 14q32 progressed to
treatment, in addition to the five cases with 5’ telomeric 14q32 deletions. Again,
even after including the 3’ centromeric 14q32 deletions to group 2, a similar
picture emerged. Cases with a sole deletion of 14q32 in this group had a median
TTFT of 3.58 years as compared to cases with a sole deletion or nullisomy of 13q,
which had a longer TTFT (6.27 years) [Figure 59A]. The p-value for this KaplanMeier distribution was considered statistically significant (p = 0.0099). We also
compared TTFT for the three groups of 14q deletions with cases that had a sole
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instance of trisomy 12 [Figure 59B], normal FISH results [Figure 59C], and a sole
deletion of either 11q or 17p [Figure 59D], but the p-values for each of these
distributions were not considered statistically significant. The progression to treatment
among cases with all types of 14q deletions remained intermediate, with a shorter
median TTFT than cases with a sole deletion or nullisomy of 13q14 and a longer
median TTFT than cases that had a sole deletion of 11q or 17p. As was the case in
group 1, the modifying effect of an additional abnormality that was a deletion of 13q or
trisomy 12 with a deletion of 14q did not alter the median TTFT. Overall, these results
suggest that cases with a 14q32 deletion of any type have an intermediate TTFT,
and the p-value for this distribution was considered statistically significant (p =
0.0095) [Figure 60].
All cases with available clinical information were categorized into two subsets,
including those that contained a 14q32 deletion (group 3) and those that did not contain
a 14q32 deletion. The TTFT was assessed in cases within these two subsets [Figure
61]. In this comparison, all types of 14q deletions were included in the subset of cases
with a 14q deletion. In the subset of cases that did not contain a 14q deletion, known
FISH abnormalities like deletions or nullisomy 13q, trisomy 12, deletions of 11q or 17p
that were observed as sole abnormalities or in combination with other abnormalities
were included, as well as those with normal FISH results. Although the p-value from
this Kaplan-Meier distribution was not considered statistically significant, we can
confirm that the majority of cases with a 14q32 deletion (82%; 28/34) progressed
to treatment in contrast to the 60% (46/77) in the other subset of cases that did not
contain a 14q32 deletion.

Figure 59. Kaplan-Meier distributions demonstrating TTFT for group 2. Cases in group 2 included
cases that contained any type of 14q32 deletion and were further categorized into three subgroups,
including (i) those with a 14q deletion as a sole abnormality, (ii) cases with a 14q32 deletion with an
additional abnormality, and (iii) cases with a 14q32 deletion with multiple abnormalities. These were then
compared against cases with A) a sole deletion or nullisomy of 13q B) a sole instance of trisomy 12 C)
normal FISH results D) a sole deletion of 11q or 17p.
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Figure 60. Kaplan-Meier distribution depicting time-to-first-treatment (TTFT) for all
abnormalities in group 2. The TTFT for cases in with a sole 14q deletion (including 5’
telomeric and 3’ centromeric deletions) had a shorter median TTFT (3.58 years) than those
with a sole deletion or nullisomy 13q (6.27 years), but a longer median TTFT than patients a
sole deletion of 11q or 17p (0.7 years).
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Figure 61. Kaplan-Meier distribution of time-to-first-treatment (TTFT) for cases
with and without deletions of 14q32 (group 3). Group 3 included all cases
containing a 14q32 deletion (including 5’ and 3’) as a sole deletion or with additional
abnormalities. When cases in this consolidated group of 14q deletions were
compared with all other cases without a 14q deletion, the cases with 14q32 deletions
had shorter median TTFT than cases without a 14q32 deletion; however, these
results were not statistically significant.
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Overall Survival (OS)
The overall survival for all cases was assessed, and again, these assessments
were separated into two distinct groups based on the type of 14q32 deletions that were
present in each FISH study [Table 18]. Overall survival was defined as the time from
diagnosis to death or last follow-up. Those cases that were alive at last follow-up were
censored, which included the majority of cases in each group. There were 95 cases
included in the analysis of OS for group 1 and 75 (79%; 75/95) of these cases were still
alive at the time of the last follow-up; however, the majority of cases (67%; 4/6) that
had a sole 5’ telomeric 14q32 deletion did not survive. The average age for these six
cases was 64.1 years, and five of these six cases were male. These cases exhibited
Modified Rai staging from low to high, with two cases each of intermediate stage and
high stage, one case of low stage, and one case with Modified Rai staging unavailable.
The IGHV mutation status information was not available for these cases. Similar to the
TTFT analysis, we compared cases with a 5’ telomeric 14q32 deletion (group 1) with
those cases that a sole deletion or nullisomy 13q [Figure 62A], sole trisomy 12 [Figure
62B], normal FISH results [Figure 62C], and a sole deletion of 11q or 17p [Figure 62D].
The majority of cases (97%) with a sole deletion or nullisomy of 13q were still alive at the
time of the last follow-up, and the Kaplan-Meier distribution including these cases with all
instances of 5’ telomeric 14q32 deletions was considered statistically significant (p =
0.0011) [Figure 62A]. Overall, it appears from all distributions that cases with a
sole 5’ telomeric 14q32 deletion or cases with a 5’ telomeric 14q32 deletion with
one additional abnormality (deletion of 13q or trisomy 12) appear to have poorer
overall survival as compared to those cases that had a 5’ telomeric 14q32 deletion
and multiple additional FISH abnormalities [Figure 63]. The p-value for this
Kaplan-Meier distribution was considered statistically significant (p = 0.006).

Figure 62. Kaplan-Meier distributions of OS for group 1. Cases that contained a 5’ telomeric
14q32 deletion were categorized into subgroups and compared against cases with A) a sole deletion
or nullisomy of 13q B) a sole instance of trisomy 12 C) normal FISH results D) a sole deletions of 11q
or 17p.
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Figure 63. Kaplan-Meier distribution showing overall (OS) for all abnormalities in group 1. The
majority of patients in this analysis were still alive at the time of study and were censored. A total of
four patients (67%; 4/6) with a sole 5’ telomeric 14q32 deletion did not survive. Although these
results suggest that patients that have a 5’ telomeric 14q32 deletion have a poorer overall survival,
various factors impacting OS should be taken into consideration before deriving a conclusion based
on this study with a limited number of cases.
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However, due to multiple factors implicating survival and because of the limited number
of cases in this study, these values should be viewed with caution. Interestingly, 90%
(10/11) of cases with a 5’ telomeric 14q32 deletion and multiple additional FISH
abnormalities were still alive at the time of the last follow-up, even considering that
seven cases in this subset had known poor-prognostic FISH abnormalities like deletions
of 11q and 17p. One patient that did not survive in this subset had a deletion of 13q14, a
5’ partial telomeric 14q32 deletion, and concurrent deletions of 20q12 and 20q13 that
were also observed in the karyotype.
The OS distribution for group 2 included cases with 5’ telomeric and 3’
centromeric deletions that were subcategorized as described previously for TTFT and
compared with cases containing other sole abnormalities. There were 103 cases that
were included in the OS analysis for group 2 and 21 (20%; 21/103) of these cases did
not survive. Only 33% (4/12) of cases with a sole 14q32 deletion included in this group
did not survive, and these were the same four cases that had a sole 5’ telomeric 14q32
deletion that did not survive from group 1. The majority of cases included in the sole
14q32 deletion category in group 2 exhibited intermediated Modified Rai staging (42%)
and were male (83%). Similar to group 1, the cases that had a sole 14q deletion, or a
14q deletion with one additional abnormality had the poorest median overall survival as
compared to those cases with a sole deletion or nullisomy 13q [Figure 64A]. The
median overall survival of cases with a sole 14q32 deletion and those with a 14q32
deletion and one additional FISH abnormality (deletion/nullisomy 13q14 or trisomy 12)
was similar, with the same number of surviving cases in each group. From these
distributions, it appears that cases with a sole 14q32 deletion, or those with a
14q32 deletion and one additional abnormality, have the shortest overall survival,
irrespective of the type of 14q32 deletion [Figure 65]. As was the case in group 1,

Figure 64. Kaplan-Meier distributions illustrating OS for group 2. Cases that contained any type of 14q32
deletion were categorized into subgroups and compared against cases with A) a sole deletion or nullisomy of
13q B) a sole instance of trisomy 12 C) normal FISH results D) a sole deletions of 11q or 17p.
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Figure 65. Kaplan-Meier distribution showing OS for all abnormalities in group
2. Similar to group 1, the patients that had any type of 14q32 deletion had poorer
overall survive than other sole abnormalities.
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the p-value for this assessment with all distributions was considered statistically
significant (p = 0.017); however, due to multiple factors that may impact overall survival,
these results should be viewed with caution. The overall survival for all cases that
contained a 14q deletion (group 3) was also compared against those cases that did not
contain a 14q deletion [Figure 66]. The cases that did not contain a 14q abnormality
included instances of sole FISH abnormalities as well as multiple FISH abnormalities
observed per case. There were 75% (27/36) of cases with a 14q deletion that were still
alive at the time of the last follow-up as compared to 80% (63/69) that were alive that did
not have a 14q deletion. The p-value for this distribution was not considered statistically
significant.
From these results, it is evident that cases with a sole deletion of 14q32 are
trending toward having an intermediate median TTFT. It does not seem as though the
type of deletion of 14q32 included in each group (3’ centromeric, 5’ telomeric, or both)
had an impact on the overall results for TTFT and OS. Although some of these results
are statistically significant, additional studies utilizing a larger cohort of cases included in
each subset need to be performed to assess the true clinical significance that 14q32
deletions have on TTFT and OS. With additional cases in each category, including those
with deletions of 14q32, it may be possible to assess the impact that these deletions
have on time-to-treatment, as well as if the presence of a 14q32 deletion or a specific
type of 14q32 deletion has an impact on overall survival.

Figure 66. Kaplan-Meier distribution depicting overall survival (OS) for consolidated
cases with any deletion of 14q32 (group 3) and cases with and without deletions of
14q32. In this comparison, cases with any type of 14q deletion (including 5’ telomeric and 3’
centromeric deletions) as a sole or with additional abnormalities had a poorer overall survival
than those without a 14q32 deletion, but nearly the same percentage of patients were alive at
the time of last follow-up (75% vs. 80%).
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CHAPTER 4: DISCUSSION
Chronic lymphocytic leukemia is the most predominant leukemia in the Western
world. It the most prevalent of the chronic leukemias with nearly 21,000 newly diagnosed
cases in the United States in 2019 (Siegel et al., 2019). CLL develops as a result of the
accumulation of incompetent lymphocytes that fail to undergo apoptosis and can involve
the bone marrow, peripheral blood, and lymphatic system (Campo et al., 2017; Naeim et
al., 2009). The incidence of this leukemia rapidly increases with age and is observed
most often in adults with an average age of 70. The occurrence of CLL exhibits variation
in ethnic groups and is very rare in Asian populations (S. M. Yang et al., 2015). The
disease prognosis varies by individual, and several prognostic markers are used to
determine the severity of the disease. Initially, the Rai and Binet clinical staging systems
helped to establish the aggressiveness of the disease. New prognostic tools including
immunophenotyping for CD38, CD49d, and ZAP-70, assessing the mutation status of
the variable segments of the immunoglobulin heavy chain genes (IGHV) and TP53, and
characterizing genetic abnormalities detected by conventional cytogenetics and FISH
are now used to predict the outcome for individuals diagnosed with CLL (Campo et al.,
2017; Wierda et al., 2020). Treatment decisions are based on prognostic markers,
clinical-stage, patient age, and patient comorbidities. CLL is a genetically heterogeneous
disease that may result in numerous cytogenetic abnormalities. Historically, cytogenetic
studies have provided insight into cancer prognosis by defining disease-specific genetic
abnormalities (Döhner et al., 2000; Schnaiter et al., 2011). The prognostic significance of
many of the recurrent cytogenetic abnormalities has been established, and taken with
other disease hallmarks can determine the overall prognosis for an individual with CLL.
The publication of a hierarchical prognostic classification for cytogenetic abnormalities
detected by interphase FISH studies highlighted FISH testing as the gold-standard for
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cytogenetic evaluation of abnormalities in CLL patients (Döhner et al., 2000). Since then,
the current gold standard for cytogenetic testing in CLL patients includes conventional
cytogenetics (G-banding) and FISH studies with a panel of probes specific to
abnormalities identified in CLL (Amare et al., 2013; Döhner et al., 2000; O'Malley et al.,
2011; Puiggros et al., 2014; Urbankova et al., 2014). Over 80% of all cases of CLL carry
genetic abnormalities identified by FISH studies (Campo et al., 2017; Döhner et al.,
2000). Recurrent cytogenetic aberrations that occur in CLL can be identified using one
or both of these techniques (Amare et al., 2013; Puiggros et al., 2014); however,
submicroscopic abnormalities may be preferably detected by FISH. More recently,
specific treatments have been defined for particular cytogenetic abnormalities.
Numerous studies have focused on the biology and the prognostic implications of
common cytogenetic abnormalities in CLL (Döhner et al., 2000; Haferlach et al., 2007;
Mehes, 2005; Schnaiter et al., 2011). FISH primarily detects several of the recurrent
abnormalities identified by cytogenetic studies; however, FISH studies are limited to the
detection of abnormalities that are interrogated by the FISH probes. One well
established disease-related locus in B-cell malignancies is the 14q32 chromosome
region that encodes many genes located in the IGH gene region. Translocations
involving 14q32 occur in a majority of B-cell malignancies but are rare in CLL (Baliakas
et al., 2015; Berkova et al., 2008; Cavazzini et al., 2008; Cavazzini et al., 2012).
Submicroscopic deletions of 14q32 in cases with CLL have been noted by FISH in a few
studies, with a relatively low overall incidence (Amare et al., 2013; Berkova et al., 2008;
Quintero-Rivera et al., 2009; Reindl et al., 2010; Wlodarska et al., 2007). Some of these
studies have distinguished the difference between deletions of the 3’ centromeric or 5’
partial or complete telomeric portions of 14q32 with the use of a dual-color break-apart
probe. Partial and complete deletions of the 5’ telomeric end of 14q have been described
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in some studies, noted by a diminished signal in the case of a partial deletion, or
complete loss of a probe signal for a complete deletion (Amare et al., 2013; Berkova et
al., 2008; Quintero-Rivera et al., 2009; Wlodarska et al., 2007). Deletions of the 3’
centromeric region were noted to be a rare occurrence (Amare et al., 2013; Wlodarska
et al., 2007). Other studies have characterized large, interstitial deletions of 14q, which
have been associated with trisomy 12 (Cosson et al., 2014; Pospisilova et al., 2007;
Reindl et al., 2010). These reports were focused on various cytogenetic aspects of CLL
with limited emphasis on the association of the 14q32 region. Also, there is a paucity of
information regarding size variations of telomeric 14q32 deletions in CLL and its impact
on prognosis. We performed a retrospective analysis to identify the frequency and
variation of this specific genetic alteration that has not been thoroughly investigated. By
combining conventional cytogenetic techniques with molecular applications, we have
now comprehensively identified the frequency and variation in deletions of 14q32. We
have studied the clinical correlation of this finding in a subset of consented cases of
CLL/SLL that were investigated at the University of Nebraska Human Genetics
Laboratory.
A total of 698 cases with a clinical indication of CLL were analyzed to assess the
frequency of cytogenetic and FISH abnormalities that are associated with chronic
lymphocytic leukemia. Of the 698 cases, the majority of individuals were males with a
nearly 2:1 male to female ratio that is consistent with the literature [Figure 20] (Campo
et al., 2017). Conventional cytogenetic studies were performed on nearly 90% of cases
in this study, with abnormal karyotypes observed in 44% of these cases [Table 5] that is
consistent with a 40 – 50% abnormality rate reported by conventional cytogenetic
studies (Döhner et al., 2000). In our study, abnormalities observed by karyotype ranged
from a single abnormality to complex karyotypes involving three or more abnormalities in
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the same clone. A karyotype identified a sole cytogenetic abnormality in 53% (146/274)
of cases [Figure 21]. The most common sole abnormality observed in this cohort of
cases was trisomy 12, which was identified by a karyotype in 31% of cases. Several of
the cases with a sole karyotypic abnormality had a loss of a sex chromosome. Only four
of these cases (17%; 4/23) had a loss of the Y chromosome in greater than 75% of cells
by conventional cytogenetics. Sex chromosome loss has been associated with
advanced age, except when the percentage of cells with sex chromosome loss exceeds
75% of the total number of cells analyzed (Wiktor et al., 2000). Trisomy 12 and loss of
the Y chromosome involve complete chromosome loss, and hence these abnormalities
are typically visible by conventional cytogenetics. Other abnormalities, including
deletions of 14q32, are often submicroscopic and can most often be detected by FISH
studies.
Two abnormalities were observed by karyotype in the same clone in 53 (19%;
53/274) cases, and a complex karyotype was detected in the remaining 75 (27%;
75/274) cases [Figure 21]. A complex karyotype has been defined as a karyotype with
at least three chromosomal aberrations (Cavazzini et al., 2008; Rigolin et al., 2017). All
recurring aberrations that are characteristic of CLL have been observed in complex
karyotypes, with many karyotypes resulting in the loss of the TP53 gene region on 17p.
Complex karyotypes are associated with an adverse prognosis in several types of
leukemia, and there is evidence to suggest that this is also the case in CLL (Baliakas et
al., 2019; Cavallari et al., 2018; Puiggros et al., 2017). In most cases, complex
karyotypes have been associated with an unmutated IGHV gene (U-CLL) (Baliakas et
al., 2014; Cavallari et al., 2018; Haferlach et al., 2010).
FISH studies were performed utilizing a panel of FISH probes specific to
recurrent aberrations that are identified in CLL cases and included the probes for 6q23

171

(MYB), 12 centromere, 11q22.3 (ATM), 13q14 and 13q34, 17p13.1 (TP53), 14q32 (IGH),
and IGH/CCND1 fusion. The combination of FISH probes used for cases with suspected
CLL has changed over the last two decades, with probes to identify IGH/CCND1 fusion
and abnormalities of 6q23 as the most recent additions. In this cohort, FISH studies
were performed on the majority of cases and were abnormal in 77% of these cases
[Table 6], which is nearly consistent with the reported 80 – 90% FISH abnormality rate
identified by the WHO and others (Campo et al., 2017; Döhner et al., 2000,Haferlach,
2007). FISH abnormalities in this cohort of cases ranged from sole abnormalities to more
than three abnormalities. Many cases showed intratumoral heterogeneity with several
populations of clonal abnormalities represented, which suggests the presence of clonal
evolution. When appropriate, additional FISH probes were added to a case to delineate
a complex karyotype further or confirm a variant signal pattern. Of the 536 cases that
were determined to be abnormal by FISH, 46% of abnormal cases were found to have a
sole abnormality by FISH, and 35% of abnormal cases had two detected abnormalities.
FISH identified three or more abnormalities in the remaining 19% of abnormal cases
[Figure 22]. Normal FISH results were observed in 160 cases that were studied with a
panel of CLL-specific probes.
Combined Used of Conventional Cytogenetics and FISH
The gold-standard for genetic testing in CLL is to utilize conventional
cytogenetics by the use of a karyotype and a panel of probes specially curated to detect
abnormalities with prognostic relevance in CLL. FISH studies are beneficial to detect
chromosomal abnormalities with prognostic significance, but conventional cytogenetics
can help further decipher abnormalities detected by FISH and detect additional
abnormalities not included in the panel of probes utilized for FISH analysis. In our study,
conventional cytogenetics and FISH studies were performed in combination in 89% of
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cases. The abnormality rate for karyotypic analysis was 44%, while the abnormality rate
for FISH studies was 75%. The combined use of both studies increased the abnormality
detection rate to 79% highlighting the importance of utilizing both conventional
cytogenetics and FISH studies [Table 7]. Although conventional cytogenetics can aid in
detection of abnormalities not interrogated by the FISH panel, including loss of a sex
chromosome, the detection of prognostically-relevant abnormalities observed in CLL
was more facilitated by FISH studies. It is important to note that some abnormalities like
deletions of 13q14 and partial deletions of 14q32 are often cryptic by conventional
cytogenetics due to the lower resolution of G-banded chromosome preparations, but are
detectable by FISH studies.
Recurrent FISH Abnormalities in CLL
Recurrent FISH abnormalities with known significance in CLL were identified in
the population of 536 abnormal cases. Overall, a total of 307 cases (57%; 307/536) had
a deletion of 13q14 or nullisomy 13q14, either as a sole abnormality or in combination
with other abnormalities detected by FISH. Although deletions of 13q are the most
common FISH abnormality detected in CLL, small deletions of 13q are much more
challenging to visualize cytogenetically, due to the limited resolution of karyotyping.
Deletions of 13q14 have been reported in the literature in over 50% of individuals with
CLL, and as the most common abnormality detected by FISH studies, which is also
consistent with our findings (Döhner et al., 2000; Hallek, 2017; Puiggros et al., 2014;
Stockero et al., 2006). In this study, deletions of 13q14 were also the most common sole
FISH abnormality and were detected in 35% of cases with sole abnormalities with
nullisomy of 13q14 occurring less frequently [Figure 23]. From a genetic standpoint, an
isolated monoallelic deletion of 13q14 suggests a benign clinical disease course and is
in the lowest risk category compared to those with normal FISH results (Hallek, 2017;
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Puiggros et al., 2014). Nullisomy or biallelic deletions observed on both homologs have
been reported in approximately 8 – 20% of cases with CLL (Döhner et al., 2000;
Ouillette, Collins, Shakhan, Li, Li, et al., 2011; Puiggros, Delgado, et al., 2013). It is
worth noting that 20% (60/307) of the cases in our study with a 13q deletion had a
deletion of 13q14 and nullisomy 13q14 detected in different percentages of cells in a
single case. The co-occurrence of both a clone with a monoallelic 13q14 deletion and a
clone with biallelic 13q14 deletions have been previously reported in the literature with a
frequency of 9.3% in one study with no significant differences in clinical outcome. This
study also noted that biallelic deletions of 13q14 occurred at nearly the same frequency
as those cases with co-occurrence of both monoallelic and biallelic deletions of 13q14
(Puiggros, Delgado, et al., 2013).
Trisomy 12 was the most common abnormality observed by conventional
cytogenetics in this study but was the third-most frequent FISH abnormality observed.
Our studies reported trisomy 12 in 28% of abnormal cases, which is higher than the
previously reported rate of 10 – 20% in the literature (Campo et al., 2017; Delgado et al.,
2012; Döhner et al., 2000; Eid et al., 2014; Mehes, 2005; Puiggros et al., 2014). Trisomy
12 was the second-most frequent sole abnormality (23%) observed by FISH studies
[Figure 23]. Cytogenetically, trisomy 12 is associated with an intermediate prognosis
(Abruzzo et al., 2018; Mehes, 2005). Cases of CLL with trisomy 12 have also been
associated with unmutated IGHV genes (U-CLL), which is a known poor prognostic
marker, and also with mutated IGHV genes (M-CLL) (Abruzzo et al., 2018; Campo et al.,
2017). It is not uncommon for trisomy 12 to be accompanied by additional cytogenetic
abnormalities detected by karyotype and/or FISH analysis, as was the case in this study.
Deletions of 11q22.3 and 17p13.1 were observed the least amount of times in
this study and were observed in approximately 10% and 9% of abnormal cases,
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respectively. The reported frequency for deletions of 11q22.3 in CLL is approximately 5 20% (Delgado et al., 2012; Döhner et al., 2000) that is consistent with our findings. In
our study population, a deletion of 11q22.3 was observed as a sole abnormality by FISH
studies in only 10 cases [Figure 23]. Of note, only one of the 10 cases with a sole 11q
deletion by FISH had complex karyotype. Deletions of 17p are historically reported in a
smaller percentage of cases (2 – 4%) with CLL at the time of diagnosis, but the
frequency of these deletions increases with disease progression (Delgado et al., 2012).
A deletion of 17p was observed in our cohort in only five cases as a sole abnormality by
FISH [Figure 23]. Three of these cases had a complex karyotype, and one case had a
normal karyotype. The remaining case was not studied by conventional cytogenetics.
Deletions of 11q and 17p are associated with the poorest prognosis from a cytogenetic
perspective, with deletions of 17p having the worst overall prognosis. Most often, both
deletions of 11q22.3 and 17p13.1 are associated with unmutated IGHV (U-CLL), a
known poor prognostic indicator (Campo et al., 2017), implying that these cases follow a
different pathway that leads to an unfavorable prognosis. Although deletions of 17p are
traditionally associated with a poorer prognosis and are frequently acquired as a
secondary event, the clinical course of CLL in cases with de novo 17p deletions is
clinically heterogeneous and varies with additional adverse factors (Tam et al., 2009).
Nearly half of the cases with a complex karyotype in this study were associated with
deletions of 11q and/or 17p by FISH studies (48%; 36/75). Complex karyotypes, with or
without 11q or 17p deletions, suggest advanced disease and poor clinical outcomes in
CLL patients (Baliakas et al., 2014; Puiggros et al., 2017). A more recent study suggests
that the presence of five or more karyotypic abnormalities presents with the highest risk
(Baliakas et al., 2019).
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Deletions of 6q were observed by FISH in 15 cases in our study; however, the
introduction of the LSI MYB (6q23) FISH probe to the CLL FISH panel did not occur until
late 2012 and was not studied by FISH in 31% of cases in our study. It is worth noting
that a deletion of 6q was observed as a sole FISH abnormality in only three cases
[Figure 23]. The reported frequency of 6q deletions in CLL from the literature is
approximately 3 – 10% (Dalsass et al., 2013; Döhner et al., 2000; Shahjahani et al.,
2015; D. M. Wang et al., 2011), with both deletions of 6q21 and 6q23 (MYB) reported.
Deletions of 6q are mostly observed as a secondary abnormality and are also
associated with complex karyotypes (Dalsass et al., 2013; Finn et al., 1998; D. M. Wang
et al., 2011). Further, deletions of 6q may also be associated with atypical morphology
and unmutated IGHV (U-CLL) (Döhner et al., 2000). Despite the later use of the FISH
probe for 6q in this series, our results are in accordance with the reported abnormality
rate and its rare existence as a sole abnormality.
Frequency of 14q32 Deletions in Retrospective Study
After the prognostic significance of abnormalities detected by FISH studies was
established, many labs implemented a specific panel of FISH probes to detect these
abnormalities. However, not all studies utilized FISH probes to assess the IGH gene
region at 14q32. Abnormalities involving the IGH gene region, including deletions and
translocations, have been reported in CLL and other mature B-cell malignancies.
Although both 14q32 deletions and translocations have been described in CLL, there is
limited data with focused studies on the frequency of abnormalities involving 14q32,
including deletions. Not all studies assessed 14q32 with the use of a dual-color breakapart probe, hampering an accurate assessment of this region. In addition, most studies
were not able to distinguish subtle deletion patterns that would be suggestive of a partial
deletion of the variable region of 14q32. Aberrations of 14q32 were the second most
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common abnormality detected by FISH studies in this series and were observed in 35%
of cases overall. This percentage of cases with a 14q32 abnormality is higher than a 29
– 32% IGH aberration rate previously reported (Amare et al., 2013; Quintero-Rivera et
al., 2009). Our study showed 14q32 (IGH) abnormalities in different forms including,
partial and complete deletions, rearrangements, and complete loss of one copy of
14q32, with most cases having a 14q32 deletion. Abnormalities involving 14q32,
including deletions, rearrangements, and other changes, were the third most common
sole abnormality that was observed in cases in this study. Sole FISH abnormalities may
be the primary event that likely causes disease initiation, and may also suggest
prognostic significance. Many studies fail to assess the presence of sole FISH
abnormalities and lump these cases into groups that have more than one FISH
abnormality. Accurate detection of sole abnormalities, including those involving 14q32,
may help ensuing studies to understand if the clonal progression and the sequence of
these acquired secondary changes.
A partial or complete deletion of 14q32 was observed in a majority of cases with
a 14q32 abnormality [Figure 29]. Several types of 14q32 deletions were observed,
including a 3’ centromeric deletion of 14q32, a 5’ complete telomeric deletion of 14q32,
and a 5’ partial telomeric deletion of 14q32, which were all distinguishable by FISH with
the use of a dual-color break-apart probe. Overall, deletions of 14q32 were observed in
37% of cases (199/536) with abnormal FISH results in this study. Partial deletions of the
5’ telomeric portion of 14q32 were observed in 82% (163/199) of cases with a 14q
deletion, and as a sole abnormality in 32 of these cases. Karyotypes were studied in
85% of cases with a 5’ partial 14q32 deletion by FISH with a deletion of 14q32 noted in
only four cases, which describes the rarity of identifying this abnormality by conventional
cytogenetics. A karyotype was also studied in a majority of cases with a sole 5’ telomeric

177

14q32 deletion; however, conventional cytogenetics was unable to detect a deletion of
14q32 due to the limited resolution of karyotyping. In most cancer studies, the band level
of a karyotype, or the total number of dark and light bands present, is low, limiting the
ability to detect small aberrations via a karyotype. The most telomeric band of
chromosome 14, at 14q32, occurs in a light band on the chromosome. It is nearly
impossible to detect a telomeric deletion of 14q32 that is not substantial in size when the
same light band of two homologous chromosomes are compared, especially if the
average band level is lower. Two normal copies of chromosome 14 by karyotype are to
be expected in these cases due to the limited resolution of metaphase analysis by
karyotype in oncology studies. A complete deletion of the 5’ telomeric portion of 14q32
was less frequent and was identified in only 10% (19/199) of cases with a 14q32
deletion, and was observed as a sole abnormality in only four cases. All four of these
cases had a normal karyotype. Deletions of 14q32 have been previously reported in CLL
with an incidence ranging from 2 – 24% (Amare et al., 2013; Berkova et al., 2008;
Quintero-Rivera et al., 2009; Reindl et al., 2010). A variety of probes have been utilized
by different investigators to study the 14q32 region, and not all of these were completely
informative. A few investigators have utilized the LSI IGH dual-color break-apart probe;
however, these studies were in a much smaller cohort. One such study reported the
complete loss of the 5’ telomeric portion of 14q32 by FISH in 22% of cases; however, a
diminished FISH probe signal indicating a partial deletion of the 5’ telomeric portion of
14q32 was not noted (Quintero-Rivera et al., 2009). Although a few studies have
distinguished the difference between partial and complete 5’ telomeric deletions of
14q32, to our knowledge, there have been no studies that have assessed these
deletions in a large study cohort.
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A study by Berkova and colleagues (2008) assessed 146 CLL cases and
mentioned the complete or partial loss of the 5’ telomeric portion of 14q32 in a subset of
these cases. Also, they identified cases with 3’ centromeric deletions in cases by utilizing
the same FISH probe. Deletions of the 5’ partial telomeric portion of 14q32 were
observed in 10% of cases in their study as compared to an overall 5’ partial deletion of
14q32 involving 23% of cases in our study. The incidence of 5’ complete telomeric
deletions occurred in approximately 10% of cases in the same study, which is higher
than the overall frequency of 5’ complete 14q32 deletions in our study (3%) (Berkova et
al., 2008). This discrepancy could be due to the difficulties in appreciating a subtly
diminished green FISH probe signal, indicating a 5’ partial telomeric 14q32 deletion. A
diminished signal or complete loss of the telomeric portion of the 14q32 FISH probe was
also noted in another study but was only assessed in 14 cases (Wlodarska et al., 2007).
The type of FISH probe used in each study may also have impacted the ability of
researchers to delineate the type of deletions, i.e., the 5’ partial telomeric deletions, 5’
complete telomeric deletions, and 3’ centromeric deletions of 14q32. Specifically, a
partial deletion of the telomeric portion of 14q32 is represented by a diminished (partial)
green probe signal, and a complete telomeric deletion is represented by the complete
loss of the green probe signal when utilizing the LSI IGH dual-color break-apart probe
(Abbott Molecular). Therefore, it is easier to determine the complete loss of the 5’
telomeric 14q32 region rather than a partial loss. The detection of 5’ partial 14q32
deletions are difficult due to the subtlety in determining the presence of the partial signal.
A 3’ centromeric deletion was the least frequently observed type of 14q32
deletion observed by FISH in this cohort and was identified in only 9% (17/199) cases,
and was observed as a sole abnormality in eight cases. A karyotype was able to
visualize this deletion in the form of a large deletion of 14q in ten of these cases. Large
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deletions of 14q that involve the 3’ centromeric portion of 14q32 are much easier to
visualize by a karyotype than deletions involving the telomeric end because of the size of
the deletion. In our study, the 3’ centromeric deletions involved breakpoints from q21 –
q32 on the long arm of chromosome 14q, which involves a large portion of the
chromosome and is more easily detected by karyotypic analysis. When defined, this
deletion is also consistently reported less frequently than 5’ telomeric deletions of 14q32
in the literature. The incidence of 3’ centromeric deletions of 14q32 is approximately 3%
(Amare et al., 2013; Berkova et al., 2008; Quintero-Rivera et al., 2009). A few studies
specifically focused on the presence of large, interstitial deletions of 14q that do not
involve the variable portion of the IGH gene region (Cosson et al., 2014; Pospisilova et
al., 2007; Reindl et al., 2010), but failed to assess the presence of 5’ telomeric 14q32
deletions. These large deletions have also been observed as a sole abnormality by
karyotype (Cosson et al., 2014; Reindl et al., 2010), and have been associated with
unmutated IGHV genes, a known poor-prognosis indicator, and are frequently observed
with trisomy 12, which confers an intermediate prognosis (Cosson et al., 2014).
A small subset of eight cases in this cohort involved more than one partial
deletion of 14q32 on one or both chromosome 14 homologs detected FISH [Figure 30].
These cases with complex deletion patterns observed by FISH were only observed in
3% (8/245) of cases with a 14q32 abnormality. We observed cases that contained a 3’
centromeric and 5’ partial telomeric deletions on the same homolog, cases with a 5’
partial deletion on both chromosome 14 homologs, cases with a 3’ centromeric and 5’
partial telomeric deletions occurring on separate chromosome 14 homologs, and one
case with the loss of one copy of chromosome 14 that resulted in a 3’ centromeric and 5’
complete 14q32 deletion on the same homolog and a 5’ partial telomeric 14q32 deletion
on the other chromosome 14 homolog. Cases with a 5’ partial deletion of 14q32
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occurring on both homologs may have a more definitive clinical impact due to the loss of
both sets of genes involved in the deleted regions. It is also possible that the presence of
two distinct deletions, like a 3’ centromeric and a 5’ telomeric deletion resulting in the
loss of different genes may have a more distinct clinical implications because of the
larger area that is deleted. It is known that deletions involving the 3’ centromeric portion
of 14q32 are associated with unmutated IGHV genes, which is an indicator of an
unfavorable prognosis. In many cases, deletions involving a more substantial portion of
the chromosome have more significant consequences in a clinical setting. At this time, it
is unclear whether two 14q32 deletions may suggest a more inferior clinical course than
a sole deletion of 14q32.
Although translocations involving the IGH gene region have been reported in
CLL, they only occur in a rare subset of cases. Several translocation partners have been
reported in the literature, including translocations involving IGH with CCND1 (11q13),
BCL2 (18q21), BCL3 (19q13), MYC (8q24), or BCL11A (2p16) (De Braekeleer et al.,
2016). The frequency of translocations in reported studies in CLL ranges from 4 – 9%
(Berkova et al., 2008; Cavazzini et al., 2008; Cavazzini et al., 2012; De Braekeleer et al.,
2016; Döhner et al., 2000). Although these translocations have been observed in a rare
population of CLL cases, it has been noted that translocations involving 14q32 result in
an unfavorable prognosis, compared to cases that have deletions of 13q, trisomy 12, or
normal cytogenetics (Cavazzini et al., 2008). In our study, an IGH rearrangement was
detected in 5% (25/536) of cases that had abnormal FISH studies and in only 4%
(25/698) of cases overall, which is within the reported range from the literature. In this
group of 25 cases, flow cytometry or final pathology was consistent with CLL/SLL,
monoclonal B-cell lymphocytosis, a lymphoproliferative disorder, or unclassified B-cell
leukemia/lymphoma. In our study, we observed a fusion or variant fusion pattern of
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IGH/BCL2 and IGH/MYC; however, in most cases, the IGH translocation partner was not
distinguished by FISH studies. A translocation between 11q13 and 14q32, resulting in
the fusion of IGH/CCND1, is a primary factor in distinguishing mantle cell lymphoma
(MCL) from CLL and is observed in >95% of cases with mantle cell lymphoma
(Swerdlow, Campo, Seto, & Müller-Hermelink, 2017). CLL and MCL are both CD5+
lymphoproliferative disorders, and cytogenetic studies are one of the tools used to
differentiate these two diseases. Instances of IGH/CCND1 fusion have been rarely
described in CLL and have been reported to be acquired later through the clinical course
of CLL or after treatment (Nishida et al., 2013; Schliemann et al., 2016). For this
purpose, there were cases with flow cytometry or final pathology of CLL/SLL,
monoclonal B-cell lymphocytosis, a lymphoproliferative disorder, or unclassified B-cell
leukemia/lymphoma and a detected IGH/CCND1 fusion by FISH studies were excluded
from our retrospective analysis. An IGH/BCL2 translocation involving 14q32 and 18q21.3
has been previously reported in several study populations of CLL cases but at a lower
incidence (Fang et al., 2019; Lu, Kong, & Yue, 2010). An IGH/MYC translocation was
observed in one case in our study has been reported in rare CLL cases (De Braekeleer
et al., 2016; Lu et al., 2010). Several cases were noted to have an IGH rearrangement
with an unknown translocation partner and, in many cases, were characterized by
additional material of unknown origin at 14q32 by karyotype. There were two cases that
FISH was not able to characterize the translocation partner with IGH that conventional
cytogenetics could clarify. One of these cases had a translocation involving 14q32 and
19q13, which encompasses the BCL3 gene locus and has been reported to be
associated with unmutated IGHV genes and a poor prognosis (De Braekeleer et al.,
2016). This translocation was not distinguishable by FISH studies because probes for
19q13 are not included in the FISH panel used for this study. However, conventional
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cytogenetics was able to characterize the translocation partner in this case. It is possible
that several cases with an unknown IGH translocation partner may have had a known
translocation like t(14;19), t(8;14), t(14;18), but these fusion probes were not studied in
the FISH panel, and therefore the true incidence of these translocations in the current
study is inconclusive. Due to the difficulty of getting CLL cells to divide in culture, these
abnormalities may not have been able to be appreciated by karyotype and may be more
prevalent in the 14 cases with unknown IGH translocations in this study.
A deletion and rearrangement of 14q32 were detected in five cases [Table 11]. In
these cases, a deletion was detected on the translocated homolog only once and on the
non-translocated homolog in the remaining cases, as well as in different cellular
populations within the same case. Only 5’ telomeric 14q32 deletions were noted in this
group of cases. Overall, this complex 14q abnormality detected by FISH occurred in less
than 1% of cases with abnormal FISH results. In the one instance where a 5’ telomeric
14q32 deletion occurs on the same homolog, it is possible that this is a subsequent
deletion that occurred following the unknown IGH rearrangement. We would expect
cases with a subsequent telomeric deletion of 14q32 following a 14q32 rearrangement to
have a more significant clinical impact because of the broader chromosomal region
involved on chromosome 14 that would impact more genes. Since translocations
involving 14q32 have been noted to have an unfavorable prognosis, it would be difficult
to determine if the prognosis worsens with the addition of a telomeric 14q32 deletion
without studying the impact of the combined aberrations in a large population of cases.
In most cases where the IGH deletion occurred on the non-translocated homolog and in
different cellular populations, the 5’ telomeric 14q32 deletion occurred in a higher
percentage of cells than the 14q32 rearrangement. Since most FISH studies in CLL
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have not investigated the various 14q32 abnormalities in great detail, it is unknown if
these abnormalities administer a variable impact on prognosis.
One additional FISH abnormality was detected in 49% of cases with a deletion of
14q32 [Figure 32]. In this group of 94 cases, 82% of these cases had a 5’ partial 14q32
deletion, 11% had a 5’ complete 14q32 deletion, and 7% had a 3’ centromeric 14q32
deletion. The three most common abnormalities that were observed with deletions of
14q32 by FISH were a deletion or nullisomy of 13q14 and trisomy 12 [Figure 33].
Deletion of 13q14 was observed in 53% (41/77) of the cases with a 5’ telomeric14q32
deletion. Nullisomy 13q14 was also observed in cases with a 5’ telomeric 14q32 deletion
but was detected at a lower frequency than a single deletion of 13q14. However, a
13q14 deletion or nullisomy 13q14 was not observed as an additional abnormality with a
3’ centromeric 14q32 deletion when looking at cases with only two abnormalities
identified by FISH. The association of deletions of 13q14 with deletions of 14q32 has
been noted by an additional study (Quintero-Rivera et al., 2009); however, it is not
possible to confirm whether these abnormalities are observed together at a higher
frequency, or if this is a coincidence because deletions of 13q14 are the most common
FISH abnormality observed in cases of CLL.
Trisomy 12 was the second most common aberration that was observed with a
deletion of 14q32 [Figure 33]. Trisomy 12 was observed in cases with 5’ partial or
complete deletions of 14q32 as well as in six of the seven cases in this group with a 3’
centromeric 14q32 deletion. It has been previously noted that trisomy 12 is associated
with approximately 45 – 50% of cases with a large deletion of 14q32 (Cosson et al.,
2014; Reindl et al., 2010). In one study, Cosson and colleagues determined that cases
with trisomy 12 had longer treatment-free survival (TFS) than cases with trisomy 12 and
a large deletion of 14q (Cosson et al., 2014). To our knowledge, there have been no
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studies that have mentioned the frequency of 5’ partial or complete telomeric 14q32
deletions with trisomy 12, as well as the prognostic implications of these two
abnormalities combined.
FISH studies detected a deletion of 11q22.3 in addition to a 5’ telomeric deletion
of 14q32 in six cases, and only one case had a deletion of 17p13.1 in addition to a 5’
partial telomeric deletion of 14q32 [Figure 33]. This finding is consistent with the lower
incidence of deletions of 11q and 17p observed by FISH in this cohort. It is interesting to
note that no cases had an 11q or 17p deletion with a 3’ centromeric 14q32 deletion as
the only additional FISH abnormality. This could be because cases with a 3’ centromeric
14q32 deletion may follow an independent path of progression rather than requiring an
additional secondary abnormality that would include the probable loss of ATM on 11q or
TP53 on 17p while suggesting that cases that have a 5’ telomeric 14q32 deletion may
follow more or a benign course without the presence of a poor-prognostic indicator like
deletions of 11q and 17p.
Overall, with our retrospective study, we have confirmed that abnormalities of
14q32, and more commonly deletions of 14q32 occur frequently, and were the secondmost-common abnormality detected by FISH studies in our study cohort. While 3’
centromeric 14q32 deletions can be detectable by conventional cytogenetic methods, 5’
partial and complete telomeric 14q32 deletions are rarely detected. Although these
deletions are rarely detectable by karyotype, a deletion of 14q32 was seen in the
majority of cases with a 14q32 abnormality. After confirming that 14q32 deletions
frequently occur within our study population, we sought to determine the size differences
of 3’ centromeric and 5’ complete and partial telomeric 14q32 deletions by utilizing
microarray studies.
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Variation in 14q32 Deletion Size by Microarray
Microarray studies are useful in deciphering genetic abnormalities and can
interrogate the same abnormalities that are detected in a standard FISH panel, except
for detecting balanced translocations and incidences of low-level mosaicism. Genomic
microarray studies are most helpful in investigating hematological neoplasms like CLL,
where primary and secondary genetic lesions are more commonly gains and losses
rather than translocations and inversions, and these abnormalities have prognostic
significance. Several studies have focused on using array-based karyotyping to detect
genetic abnormalities associated with CLL and have highlighted several advantages and
disadvantages to using this technique. Most notably, the addition of microarray studies
has enhanced the detection of cryptic alterations and uncovered novel aberrations that
may become critical prognostic indicators in the future in these cases. The use of copynumber microarray to complement conventional cytogenetics and FISH studies for CLL
has been suggested by several investigators (Houldsworth et al., 2014; Kolquist et al.,
2011; O'Malley et al., 2011; Ouillette, Collins, Shakhan, Li, Peres, et al., 2011; Puiggros,
Puigdecanet, et al., 2013; Stevens-Kroef et al., 2014). Several array platforms have
been utilized to assess further genetic copy number abnormalities associated with CLL,
including bacterial artificial chromosome (BAC) and oligonucleotide arrays, and most
recently, single nucleotide polymorphism (SNP) arrays (Chun et al., 2018; Gunnarsson
et al., 2013). High-resolution array-based technologies have added value to assessing
genomic aberrations across the genome at a higher resolution than conventional
cytogenetics and FISH testing. While these arrays provide a detailed picture of gains
and losses present in tumor samples, SNP arrays can also detect copy-neutral loss of
heterozygosity (CN-LOH). The number of copy number changes observed in CLL at the
time of diagnosis have been noted to be lower than other hematological malignancies,
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with chromosome loss occurring more frequently than gains. At diagnosis, approximately
80 – 90% of CLL cases have at least one copy number change (Chun et al., 2018;
Ouillette & Malek, 2013). The majority of aberrations detected in CLL patient samples
are copy-number based. On average, the number of copy number changes per patient
with CLL is generally low, with 0 – 2 aberrations detected per patient (Chun et al., 2018;
Ouillette & Malek, 2013). It is essential to establish a minimal deleted region (MDR) for
deletions detected by microarray as well as a commonly gained region to pinpoint
specific genes that are lost or gained in common aberrations observed in multiple cases.
Although SNP microarray studies are a beneficial tool for detecting clonal copy number
changes, the lower limit of abnormality detection is hindered by the level of mosaicism
present in the tumor (Hagenkord et al., 2010; Pfeifer et al., 2007).
The IGH variable region at chromosome band 14q32 is one of the most complex
regions in the human genome, and is highly polymorphic and varies from individual to
individual. Rearrangements and deletions have been reported in this region in many Bcell malignancies, including CLL. However, it is unknown whether the deletion size
contributes to the disease status, or if a 14q32 deletion of any size is enough to have
prognostic implications. Although the studies of Quintero-Rivera et al. focused on the
frequency of 14q32 (IGH gene region) deletions in CLL (Quintero-Rivera et al., 2009),
there have been no studies addressing the variation in size of 5’ telomeric 14q32
deletions. From our retrospective analysis, we confirmed that deletions of the IGH gene
region occur frequently and noted 57 cases as having a sole 14q32 deletion. After
confirming that 14q32 deletions frequently occur within our population of cytogenetically
abnormal cases, we aimed to assess the variation in the size of the 14q32 deletion
observed in a subset of cases. FISH studies permit the detection of a partial loss of
14q32 resulting in either a 3’ centromeric or 5’ partial or complete telomeric deletion but
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are not able to determine the size of the deletion or the specific genes involved.
Specifically, when FISH studies detect 5’ partial deletions of 14q32, it is unknown what
portion of the diminished probe signal is lost. SNP microarray studies in combination
with conventional cytogenetic karyotyping and FISH analysis made it possible to
determine the specific breakpoints involved in a subset of 40 cases with confirmed
14q32 deletions by FISH. Overall, a 5’ partial or complete telomeric 14q32 deletion was
detected by FISH in 35 cases in this subset. A 3’ centromeric deletion was detected in
two cases, two cases had a loss of one copy of 14q32, and one case had a 3’
centromeric and 5’ partial telomeric 14q32 deletion occurring on the same homolog.
SNP microarray confirmed a 5’ partial or complete telomeric deletion in 33 of the
35 cases [Table 14]. Microarray studies were not able to detect a 5’ telomeric 14q32
deletion in two cases due to low-level mosaicism. These two cases had a 5’ partial
14q32 deletion that only occurred in 12% of cells by FISH and therefore was
undetectable by microarray. We also determined the approximate size variation of the 5’
telomeric 14q32 deletions, ranging from 236 to 1,401 kb. The minimum deleted region
(MDR) for the 33 cases with a 5’ telomeric 14q32 deletion was 123 kb in size but did not
include any genes of interest. However, 32 of these cases had an identical 214 kb MDR
that included LINC00221 [Figure 35]. Sole 5’ telomeric 14q32 deletions were detected in
six cases overall by microarray, four with a 5’ partial telomeric 14q32 deletion and two
with a 5’ complete telomeric deletion of 14q32. The MDR for the sole 5’ partial telomeric
14q32 deletions overlapped LINC00226 and LINC00221 [Figure 38], while the MDR for
the cases with 5’ complete telomeric deletions was 971 kb. Overall, four main genes
were involved in the 5’ partial and complete telomeric 14q32 deletions; however, the
majority of these genes are non-protein coding. These genes include FAM30A, ADAM6,
LINC00226, and LINC00221. Long non-coding RNAs (lncRNA), which are non-coding
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RNAs greater than 200 base pairs in length, are involved in many biological processes,
including regulatory functions, and chromatin remodeling (Dahl, Kristensen, & Grønbæk,
2018; G. Yang, Lu, & Yuan, 2014), and cellular processes like proliferation,
differentiation, and apoptosis (Abo Elwafa, Abd Elrahman, & Ghallab, 2020). Because
CLL arises due to an apoptosis defect, these regions may have an impact on the
pathogenesis of CLL. Recently, lncRNAs are emerging as critical regulators in many
cancers and hematologic malignancies. The lncRNAs are reported to bind to miRNAs
and facilitate tumorigenesis and metastasis in several diseases, including leukemia
(Huang et al., 2020). One particular lncRNA, GAS5, has been speculated to facilitate
tumorigenesis and metastasis of B-cell lymphocytic leukemia by acting as a sponge of
miR-222 and that the loss of this lncRNA may stimulate the progression of B lymphocytic
leukemia (Jing et al., 2019). FAM30A is an immune-related long non-coding RNA that is
highly expressed in B-cells and correlates with the expression of neighboring
immunoglobulin heavy genes (de Lima et al., 2019). In one study, FAM30A was
differentially upregulated and positively correlated with the fraction of plasma cells in oral
disease and was involved in immune response (Wu et al., 2020). ADAM6 (ADAM
metallopeptidase domain 6, pseudogene) is within the deleted 14q32 region in many
cases, but there is minimal information about the function of this pseudogene. This
pseudogene belongs to a family of proteins that are involved in cell adhesion, migration,
proteolysis, and cell signaling (van Goor, Melenhorst, Turner, & Holgate, 2009). ADAM6
has recently been implicated as a potential marker involved in the miRNA-lncRNAmRNA interaction network and could be used as a therapeutic target in lung
adenocarcinoma (Hu et al., 2019) and has also been targeted as a prognostic biomarker
in melanoma (Chiu et al., 2014). Long intergenic non-coding RNAs (lincRNA) like
LINC00226 and LINC00221 can alter gene expression by targeting chromatin
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modification or RNA binding proteins (Tsai, Spitale, & Chang, 2011). However, they do
not overlap annotated protein-coding genes (Ransohoff, Wei, & Khavari, 2018). Although
these lincRNAs are not translated into a protein, the loss of these regions may still
impact a gene that does not fall within the deleted area. Since 32/33 of cases with a 5’
telomeric deletion resulted in the loss of LINC00221, and 28/33 cases overlapped
LINC00226, we suspect that these non-coding RNAs may have significance. LINC00226
is noted to be downregulated in pancreatic ductal carcinoma (Yu, Lin, Sui, Zou, & Lv,
2017). Although FAM30A, ADAM6, or LINC00226 have been reported in various
cancers, little is known about the association of these regions in hematological
malignancies. In contrast, the long intergenic non-protein coding RNA 221, or
LINC00221, which was the only gene detected in the MDR for 32 cases with 5’ telomeric
14q32 deletions by microarray studies, has been implicated in several cancers,
hematological malignancies. LINC00221 has also been shown to be highly expressed in
cisplatin-resistant non-small-cell lung cancer (NSCLC) cells and tissues, and is closely
associated with a poor prognosis. In this study, LINC00221 regulated the sensitivity of
cisplatin-resistant cells by preventing the binding of miR-519a (Tang, Han, Li, Li, & Hao,
2019). In another study, the upregulation of LINC00221 was significantly related to the
progression of muscle-invasive bladder cancer (H. Wang et al., 2016). Another study
identified LINC00221 as a prognostic biomarker for hepatocellular carcinoma (HCC).
More recently, LINC00221 has been associated with acute myeloid leukemia (AML) and
acute lymphocytic leukemia (ALL). Huang et al. (2020) noted that LINC00221 was downregulated in AML and ALL cells when compared to control cells. They also noted that
LINC00221 demonstrated anti-proliferation and pro-apoptosis effects on ALL cells by
down-regulating the ATP2A2 gene that provides instructions for enzyme production.
These previous findings suggest that LINC00221 might correlate with the associated
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prognosis in several cancers, including leukemia. We therefore speculate that the
deletion of LINC00221 may be playing a role CLL pathogenesis, specifically because it
existed as a sole abnormality in at least five cases, as confirmed by microarray studies,
and was also detected as a sole abnormality by FISH. However, additional research is
needed to elucidate the mechanism(s) that this lncRNA may play a role in
tumorigenesis.
A 3’ centromeric deletion of the IGH gene region was observed in only two cases
in this subset. A karyotype was studied in both of these cases, but a large deletion of
14q was only noted in one of them. By microarray, both 3’ centromeric deletions were
approximately 37,000 kb in size and spanned a nearly identical linear location. Both of
these cases are either distal to or involving a deletion of the ZFP36L1 gene, which has
previously been reported to be involved in large 14q deletions and may serve a tumorsuppressor role (Cosson et al., 2014; Pospisilova et al., 2007; Reindl et al., 2010). The
MDR for these two cases was approximately 37,000 kb in size and involved several
genes. One case had a loss of one copy of the IGH gene region resulting in both a 3’
centromeric and 5’ telomeric deletion of 14q32 that was detected by FISH studies.
Microarray studies clarified this deletion as not complete loss of the entire region
spanned by the FISH probes but as two distinct deletions. A complete karyotypic study
was not achieved in this case due to a low mitotic index; however, based on the deletion
pattern observed by microarray, the deletion would have been difficult to detect by
karyotype.
Deletions of 13q in Microarray Cohort with Confirmed 14q32 Deletions
Deletions of 13q are the most frequently observed cytogenetic abnormality
observed in CLL and are also readily detected by microarray and are a known Tier 1A
acquired variant with strong clinical significance (Mikhail et al., 2019). These deletions
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have been reported in the literature with heterogeneous size differences, suggesting a
prognostic impact. Deletion of 13q was reported by FISH in 16 cases in our cohort, with
confirmation of the deletion by microarray in 13 cases. Three of the cases with a deletion
of 13q detected by FISH were not identified by microarray due to low-level mosaicism,
with a deletion ranging from 11 – 14.5% as detected by FISH. The size of the 13q
deletion varied greatly by case, with most deletions in our study involving deletions of
DLEU1, and the DLEU2 gene locus that includes the miR-15a/mir-16-1 cluster, TRIM13,
and DLEU7, which have been noted by other studies (Grygalewicz et al., 2016; Kolquist
et al., 2011). Loss of the MIR-15A/MIR-16-1 cluster, which functions as a tumorsuppressor in CLL, causes the overexpression of the BCL2 protein that suppresses
apoptosis and contributes to the pathogenesis of CLL (Calva-Lopez & Tirado, 2018;
Pekarsky & Croce, 2015). In these 13 cases, the 13q14 deletion ranged from 928 kb to
66,010 kb, with some of these deletions also being visible by a conventional karyotype.
Deletions of 13q14 are known to confer a favorable prognosis in CLL, but these
deletions are heterogeneous in size. Interpretation of FISH results for a 13q14 deletion is
limited by the type of FISH probes utilized in each study. The FISH probes used in our
study does not include the ability to identify a loss of RB1, which has been associated
with inferior prognosis as opposed to 13q14 deletions that do not include the RB1 gene.
One study distinguished the difference between type I deletions that were exclusive of
RB1, and type II deletions that included RB1, and suggested that large type II deletions
were associated with shortened overall survival due to the inclusion of the RB1 gene in
the deleted region. These deletions that involve RB1 were also associated with shorter
time-to-first-treatment (TTFT) than smaller deletions of 13q that did not involve the loss
of RB1 (Mosca et al., 2010; Ouillette, Collins, Shakhan, Li, Li, et al., 2011; Parker et al.,
2011), while another study has concluded that the incidence of a larger deletion of 13q
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involving RB1 was not sufficient to be considered as a measurement of adverse
prognosis (Grygalewicz et al., 2016). In our cohort, seven cases with a 13q14 deletion
did not encompass RB1 (type I), and six cases had a 13q14 deletion that overlapped
RB1 (type II) that was identified by microarray. It is worth noting that there was no
consistent 14q32 deletion size associated with cases that only had a deletion of 13q14
and a 14q32 deletion as the only abnormalities detected by FISH studies. Two cases
had nullisomy of 13q14 that was detected by both FISH and microarray, and three cases
had populations of cells with a deletion of 13q14 and a nullisomy 13q14. Although the
loss of both copies of 13q14 would be expected to confer a more adverse prognosis,
several studies suggest that this is not the case (Grygalewicz et al., 2016; Puiggros,
Delgado, et al., 2013). However, two of the cases with nullisomy 13q14 also had CNLOH that was detectable only by microarray studies.
Genomic Complexity and Novel Abnormalities Detected by Microarray
CLL has a relatively stable genome at the time of diagnosis; however, increased
genomic instability has been previously reported in a small percentage of cases.
Genomic complexity resulting in three or more copy number alterations occurs in
approximately 20% CLL cases (Haferlach et al., 2007; Ouillette, Collins, Shakhan, Li,
Peres, et al., 2011). Complex karyotypes can be further clarified with genomic
microarray studies by deciphering unknown ring or marker chromosomes, or additional
material that cannot be distinguished as any particular chromosome by karyotype.
Microarray studies, and in particular SNP array studies, provide an overall view of the
genome, and a higher understanding of the genomic complexity and size of
chromosomal aberrations detected (Mian et al., 2013). In our study, microarray identified
three or more novel copy number changes or CN-LOH in seven cases [Table 17].
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Novel Chromosome Gains and Losses
Although karyotyping and FISH studies can identify cytogenetic abnormalities
associated with a poorer prognosis, not all cases with aggressive disease are identified
by these methods. Novel and cryptic abnormalities identified by microarray studies have
been reported in the literature, with one report noting these changes in 59% of cases
(Kolquist et al., 2011). Identification of novel copy number changes may help understand
the mechanism of disease in cases with poorer clinical outcomes. In this cohort of cases,
microarray studies revealed novel chromosome abnormalities that were undetectable by
a karyotype and were outside of the targeted probe regions for FISH. A total of 16 cases
in our cohort were further characterized by abnormalities not observed by karyotyping
and FISH studies. Numerous gains and losses were detected, as well as CN-LOH that
would have gone otherwise undetected by conventional cytogenetics and FISH.
Previous studies using copy number microarray have highlighted additional
abnormalities involving known cancer-related genes not included in the traditional CLL
panel, and regions with unknown clinical significance.
Novel chromosome loss was identified in 11 cases by microarray in our study.
Partial or complete loss of chromosome 1, 2, 3, 7, 9, 11, 13, 14, 15, 18, 19, and 22 were
detected. Although many of these losses were only observed in one case, the deletion of
the long arm of chromosome 22 and the short arm of chromosome 3 were observed in
multiple cases. Four cases had a deletion of 22q11.22, with an MDR that overlapped
only MIR650. Higher expression of this microRNA has been associated with a more
favorable CLL prognosis, so a deletion of this region that causes a reduction in
expression could have a potential impact (Mraz et al., 2012). Although these deletions of
22q were not solely associated with one specific type of 14q32 deletion, there was a
commonly deleted region involved in all four of these cases that overlapped LINC00226
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and LINC00221 on 14q32. Two cases involved a nearly identical 8,700 kb loss of the
short arm of chromosome 3. In a study by O’Malley and colleagues (2011), additional
abnormalities, including loss of 8p, 10q, and 18q, were observed that were undetected in
the traditional FISH panel. Their data showed that microarray was able to detect
chromosome abnormalities in 80% of cases compared to the 60% of cases detected by
FISH. However, they did notice discordant results in that some abnormalities were
detected only by FISH, and others only by microarray (O'Malley et al., 2011).
Novel chromosome gains were detected in seven cases in this study. Whole
chromosome gain of 7, 10, and 18 were detected, as well as partial gain of 1, 3, 5, 6, 7,
8, 9, 12, 17, and 19. Many of these instances of whole or partial chromosome gain
detected by microarray can be categorized as Tier 2 variants with some clinical
significance based on ACMG guidelines, as some of these gains have been reported in
CLL and other neoplasms and overlap known cancer genes (Mikhail et al., 2019). While
many of these instances of chromosomal gain were observed in a single case, there
were four cases with a substantial gain of 8q that all overlapped MYC at 8q24.21 and
numerous other genes. It is worth noting that all four of these cases were characterized
by complex FISH and microarray results, with >5 aberrations detected by FISH and/or
microarray. Gains of 8q have been reported in a small percentage of cases with CLL and
were noted to have shorter progression-free survival and time-to-first-treatment (TTFT)
(Brown et al., 2012; Edelmann et al., 2012; Gunn et al., 2008; Houldsworth et al., 2014;
Urbankova et al., 2014). It is worth noting that three of the four cases with a gain of 8q in
our study, including the MYC gene region, were also noted to have a deletion of 17p,
resulting in the loss of the TP53 gene, in addition to other chromosomal aberrations.
One study suggested that chromosome 8 abnormalities, including gains of 8q, are
associated with complex karyotypes and may aggravate patient outcomes in cases with
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a deletion of 17p. However, this study was in a small cohort of patients and would
benefit from further investigation (Blanco et al., 2016). Chapiro and colleagues also
identified gain of 8q24 in a subset of cases with CLL that strongly impacted overall
patient survival, and again noted that gains of 8q24 are higher in the population with
deletions of 17p (Chapiro et al., 2018), implying that gain of a region containing a known
oncogene, coupled with the loss of a region containing a tumor-suppressor gene
culminates into an aggressive course of the disease. Whole chromosome gains were
also observed in our study, and notably included a gain of 18 as a novel finding by
microarray in one case that did not have karyotypic analysis. Trisomy 18 and 19 have
been observed in cases with trisomy 12, and cases that have trisomy 19 represent a
distinct subgroup of these cases, with trisomy 18 suggesting clonal evolution (Chun et
al.; Ibbotson et al., 2012). There has also been a study that notes trisomy 18 to be more
prevalent in CLL patients of Asian descent as opposed to Caucasian patients and
suggests that gain of 18, and in particular a gain of 18q, may be a mechanism that
causes overexpression of BCL2 protein that inhibits apoptosis (Kawamata et al., 2013).
In our study, there was one case with a gain of the long arm of chromosome 3 that
overlapped many genes, including BCL6 and PIK3CA. Gains of 3q have also been noted
in cases with CLL and are associated with an unfavorable prognosis, and also have
been reported in cases of CLL in the Asian population (Chun et al., 2018; Houldsworth et
al., 2014; Kawamata et al., 2013).
Although the novel copy number changes detected in this subset were incidental,
microarray studies identified a subset of aberrations that have been previously noted to
affect overall survival and patient prognosis. Microarray also revealed areas of gains and
losses that have not been extensively studied, and the independent prognostic value of
many of these abnormalities has not been identified in CLL. If 5’ telomeric deletions do
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not impact disease progression, the additional changes observed in this select group of
cases with 5’ telomeric deletions suggests that that cases containing a sole 5’ telomeric
14q32 deletion will benefit from further scrutiny with microarray studies to detect
submicroscopic aberrations that were not interrogated by the panel of FISH probes.
Future testing to determine the impact of these abnormalities on the progression of CLL
and their association with 14q32 deletions is warranted to determine the significance of
these abnormalities.
Detection of CN-LOH
The use of SNP microarray in this study allowed for the ability to detect
consecutive probes without heterozygous calls, or loss of heterozygosity (LOH). Loss of
heterozygosity is not expected to occur by chance, as SNPs have a greater than 30%
rate of heterozygosity (Hagenkord et al., 2010). Acquired homozygosity through CNLOH can contribute to the inactivation of tumor suppressor genes and reveal mutated
tumor suppressor genes, as well as triggering oncogenes. Incidences of CN-LOH in CLL
have been reported to be rare, but clinically significant (Chun et al., 2018; Hagenkord et
al., 2010; Malek, 2013; Xu et al., 2013). The most common chromosomal regions with
CN-LOH reported in CLL include 11q, 13q, and 17p (Edelmann et al., 2012). Copyneutral loss of heterozygosity (CN-LOH) was an exclusive finding by microarray studies
in this cohort and would not be detectable by cytogenetics and FISH studies. In our
cohort, seven cases were further defined by CN-LOH involving part or all of a
chromosome arm. CN-LOH was observed on chromosomes 1p, 9q, 11q, 13q, and 14q
[Table 16]. All but one of the regions had CN-LOH that was over 68 MB in size and
included terminal portions of the chromosomes, which strongly suggests that these
areas of CN-LOH are acquired and not constitutional. There were three instances where
the CN-LOH was found in a mosaic state. Mosaic CN-LOH was found in two cases with
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nullisomy 13q14. The region of CN-LOH spanned nearly the entire arm of chromosome
13, with the biallelic deletion of 13q involving only a small part of the chromosome. CNLOH of chromosome 13 located proximal to the biallelic 13q14 deletions and extending
to the end of the chromosome have been reported in several other studies (Edelmann et
al., 2012; Pfeifer et al., 2007; Stevens-Kroef et al., 2014). Four cases were found to have
CN-LOH of the entirety of the long arm of chromosome 9, with one of these cases
showing CN-LOH in a mosaic state.
Advantages of Microarray Studies
Microarray studies can detect cryptic abnormalities that would otherwise remain
concealed by conventional cytogenetics and FISH. High-density microarray studies allow
for the detection of genomic aberrations across the entire genome, instead of being
limited to analysis of a limited number of regions like FISH. The significance of this
technique and its power to identify new abnormalities can provide new information about
genes associated with leukemias and lymphomas that have not been categorized. Once
these aberrations are clinically identified by microarray, further testing with specific FISH
probes typically not included in the traditional CLL FISH panel can be used as a followup study. Without microarray, a potentially significant subset of genomic alterations
would go undetected and could negatively impact treatment approaches. CLL is an ideal
disease to study with microarray because most genetic lesions observed in CLL are
chromosomal gains and losses, instead of translocations and inversions. In CLL,
chromosomal translocations are rare, and usually, the tumor burden is high in a
peripheral blood draw, resulting in adequate DNA specimens for microarray analysis.
Although microarray can identify characterized abnormalities associated with
CLL and detect novel abnormalities that would have gone otherwise unnoticed by
traditional cytogenetics and FISH, microarray should not be used as a replacement for
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conventional cytogenetics and FISH studies at this time. Instead, it should be used to
complement conventional cytogenetics and FISH studies. The addition of methodologies
like microarray studies provides a whole-genome view of patient-specific information that
can be used for prognostic purposes. Microarray studies can detect novel copy-number
changes, as well as CN-LOH that is not able to be identified by a karyotype or FISH
study. However, microarray cannot assess regions of the genome that are not
represented on the array. FISH studies and high-resolution microarray have a higher
abnormality detection rate than conventional cytogenetics; however, they may not be
able to rule out balanced translocations, inversions, or decipher complex karyotypes
without the help of conventional cytogenetics. Microarray studies have limited sensitivity
in detecting abnormalities in specimens with low-level mosaicism; however, it is still
possible to detect copy-number changes by SNP array in as little as 15% of cells, which
is consistent with sensitivity reported in the literature (Stevens-Kroef et al., 2014). Even
though microarray has a lower detection limit than FISH, it can further define
abnormalities that would be missed by the standard targeting areas of the FISH probes.
However, follow-up studies to detect changes in the percentage of cells containing the
abnormalities would be best studied by FISH, utilizing a specific probe set.
Impact of 14q32 Deletions on TTFT and OS
Numerous factors are assessed to estimate the prognostic outcome for patients
diagnosed with CLL, and more recently, prognostic scoring systems have been used to
estimate patient outcomes based on a variety of factors. One of the most commonly
used prognostic scoring systems is the CLL-IPI scoring system that evaluates five
factors, including age, clinical stage, IGHV mutation status, TP53 deletion and/or
mutation, and serum β2M concentration to evaluate patient risk (Group, 2016; Hallek,
2019). There has also been a prognostic hierarchy established for the cytogenetic
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abnormalities detected by FISH in CLL that categorized patients into five distinct risk
categories with patients having a deletion of 17p (TP53) as the least favorable, to
patients with an isolated deletion of 13q14 as the most favorable (Döhner et al., 2000).
These abnormalities, including deletions of 11q, 13q, 17p, and trisomy 12, have also
been characterized as Tier 1A variants with strong clinical significance in CLL as defined
by the ACMG guidelines for acquired copy-number testing (Mikhail et al., 2019).
However, the clinical outcomes in patients with deletions of 14q have rarely been
studied. To our knowledge, there have been no studies that have studied the impact of
5’ telomeric 14q32 deletions specifically. We sought to determine the clinical impact of
deletions of 14q32 by assessing overall survival (OS) and time-to-first-treatment (TTFT)
in a select group of patients with available clinical data.
A previous study by Reindl and colleagues (2010) assessed the impact that 14q
deletions have on clinical outcomes in patients with CLL. In the study, 47 patients were
assessed and found to have deletions of 14q with various breakpoints by FISH studies.
All 47 cases had a visible deletion of 14q that involved a large portion of the long arm of
chromosome 14 by karyotype, and 32 of these patients had available clinical follow-up
information for comparison to patients without a deletion of 14q32. This study compared
the 3-year overall survival for patients with and without a 14q deletion, and time-totreatment. Although there was no significant difference in OS in patients with and without
a 14q32 deletion, those patients with a 14q32 deletion had a noticeably shorter time-totreatment than patients without a 14q32 deletion (Reindl et al., 2010). It is unknown
whether the instances of trisomy 12, deletion of 11q, and deletion of 17p were observed
and compared as sole abnormalities in this study, which may impact their results. To our
knowledge, this is one of the few studies assessing the clinical significance of 14q
deletions. However, it seems as though all cases in this study had a visible deletion of
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14q by karyotype and suggest that more than just the 5’ telomeric portion of 14q32 is
involved in the deletion.
From our studies, we were able to determine that deletions of 14q32 that
involved the 3’ centromeric portion resulted in a visible 14q deletion by a karyotype in
69% (11/16) of these cases. In comparison, deletions of the 5’ telomeric portion were
rarely visible. We suspect that the deletions observed in this previous study would have
involved the loss of the 3’ centromeric portion of the Abbott Vysis LSI IGH dual-color
break-apart probe and were not representative of all types of 14q deletions, including 5’
telomeric deletions of 14q32. We would also expect that there were no instances of sole
5’ partial telomeric deletions observed in this study based on the breakpoints assessed
for these 47 cases. A study by Cosson and colleagues (2014) associated deletions of
14q32 with trisomy 12 and assessed treatment-free survival (TFS) in patients that had
trisomy 12 against patients that had trisomy 12 and a deletion of 14q32. They observed
that patients with a deletion of 14q32 and trisomy 12 had a significantly shorter median
TFS than patients with trisomy 12 only. In that study, all cases with a 14q32 deletion
were detected by conventional cytogenetics, which suggests that the majority of these
cases most likely had a 14q32 deletion at least involving the 3’ centromeric portion of
14q32 and possibly the 5’ telomeric portion as well. Few studies have assessed the
clinical outcomes of 14q deletions, and no studies have specifically assessed 5’
telomeric 14q32 deletions alone. Because of this, we sought to determine the potential
clinical impact of cases that had these deletions and how deletions of 14q32 compare to
instances where deletion of 13q14, trisomy 12, or deletion of 11q or 17p were the sole
abnormalities observed.
In our study, 115 cases of confirmed CLL/SLL had available clinical follow-up
information and were used to assess the prognostic significance of 14q32 deletions. All
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cases included FISH studies assessing the 14q32 gene region using the LSI IGH dualcolor break-apart probe. We performed two different assessments of TTFT and OS
based on the type of 14q32 deletions that were present and other sole FISH
abnormalities that were observed in each case [Table 18 and Table 19]. The category
of sole deletions of 13q included instances of a sole deletion of 13q14, sole nullisomy
13q14, or cases with both a deletion of 13q14 and nullisomy 13q14 observed in different
populations. It has been previously noted that there was no significant prognostic
difference between patients with a monoallelic deletion of 13q14 compared to patients
with biallelic 13q14 deletions (Garg et al., 2012; Puiggros, Delgado, et al., 2013; Van
Dyke et al., 2010), which is why they were combined in this study. Like the two
previously mentioned studies, we also aimed to assess TTFT for cases with and without
deletions of 14q32 and further separated deletions of 14q32 into cases with a 5’
telomeric 14q32 deletion only (group 1) and cases with all types of 14q32 deletions
(group 2). In group 1, 83% (5/6) of cases with a sole 5’ telomeric deletion of 14q32
progressed to needing treatment. The median TTFT for sole 5’ telomeric 14q32
deletions was shorter than those with a sole deletion or nullisomy of 13q14 [Figure 57A],
and longer than those with sole deletions of 11q or 17p [Figure 57D]. The median TTFT
for cases with one FISH abnormality and a 5’ telomeric 14q32 deletion had a similar
overall picture. However, it seems as though those cases with more than two FISH
abnormalities in addition to a 5’ telomeric 14q32 deletion had a shorter median TTFT
(1.13 years) than those cases with only one additional abnormality (3.7 years), or sole 5’
14q32 deletions (2.98 years). These results are to be expected as complex karyotypes,
which contain three or more FISH abnormalities, have been associated with a shorter
median TTFT than patients without complex karyotypes (Rigolin et al., 2017). Overall,
these results suggest that cases with a 5’ telomeric 14q32 deletion have an intermediate
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TTFT compared to those with a sole deletion or nullisomy 13q or a sole deletion of 11q
or 17p [Figure 58].
In group 2, we combined all types of 14q32 deletions to evaluate if the overall
median TTFT for these cases would change based on the introduction of a subset of
cases with large 14q32 deletions that have a known shorter TTFT. We combined all
cases with a sole 14q32 deletion (5’ telomeric, 3’ centromeric, or both) in this group to
see if the addition of cases with a larger 14q32 deletion had an impact in TTFT and OS.
The addition of cases with a 3’ centromeric 14q32 deletion or both a 3’ centromeric and
5’ telomeric deletion in group 2 increased the number of cases with a sole 14q32
deletion to 12, and 75% of these cases progressed to treatment. As in group 1, the
median TTFT for cases that had a sole deletion of 14q32 and a deletion of 14q32 with
one additional FISH abnormality were all nearly equivalent in this group, suggesting that
deletions of 14q32 have a shorter median TTFT than cases with a deletion or nullisomy
of 13q [Figure 59A], and longer median TTFT than cases with a deletion of 11q or 17p
[Figure 59D]. Interestingly, there were no additional cases added to the subset of
patients with a 14q32 deletion and multiple additional abnormalities. This means that
only cases that contained a 5’ telomeric 14q32 deletion had two or more FISH
abnormalities in addition to a deletion of 14q32 detected at the time of diagnosis and that
these were the only cases that had incidences of a deletion of 11q or 17p. This suggests
that cases with at least a 3’ centromeric 14q32 deletion may follow a different disease
progression and do not require additional cytogenetic abnormalities to advance the
disease. As previously mentioned, Reindl and colleagues concluded that patients with
large deletions of 14q32 (most likely involving the 3’ centromeric portion of our FISH
probe) have a significantly shorter TTFT as compared to patients without a 14q32
deletion (Reindl et al., 2010). Although not statistically significant, our clinical
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comparisons yielded similar results, showing that those cases with a 14q deletion had a
shorter median TTFT than cases without a 14q deletion [Figure 61].
Overall survival is affected by several factors, including minimal residual disease
(MRD), mutations involving TP53, deletions of 11q and/or 17p, and IGHV mutation
status. Patients with unmutated IGHV have been reported to have more aggressive
disease and are associated with a median overall survival (Montserrat et al., 2016;
Parikh & Shanafelt, 2016). However, information on the mutational status of IGHV and
TP53 was not available for our study. In group 1, only 33% (2/6) of cases that had a 5’
telomeric 14q32 deletion were still alive at last follow-up, as compared to 97% (28/29) of
cases that had a sole deletion or nullisomy of 13q14 FISH results, and 50% (2/4) of
cases that had a sole 11q or 17p deletion [Figure 62]. An assessment of a larger cohort
of cases is needed to confirm whether 5’ telomeric 14q32 deletions as a sole
abnormality have more impact on overall survival. In group 2, 74% of cases with a 14q32
deletion, including 5’ telomeric, 3’ centromeric, and the presence of both deletions, were
still alive at last follow-up. Although these results were not statistically significant, they
were similar in percentage to cases with a 5’ telomeric 14q32 deletion in group 1.
Interestingly, most cases with a 14q32 deletion and at least two additional abnormalities
were still alive at the time of the last follow-up. It is possible that these cases were
treated sooner because of numerous factors, including the presence of a complex
karyotype. Although it has previously been reported that the 3-year overall survival did
not differ between cases that did or did not have a 14q32 deletion (Reindl et al., 2010),
our studies suggest that this may not be the case. However, those cases with sole
deletions of 14q32 or a deletion of 14q32 with one additional FISH abnormality may
benefit from earlier treatment or different treatment types to improve their overall
survival.
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One factor that has been correlated with shorter TTFT in CLL is the percentage
of abnormal cells with a detected FISH abnormality including cases of sole 13q14
deletions, which are known to have the longest TTFT (Dal Bo et al., 2011; Puiggros,
Delgado, et al., 2013; Van Dyke et al., 2010). This effect has also been described in
cases with a de novo 17p deletion, with cases having ≥75% of cells with a 17p deletion
having the shortest time-to-treatment (Tam et al., 2009). Cases with a sole 5’ telomeric
14q32 deletion in our study ranged from 31 – 79.5% abnormal cells detected by FISH.
Interestingly, cases that did not survive had only 31 – 52.5% of cells with a 5’ telomeric
14q32 deletion detected by FISH. The two cases that were still alive at the time of the
last follow-up had a 5’ telomeric 14q32 deletion detected in 73 – 79.5% of cells, which
suggests that additional factors played a role in the clinical outcomes of these cases. It
has also been reported large-sized deletions of 13q (involving RB1; type 1 deletion) are
associated with shorter TTFT and OS (Dal Bo et al., 2011; Ouillette, Collins, Shakhan,
Li, Li, et al., 2011). Although these results from our study suggest that the type of 14q32
deletion observed does not have a large impact on median TTFT, we hypothesize that
differently sized deletions of 14q32 may impact time-to-treatment and survival when a
larger number of cases are studied. Our results suggest that cases carrying a sole
14q32 deletion, or a 14q32 deletion with one additional abnormality may have poorer
overall survival than those with a 14q32 deletion and multiple additional FISH
abnormalities; however, further studies will need to be performed to confirm these
results.
Limitations of this Study
There are limitations to all types of cytogenetic testing in hematological
malignancies. Traditional conventional cytogenetics and FISH methods used to
determine the prognostic significance of abnormalities in CLL have several limitations.
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Conventional cytogenetic analysis with a G-banded karyotype is limited to the amount of
actively dividing tumor cells in circulation. G-banded karyotypes are limited to the
amount of resolution able to be observed and are not able to appreciate cryptic
abnormalities, including small deletions, duplications, and cryptic rearrangements. FISH
studies are limited to detecting only abnormalities that would be interrogated with the
chosen panel of probes used. Both conventional cytogenetics and FISH studies are not
able to detect CN-LOH, which could fail to detect abnormalities with prognostic
significance.
There are several technical limitations to microarray studies, including the
inability to detect balanced translocations and inversions. In some instances, DNA
extraction of specimens selected for microarray did not occur at the time of culture
initiation for the cytogenetics and FISH studies. A delay in specimen processing could
attribute to lower-level detection rates of abnormalities by microarray. Microarray studies
were not able to identify abnormalities observed in the FISH panel in some cases with
low tumor-burden. Microarray is also limited by the percentage of mosaicism of the
abnormal cells, and it was unable to detect a chromosome aberration that occurred in
under 15% of cells in our study. This percentage is nearly identical to another study that
utilized the same platform. In this study, genomic aberrations that were detected by
FISH in over 16% of cells were also able to be detected by the CytoScan™ HD Array
SNP Array (Stevens-Kroef et al., 2014). The continued use of FISH technology is
necessary due to the inability of the array platform to detect abnormalities with low-level
mosaicism. The SNP array does not contain dense probe coverage in the 14q32 region,
and this made detection of the deletions using the ChAS software difficult. Thus,
approximately half of the breakpoints of the 14q32 deletions identified in this study had
to be examined manually.
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TTFT is a valuable disease-specific endpoint to assess because this metric is
determined from the day of diagnosis to the start of therapy. However, assessing TTFT
as an endpoint in our analysis has several limitations. First, there is some variability in
choosing an appropriate time for treatment that can vary between a physician and a
patient. Some physicians may choose to treat sooner, and some patients may choose to
forego treatment until necessary. Additionally, our study was limited because of missing
information in the dataset about important prognostic variables, including the IGHV
mutation status for each case, as well as clinical staging information. Some cases did
not have staging information available at the time of our study. It is possible that some
CLL cases included in our study may have been diagnosed earlier and did not require
immediate treatment, while some cases were diagnosed at a later stage of CLL and
were treated sooner, which would skew the results of the TTFT analysis. In addition, we
did not have clinical information for this study regarding several factors that affect OS,
including the mutation status of TP53 and IGHV that may have had an impact on our
results.
Summary
The purpose of this study was to determine the frequency and variation of IGH
deletions in CLL, delineate the size variations in IGH deletions using copy-number
microarray studies, analyze the frequency of additional abnormalities associated with
deletions of 14q32, decipher unknown abnormalities in CLL with the help of microarray
studies, and investigate the potential clinical impact of IGH deletions. This study
suggests that abnormalities involving the 14q32 region frequently occur in this
population and that these deletions have a broad range in size. This comprehensive
analysis of the chromosome 14q32 region underscored the need to perform a detailed
analysis of genetic abnormalities that are recurrently observed in hematologic
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malignancies. A few highlights of this comprehensive assessment of 14q32 in CLL are
as follows:
1) The use of both cytogenetics and FISH techniques to assess genetic
abnormalities increased the detection of abnormalities; however, the
detection of recurrent abnormalities associated with CLL was more facilitated
by FISH studies.
2) An abnormality of the IGH gene region at chromosome 14q32 was observed
in the second-largest group of cases overall in this study cohort. Many
different types of IGH abnormalities were detected, including IGH
rearrangements, gain or loss of one copy of 14q32, and deletions involving
the 3’ centromeric and 5’ complete and partial telomeric portions of 14q32.
Our results suggest that deletions of 14q32, and specifically 5’ telomeric
14q32 deletions occur most frequently among cases with an IGH abnormality.
3) FISH identified sole abnormalities of 14q32 in 53 cases, and microarray
studies confirmed the finding of sole 14q32 deletions in CLL. The majority of
these cases involved a 5’ telomeric 14q32 deletion. Sole abnormalities signify
that these are most likely primary pathogenic events, either awaiting a
necessary secondary change or offering a different pathogenic trajectory to
the disease.
4) Deletion of 13q14 was the most common additional abnormality observed in
cases with 5’ partial and complete telomeric 14q32 deletions. Trisomy 12 was
the most commonly observed additional abnormality in cases with a 3’
centromeric 14q32 deletion. The association of each deletion type with known
recurrent abnormalities observed in CLL suggests that 5’ telomeric and 3’
centromeric 14q32 deletions may follow different paths of progression.
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5) An identical 123 kb minimal deleted region (MDR) was found by microarray in
33 cases with a 5’ telomeric 14q32 deletion that did not include any genes.
However, all of these cases had an identifiable telomeric deletion that
overlapped one or both of the long intergenic non-protein coding RNAs,
LINC00226 and LINC00221, including the four cases with sole 5’ partial
telomeric 14q32 deletions. Further, microarray studies confirmed that 14q32
deletions existed as sole abnormalities and therefore, could be an important
initial event in CLL pathogenesis.
6) Although the 3’ centromeric deletions were observed in a smaller subset of
cases in this study, these deletions impacted a larger portion of chromosome
14. The MDR was 37,626 kb in size that was distal to the ZFP36L1 gene,
which has been suggested to function as a tumor-suppressor.
7) Deletions of 13q were observed by microarray in 13 cases with an identical
928 kb MDR that included DLEU1 and the DLEU2 gene locus that includes
the miR-15a/mir-16-1 cluster. Seven of these cases had only two
abnormalities, a 5’ partial telomeric 14q32 deletion and a deletion of 13q14.
The MDR for the 5’ telomeric deletions that also had a deletion of 13q was
368 kb and overlapped LINC00221. It has been reported in the literature that
the size of the 13q14 deletion may have a clinical impact. Without microarray
studies, the size variation of these deletions would not be deciphered.
8) Six cases studied by microarray had a sole 5’ telomeric 14q32 deletion by
FISH studies. Five of these cases did not have any novel gains, losses, or
CN-LOH detected by microarray studies emphasizing its importance as a
primary abnormality in CLL.
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9) Cases from this subset with any type of 14q32 deletion had an intermediate
median TTFT that was shorter than the median TTFT for a sole instance of a
deletion or nullisomy 13q, which is a known good prognostic indicator, and
longer than cases with a sole deletion of 11q or 17p, which have been
associated with a more unfavorable prognosis.
10) Cases with a sole deletion of 14q32 or a deletion of 14q32 with one additional
FISH abnormality had poorer overall survival than those with a 14q32
deletion and multiple additional FISH abnormalities, and poorer overall
survival than most cases in this cohort. A larger percentage of cases with a
sole deletion of 13q14 (including nullisomy 13q14) and cases with a sole
instance of trisomy 12 were still alive at the time of the last follow-up
compared to those with 14q32 deletions.
Conventional cytogenetics and FISH studies are crucial in determining the
prognosis of a patient with CLL. While multiple cytogenetic abnormalities have been
associated with prognostic significance, deletions of 14q remain in an uncharted
category. We determined that deletions of 14q32, including both 5’ partial and complete
telomeric deletions, and 3’ centromeric deletions, occur in a higher frequency of cases in
this cohort than have been previously reported in the literature. These deletions have
been observed as a sole FISH abnormality and in conjunction with known recurrent
FISH abnormalities in CLL. Microarray provides a novel platform for the detection of
genomic abnormalities. It can identify candidate gene(s) that may play a role in disease
causation or progression by defining specific breakpoints and pinpointing genes involved
in the aberration. Initial microarray studies in CLL cases can identify therapeutic targets
early in disease management so that treatments can be better directed to the specific
abnormalities in each patient. Therapy could potentially be altered based on additional
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analyses as the disease progresses; however, at this time, it is unknown whether
deletions of 14q32 are drivers or just indicators of the disease. Assessment of TTFT and
OS for CLL cases that have a deletion of 14q32, including 3’ centromeric and 5’
telomeric 14q32 deletions, suggests that these cases have an intermediate TTFT that is
shorter than cases with a sole deletion or nullisomy of 13q14. A larger study with more
cases will further confirm whether there is a true difference in the prognostic impact
among subtypes of 14q32 deletions (5’ telomeric and 3’ centromeric) and where these
deletions fall within the prognostic hierarchy of cytogenetic abnormalities for CLL.
The results from this study confirm the frequency of deletions of 14q32 that are
observed in cases with suspected or confirmed CLL and provide novel information
regarding the range in size of the deletions and genes included in the deleted region. A
more sensitive assay like SNP microarray may facilitate the detection of cryptic
abnormalities not observed by conventional cytogenetics and not targeted by the
traditional FISH panel. Specifically, the detection of CN-LOH that is exclusively identified
by microarray studies can help determine disease progression. Clinical correlation of
treatment and survival data from additional cases with 14q32 deletions will determine the
risks and implications associated with IGH deletions in CLL.
Future Directions
Deletions of 14q32 have been observed in other mature B-cell malignancies,
including multiple myeloma and marginal zone lymphoma; however, characterization of
the deletions in a large cohort of cases has not been reported. A detailed analysis of the
occurrence of 14q32 deletions, and more specifically, deletions of the 5’ telomeric region
of 14q32 in the diseases will determine the overall frequency of 14q32 deletions in these
diseases. Assessing clinical outcomes for both types of 14q32 deletions in cases of
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multiple myeloma and marginal zone lymphoma may suggest a different overall
prognosis than what is observed in cases of CLL with the same abnormalities.
CLL commonly occurs in Caucasian populations and is rare in Asian populations.
Although CLL has been well-characterized in Caucasian populations, there is limited
information regarding genetic abnormalities associated with CLL in Asian populations.
Genetic and environmental factors have been thought to contribute to the stark contrast
in the incidence of CLL between these two geographically-distinct populations. There
may be distinct genetic abnormalities, including deletions of 14q32 that are observed
more frequently in one population. By performing a comprehensive analysis of
conventional cytogenetics, FISH, and microarray studies, we may determine if deletions
of 14q occur more or less frequently than our current study population and if these
deletions vary in size.
Further microarray testing on a more significant subset of confirmed CLL cases
would help determine the exact incidence of novel copy-number changes and CN-LOH,
which may impact the prognosis and progression of CLL. Associating copy number
changes and CN-LOH with 14q32 deletions is warranted to determine the significance of
these abnormalities. The abnormality detection rate of microarray studies could
potentially be enhanced by performing cell-separation to achieve an enriched-specimen
containing a purified population of disease-associated cells that then could be used for
DNA extraction followed by microarray.
In the future, additional studies to assess the functional consequences and
individual impact of individual genes involved in the 5’ telomeric 14q32 deletions, and
specifically the impact of LINC00221, may be warranted. LncRNAs, like LINC00221,
have been reported to be critical regulators in various cancers. LINC00221 was the only
gene within the MDR for the majority of cases with a 5’ partial telomeric deletion in our
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study and has also been reported to be dysregulated in hematological malignancies. It is
unknown whether the loss of LINC00221 is necessary, but not sufficient by itself to drive
the pathogenesis of CLL. However, this abnormality could be a hidden primary
abnormality because studies have not investigated this gene in this depth before.
A larger study including more cases for the analysis of TTFT and OS will improve
the statistical power of our results and confirm whether those with a 14q32 deletion as a
sole abnormality have an intermediate outcome as compared to cases with an isolated
deletion of 13q14 or cases with trisomy 12 or normal FISH results. Additionally,
multivariate analysis of genetic abnormalities, and specifically 14q32 deletions, with
other prognostic factors like IGHV and TP53 mutation status may shed light on the true
impact of 14q32 deletion and prognosis. The literature suggests that cases with 3’
centromeric 14q32 deletions may be associated with unmutated IGHV genes. However,
it is unknown if cases with 5’ telomeric 14q32 deletions are associated with mutated or
unmutated IGHV genes. The impact of the IGHV mutation status in each case will be a
contributor in determining the overall patient prognosis. By increasing the power of the
statistical studies, and having complete clinical information for each case, we will be able
to determine if the type of partial 14q32 deletion (3’ centromeric or 5’ telomeric) can
affect TTFT and OS.

213

BIBLIOGRAPHY
Abo Elwafa, R., Abd Elrahman, A., & Ghallab, O. (2020). Long intergenic non-coding
RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia. Clin
Transl Oncol. doi:10.1007/s12094-020-02398-4
Abruzzo, L. V., Herling, C. D., Calin, G. A., Oakes, C., Barron, L. L., Banks, H. E., Katju,
V., Keating, M. J., & Coombes, K. R. (2018). Trisomy 12 chronic lymphocytic
leukemia expresses a unique set of activated and targetable pathways.
Haematologica, 103(12), 2069-2078. doi:10.3324/haematol.2018.190132
Amare, P. S., Gadage, V., Jain, H., Nikalje, S., Manju, S., Mittal, N., Gujral, S., & Nair, R.
(2013). Clinico-pathological impact of cytogenetic subgroups in B-cell chronic
lymphocytic leukemia: experience from India. Indian journal of cancer, 50(3),
261-267. doi:10.4103/0019-509X.118730 [doi]
Aoun, P., Blair, H. E., Smith, L. M., Dave, B. J., Lynch, J., Weisenburger, D. D., Pavletic,
S. Z., & Sanger, W. G. (2004). Fluorescence in situ hybridization detection of
cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small
lymphocytic lymphoma. Leukemia & lymphoma, 45(8), 1595-1603.
doi:10.1080/10428190410001680546 [doi]
Baliakas, P., Hadzidimitriou, A., Sutton, L. A., Rossi, D., Minga, E., Villamor, N.,
Larrayoz, M., Kminkova, J., Agathangelidis, A., Davis, Z., Tausch, E., Stalika, E.,
Kantorova, B., Mansouri, L., Scarfo, L., Cortese, D., Navrkalova, V., Rose-Zerilli,
M. J., Smedby, K. E., Juliusson, G., et al. (2015). Recurrent mutations refine
prognosis in chronic lymphocytic leukemia. Leukemia, 29(2), 329-336.
doi:10.1038/leu.2014.196
Baliakas, P., Iskas, M., Gardiner, A., Davis, Z., Plevova, K., Nguyen-Khac, F., Malcikova,
J., Anagnostopoulos, A., Glide, S., Mould, S., Stepanovska, K., Brejcha, M.,
Belessi, C., Davi, F., Pospisilova, S., Athanasiadou, A., Stamatopoulos, K., &
Oscier, D. (2014). Chromosomal translocations and karyotype complexity in
chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic
data. Am J Hematol, 89(3), 249-255. doi:10.1002/ajh.23618
Baliakas, P., Jeromin, S., Iskas, M., Puiggros, A., Plevova, K., Nguyen-Khac, F., Davis,
Z., Rigolin, G. M., Visentin, A., Xochelli, A., Delgado, J., Baran-Marszak, F.,
Stalika, E., Abrisqueta, P., Durechova, K., Papaioannou, G., Eclache, V., Dimou,
M., Iliakis, T., Collado, R., et al. (2019). Cytogenetic complexity in chronic
lymphocytic leukemia: definitions, associations, and clinical impact. Blood,
133(11), 1205-1216. doi:10.1182/blood-2018-09-873083
Berkova, A., Pavlistova, L., Babicka, L., Houskova, L., Tajtlova, J., Balazi, P., Cmunt, E.,
Schwarz, J., Karban, J., Trneny, M., Brezinova, J., Zemanova, Z., & Michalova,
K. (2008). Combined molecular biological and molecular cytogenetic analysis of
genomic changes in 146 patients with B-cell chronic lymphocytic leukemia.
Neoplasma, 55(5), 400-408.
Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier,
G., Potron, G., Colona, P., Oberling, F., Thomas, M., Tchernia, G., Jacquillat, C.,
Boivin, P., Lesty, C., Duault, M. T., Monconduit, M., Belabbes, S., & Gremy, F.
(1981). A new prognostic classification of chronic lymphocytic leukemia derived
from a multivariate survival analysis. Cancer, 48(1), 198-206. doi:10.1002/10970142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v
Blanco, G., Puiggros, A., Baliakas, P., Athanasiadou, A., Garcia-Malo, M., Collado, R.,
Xochelli, A., Rodriguez-Rivera, M., Ortega, M., Calasanz, M. J., Luno, E.,
Vargas, M., Grau, J., Martinez-Laperche, C., Valiente, A., Cervera, J.,

214

Anagnostopoulos, A., Gimeno, E., Abella, E., Stalika, E., et al. (2016). Karyotypic
complexity rather than chromosome 8 abnormalities aggravates the outcome of
chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget, 7(49),
80916-80924. doi:10.18632/oncotarget.13106
Bosch, F., & Dalla-Favera, R. (2019). Chronic lymphocytic leukaemia: from genetics to
treatment. Nat Rev Clin Oncol, 16(11), 684-701. doi:10.1038/s41571-019-0239-8
Brejcha, M., Stoklasova, M., Brychtova, Y., Panovska, A., Stepanovska, K., Vankova,
G., Plevova, K., Oltova, A., Horka, K., Pospisilova, S., Mayer, J., & Doubek, M.
(2014). Clonal evolution in chronic lymphocytic leukemia detected by
fluorescence in situ hybridization and conventional cytogenetics after stimulation
with CpG oligonucleotides and interleukin-2: a prospective analysis. Leukemia
research, 38(2), 170-175. doi:10.1016/j.leukres.2013.10.019 [doi]
Brown, J. R. (2013). Inherited susceptibility to chronic lymphocytic leukemia: evidence
and prospects for the future. Ther Adv Hematol, 4(4), 298-308.
doi:10.1177/2040620713495639
Brown, J. R., Hanna, M., Tesar, B., Werner, L., Pochet, N., Asara, J. M., Wang, Y. E.,
Dal Cin, P., Fernandes, S. M., Thompson, C., Macconaill, L., Wu, C. J., Van de
Peer, Y., Correll, M., Regev, A., Neuberg, D., & Freedman, A. S. (2012).
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at
8q24 in chronic lymphocytic leukemia. Clin Cancer Res, 18(14), 3791-3802.
doi:10.1158/1078-0432.Ccr-11-2342
Byrd, J. C., Jones, J. J., Woyach, J. A., Johnson, A. J., & Flynn, J. M. (2014). Entering
the era of targeted therapy for chronic lymphocytic leukemia: impact on the
practicing clinician. J Clin Oncol, 32(27), 3039-3047.
doi:10.1200/JCO.2014.55.8262
Caligaris-Cappio, F., & Hamblin, T. J. (1999). B-cell chronic lymphocytic leukemia: a bird
of a different feather. Journal Of Clinical Oncology: Official Journal Of The
American Society Of Clinical Oncology, 17(1), 399-408.
Call, T. G., Norman, A. D., Hanson, C. A., Achenbach, S. J., Kay, N. E., Zent, C. S.,
Ding, W., Cerhan, J. R., Rabe, K. G., Vachon, C. M., Hallberg, E. J., Shanafelt,
T. D., & Slager, S. L. (2014). Incidence of chronic lymphocytic leukemia and
high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. Cancer,
120(13), 2000-2005. doi:10.1002/cncr.28690
Calva-Lopez, A., & Tirado, C. A. (2018). The Role of miR-15a and miR-16-1 in the
Pathogenesis of Chronic Lymphocytic Leukemia, and the Importance of
microRNAs in Targeted Therapies. J Assoc Genet Technol, 44(3), 84-87.
Campo, E., Ghia, P., Harris, N. L., Montserrat, E., Müller-Hermelink, H. K., Stein, H., &
Swerdlow, S. H. (2017). Chronic lymphocytic leukaemia/small lymphocytic
lymphoma. In S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri, H.
Stein, & J. Thiele (Eds.), WHO Classification of Tumors of Haematopoietic and
Lymphoid Tissues (4th ed., pp. 216-221). Lyon, France: International Agency for
Research on Cancer (IARC).
Carter, R. H. (2006, 2006). B cells in health and disease. Paper presented at the Mayo
Clinic Proceedings.
Castro, J. E., & Kipps, T. J. (2016). Adoptive cellular therapy for chronic lymphocytic
leukemia and B cell malignancies. CARs and more. Best Pract Res Clin
Haematol, 29(1), 15-29. doi:10.1016/j.beha.2016.08.011
Cavallari, M., Cavazzini, F., Bardi, A., Volta, E., Melandri, A., Tammiso, E., Saccenti, E.,
Lista, E., Quaglia, F. M., Urso, A., Laudisi, M., Menotti, E., Formigaro, L.,
Dabusti, M., Ciccone, M., Tomasi, P., Negrini, M., Cuneo, A., & Rigolin, G. M.

215

(2018). Biological significance and prognostic/predictive impact of complex
karyotype in chronic lymphocytic leukemia. Oncotarget, 9(76), 34398-34412.
doi:10.18632/oncotarget.26146
Cavazzini, F., Ciccone, M., Negrini, M., Rigolin, G. M., & Cuneo, A. (2009).
Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic
leukemia. Expert Rev Hematol, 2(3), 305-314. doi:10.1586/ehm.09.22
Cavazzini, F., Hernandez, J. A., Gozzetti, A., Russo Rossi, A., De Angeli, C., Tiseo, R.,
Bardi, A., Tammiso, E., Crupi, R., Lenoci, M. P., Forconi, F., Lauria, F., Marasca,
R., Maffei, R., Torelli, G., Gonzalez, M., Martin-Jimenez, P., Maria Hernandez, J.,
Rigolin, G. M., & Cuneo, A. (2008). Chromosome 14q32 translocations involving
the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify
a disease subset with poor prognosis. Br J Haematol, 142(4), 529-537.
doi:10.1111/j.1365-2141.2008.07227.x
Cavazzini, F., Rizzotto, L., Sofritti, O., Daghia, G., Cibien, F., Martinelli, S., Ciccone, M.,
Saccenti, E., Dabusti, M., Elkareem, A. A., Bardi, A., Tammiso, E., Cuneo, A., &
Rigolin, G. M. (2012). Clonal evolution including 14q32/IGH translocations in
chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105
patients. Leuk Lymphoma, 53(1), 83-88. doi:10.3109/10428194.2011.606384
Chapiro, E., Lesty, C., Gabillaud, C., Durot, E., Bouzy, S., Armand, M., Le GarffTavernier, M., Bougacha, N., Struski, S., Bidet, A., Laharanne, E., Barin, C.,
Veronese, L., Prie, N., Eclache, V., Gaillard, B., Michaux, L., Lefebvre, C.,
Gaillard, J. B., Terre, C., et al. (2018). "Double-hit" chronic lymphocytic leukemia:
An aggressive subgroup with 17p deletion and 8q24 gain. Am J Hematol, 93(3),
375-382. doi:10.1002/ajh.24990
Chiorazzi, N., Hatzi, K., & Albesiano, E. (2005). B-cell chronic lymphocytic leukemia, a
clonal disease of B lymphocytes with receptors that vary in specificity for
(auto)antigens. Ann N Y Acad Sci, 1062, 1-12. doi:10.1196/annals.1358.002
Chiorazzi, N., Rai, K. R., & Ferrarini, M. (2005). Chronic lymphocytic leukemia. N Engl J
Med, 352(8), 804-815. doi:10.1056/NEJMra041720
Chiu, C. G., Nakamura, Y., Chong, K. K., Huang, S. K., Kawas, N. P., Triche, T.,
Elashoff, D., Kiyohara, E., Irie, R. F., Morton, D. L., & Hoon, D. S. (2014).
Genome-wide characterization of circulating tumor cells identifies novel
prognostic genomic alterations in systemic melanoma metastasis. Clin Chem,
60(6), 873-885. doi:10.1373/clinchem.2013.213611
Chun, K., Wenger, G. D., Chaubey, A., Dash, D. P., Kanagal-Shamanna, R., Kantarci,
S., Kolhe, R., Van Dyke, D. L., Wang, L., Wolff, D. J., & Miron, P. M. (2018).
Assessing copy number aberrations and copy-neutral loss-of-heterozygosity
across the genome as best practice: An evidence-based review from the Cancer
Genomics Consortium (CGC) working group for chronic lymphocytic leukemia.
Cancer Genet, 228-229, 236-250. doi:10.1016/j.cancergen.2018.07.004
Cosson, A., Chapiro, E., Belhouachi, N., Cung, H. A., Keren, B., Damm, F., Algrin, C.,
Lefebvre, C., Fert-Ferrer, S., Luquet, I., Gachard, N., Mugneret, F., Terre, C.,
Collonge-Rame, M. A., Michaux, L., Rafdord-Weiss, I., Talmant, P., Veronese, L.,
Nadal, N., Struski, S., et al. (2014). 14q deletions are associated with trisomy 12,
NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia
and small lymphocytic lymphoma. Genes Chromosomes Cancer, 53(8), 657-666.
doi:10.1002/gcc.22176
Court Brown, W. M., & Doll, R. (1959). Adult leukaemia; trends in mortality in relation to
aetiology. Br Med J, 1(5129), 1063-1069. doi:10.1136/bmj.1.5129.1063

216

Dahl, M., Kristensen, L. S., & Grønbæk, K. (2018). Long Non-Coding RNAs Guide the
Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy.
International journal of molecular sciences, 19(9), 2475.
doi:10.3390/ijms19092475
Dal Bo, M., Rossi, F. M., Rossi, D., Deambrogi, C., Bertoni, F., Del Giudice, I., Palumbo,
G., Nanni, M., Rinaldi, A., Kwee, I., Tissino, E., Corradini, G., Gozzetti, A.,
Cencini, E., Ladetto, M., Coletta, A. M., Luciano, F., Bulian, P., Pozzato, G.,
Laurenti, L., et al. (2011). 13q14 deletion size and number of deleted cells both
influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes
Cancer, 50(8), 633-643. doi:10.1002/gcc.20885
Dalsass, A., Mestichelli, F., Ruggieri, M., Gaspari, P., Pezzoni, V., Vagnoni, D., Angelini,
M., Angelini, S., Bigazzi, C., Falcioni, S., Troiani, E., Alesiani, F., Catarini, M.,
Attolico, I., Scortechini, I., Discepoli, G., & Galieni, P. (2013). 6q Deletion
Detected by Fluorescence in Situ Hybridization using Bacterial Artificial
Chromosome in Chronic Lymphocytic Leukemia. European journal of
haematology, 91(1), 10-19. doi:10.1111/ejh.12115 [doi]
Dave, B. J., Nelson, M., & Sanger, W. G. (2011). Lymphoma cytogenetics. Clin Lab
Med, 31(4), 725-761, x-xi. doi:10.1016/j.cll.2011.08.001
De Braekeleer, M., Tous, C., Gueganic, N., MJ, L. E. B., Basinko, A., Morel, F., & DouetGuilbert, N. (2016). Immunoglobulin gene translocations in chronic lymphocytic
leukemia: A report of 35 patients and review of the literature. Mol Clin Oncol,
4(5), 682-694. doi:10.3892/mco.2016.793
de Lima, D. S., Cardozo, L. E., Maracaja-Coutinho, V., Suhrbier, A., Mane, K., Jeffries,
D., Silveira, E. L. V., Amaral, P. P., Rappuoli, R., de Silva, T. I., & Nakaya, H. I.
(2019). Long noncoding RNAs are involved in multiple immunological pathways
in response to vaccination. Proc Natl Acad Sci U S A, 116(34), 17121-17126.
doi:10.1073/pnas.1822046116
Delgado, J., Espinet, B., Oliveira, A. C., Abrisqueta, P., de la Serna, J., Collado, R.,
Loscertales, J., Lopez, M., Hernandez-Rivas, J. A., Ferra, C., Ramirez, A.,
Roncero, J. M., Lopez, C., Aventin, A., Puiggros, A., Abella, E., Carbonell, F.,
Costa, D., Carrio, A., & Gonzalez, M. (2012). Chronic lymphocytic leukaemia with
17p deletion: a retrospective analysis of prognostic factors and therapy results.
Br J Haematol, 157(1), 67-74. doi:10.1111/j.1365-2141.2011.09000.x
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner,
K., Bentz, M., & Lichter, P. (2000). Genomic aberrations and survival in chronic
lymphocytic leukemia. New England Journal of Medicine, 343(26), 1910-1916.
Dun, K. A., Riley, L. A., Diano, G., Adams, L. B., Chiu, E., & Sharma, A. (2018). DSP30
and interleukin-2 as a mitotic stimulant in B-cell disorders including those with a
low disease burden. Genes Chromosomes Cancer, 57(5), 260-267.
doi:10.1002/gcc.22527
Edelmann, J., Holzmann, K., Miller, F., Winkler, D., Buhler, A., Zenz, T., Bullinger, L.,
Kuhn, M. W., Gerhardinger, A., Bloehdorn, J., Radtke, I., Su, X., Ma, J., Pounds,
S., Hallek, M., Lichter, P., Korbel, J., Busch, R., Mertens, D., Downing, J. R., et
al. (2012). High-resolution genomic profiling of chronic lymphocytic leukemia
reveals new recurrent genomic alterations. Blood, 120(24), 4783-4794.
doi:10.1182/blood-2012-04-423517
Ehrlich, P. (1891). Farbenanalytische Untersuchungen zur Histologie und Klinik des
Blutes (Vol. 1): A. Hirschwald.
Eichhorst, B., Dreyling, M., Robak, T., Montserrat, E., Hallek, M., & Group, E. G. W.
(2011). Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for

217

diagnosis, treatment and follow-up. Ann Oncol, 22 Suppl 6, vi50-54.
doi:10.1093/annonc/mdr377
Eichhorst, B., Fink, A. M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C., Lange, E.,
Koppler, H., Kiehl, M., Sokler, M., Schlag, R., Vehling-Kaiser, U., Kochling, G.,
Ploger, C., Gregor, M., Plesner, T., Trneny, M., Fischer, K., Dohner, H., Kneba,
M., et al. (2016). First-line chemoimmunotherapy with bendamustine and
rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with
advanced chronic lymphocytic leukaemia (CLL10): an international, open-label,
randomised, phase 3, non-inferiority trial. Lancet Oncol, 17(7), 928-942.
doi:10.1016/s1470-2045(16)30051-1
Eid, O. M., Eid, M. M., Kayed, H. F., Mahmoud, W. M., Mousafa, S. S., Ismail, M. M., &
Abdeen, D. M. (2014). Detection of cytogenetics abnormalities in chronic
lymphocytic leukemia using FISH technique and their prognostic impact. Gulf J
Oncolog, 1(15), 68-75.
Fang, H., Reichard, K. K., Rabe, K. G., Hanson, C. A., Call, T. G., Ding, W., Kenderian,
S. S., Muchtar, E., Schwager, S. M., Leis, J. F., Chanan-Khan, A. A., Slager, S.
L., Braggio, E., Smoley, S. A., Kay, N. E., Shanafelt, T. D., Van Dyke, D. L., &
Parikh, S. A. (2019). IGH translocations in chronic lymphocytic leukemia:
Clinicopathologic features and clinical outcomes. Am J Hematol, 94(3), 338-345.
doi:10.1002/ajh.25385
Finn, W. G., Kay, N. E., Kroft, S. H., Church, S., & Peterson, L. C. (1998). Secondary
abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a
sequential study of karyotypic instability in 51 patients. Am J Hematol, 59(3),
223-229. doi:10.1002/(sici)1096-8652(199811)59:3<223::aid-ajh7>3.0.co;2-y
Gahrton, G., Robert, K. H., Friberg, K., Zech, L., & Bird, A. G. (1980). Nonrandom
chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal
B-cell-mitogen stimulation. Blood, 56(4), 640-647.
Garg, R., Wierda, W., Ferrajoli, A., Abruzzo, L., Pierce, S., Lerner, S., Keating, M., &
O'Brien, S. (2012). The prognostic difference of monoallelic versus biallelic
deletion of 13q in chronic lymphocytic leukemia. Cancer, 118(14), 3531-3537.
doi:10.1002/cncr.26593
Gerrie, A. S., Bruyere, H., Chan, M. J., Dalal, C. B., Ramadan, K. M., Huang, S. J.,
Toze, C. L., & Gillan, T. L. (2012). Immunoglobulin heavy chain (IGH@)
translocations negatively impact treatment-free survival for chronic lymphocytic
leukemia patients who have an isolated deletion 13q abnormality. Cancer Genet,
205(10), 523-527. doi:10.1016/j.cancergen.2012.05.011
Gerrie, A. S., Huang, S. J., Bruyere, H., Dalal, C., Hrynchak, M., Karsan, A., Ramadan,
K. M., Smith, A. C., Tyson, C., Toze, C. L., & Gillan, T. L. (2014). Populationbased characterization of the genetic landscape of chronic lymphocytic leukemia
patients referred for cytogenetic testing in British Columbia, Canada: the role of
provincial laboratory standardization. Cancer Genet, 207(7-8), 316-325.
doi:10.1016/j.cancergen.2014.08.006
Greipp, P. T., Smoley, S. A., Viswanatha, D. S., Frederick, L. S., Rabe, K. G., Sharma,
R. G., Slager, S. L., Van Dyke, D. L., Shanafelt, T. D., Tschumper, R. C., & Zent,
C. S. (2013). Patients with chronic lymphocytic leukaemia and clonal deletion of
both 17p13.1 and 11q22.3 have a very poor prognosis. Br J Haematol, 163(3),
326-333. doi:10.1111/bjh.12534
Group, T. I. C.-I. W. (2016). An international prognostic index for patients with chronic
lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
Lancet Oncol, 17(6), 779-790. doi:10.1016/s1470-2045(16)30029-8

218

Grygalewicz, B., Woroniecka, R., Rygier, J., Borkowska, K., Rzepecka, I., Łukasik, M.,
Budziłowska, A., Rymkiewicz, G., Błachnio, K., Nowakowska, B., Bartnik, M.,
Gos, M., & Pieńkowska-Grela, B. (2016). Monoallelic and biallelic deletions of
13q14 in a group of CLL/SLL patients investigated by CGH Haematological
Cancer and SNP array (8x60K). Molecular cytogenetics, 9, 1-1.
doi:10.1186/s13039-015-0212-x
Gunn, S. R., Mohammed, M. S., Gorre, M. E., Cotter, P. D., Kim, J., Bahler, D. W.,
Preobrazhensky, S. N., Higgins, R. A., Bolla, A. R., Ismail, S. H., de Jong, D.,
Eldering, E., van Oers, M. H. J., Mellink, C. H. M., Keating, M. J., Schlette, E. J.,
Abruzzo, L. V., & Robetorye, R. S. (2008). Whole-genome scanning by array
comparative genomic hybridization as a clinical tool for risk assessment in
chronic lymphocytic leukemia. The Journal Of Molecular Diagnostics: JMD,
10(5), 442-451. doi:10.2353/jmoldx.2008.080033
Gunnarsson, R., Mansouri, L., & Rosenquist, R. (2013). Exploring the genetic landscape
in chronic lymphocytic leukemia using high-resolution technologies. Leuk
Lymphoma, 54(8), 1583-1590. doi:10.3109/10428194.2012.751530
Haferlach, C., & Bacher, U. (2011). Cytogenetic methods in chronic lymphocytic
leukemia. Methods Mol Biol, 730, 119-130. doi:10.1007/978-1-61779-074-4_9
Haferlach, C., Dicker, F., Schnittger, S., Kern, W., & Haferlach, T. (2007).
Comprehensive genetic characterization of CLL: a study on 506 cases analysed
with chromosome banding analysis, interphase FISH, IgV(H) status and
immunophenotyping. Leukemia, 21(12), 2442-2451. doi:10.1038/sj.leu.2404935
Haferlach, C., Dicker, F., Weiss, T., Schnittger, S., Beck, C., Grote-Metke, A., Oruzio, D.,
Kern, W., & Haferlach, T. (2010). Toward a comprehensive prognostic scoring
system in chronic lymphocytic leukemia based on a combination of genetic
parameters. Genes Chromosomes Cancer, 49(9), 851-859.
doi:10.1002/gcc.20794
Hagenkord, J. M., Monzon, F. A., Kash, S. F., Lilleberg, S., Xie, Q., & Kant, J. A. (2010).
Array-based karyotyping for prognostic assessment in chronic lymphocytic
leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0
arrays. J Mol Diagn, 12(2), 184-196. doi:10.2353/jmoldx.2010.090118
Hallek, M. (2013). Chronic lymphocytic leukemia: 2013 update on diagnosis, risk
stratification and treatment. American Journal of Hematology, 88(9), 803-816.
doi:10.1002/ajh.23491; 10.1002/ajh.23491
Hallek, M. (2015). Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk
stratification, and treatment. Am J Hematol, 90(5), 446-460.
doi:10.1002/ajh.23979
Hallek, M. (2017). Chronic lymphocytic leukemia: 2017 update on diagnosis, risk
stratification, and treatment. Am J Hematol, 92(9), 946-965.
doi:10.1002/ajh.24826
Hallek, M. (2019). Chronic lymphocytic leukemia: 2020 update on diagnosis, risk
stratification and treatment. Am J Hematol, 94(11), 1266-1287.
doi:10.1002/ajh.25595
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Dohner, H.,
Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., Stilgenbauer, S., Rai, K.
R., Byrd, J. C., Eichhorst, B., O'Brien, S., Robak, T., Seymour, J. F., & Kipps, T.
J. (2018). iwCLL guidelines for diagnosis, indications for treatment, response
assessment, and supportive management of CLL. Blood, 131(25), 2745-2760.
doi:10.1182/blood-2017-09-806398

219

Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H.,
Hillmen, P., Keating, M. J., Montserrat, E., & Rai, K. (2008). Guidelines for the
diagnosis and treatment of chronic lymphocytic leukemia: a report from the
International Workshop on Chronic Lymphocytic Leukemia updating the National
Cancer Institute–Working Group 1996 guidelines. Blood, 111(12), 5446-5456.
Hamblin, T. (2000). Historical aspects of chronic lymphocytic leukaemia. Br J Haematol,
111(4), 1023-1034. doi:10.1046/j.1365-2141.2000.02215.x
Heerema, N. A., Byrd, J. C., Dal Cin, P. S., Dell'Aquila, M. L., Koduru, P. R., Aviram, A.,
Smoley, S. A., Rassenti, L. Z., Greaves, A. W., Brown, J. R., Rai, K. R., Kipps, T.
J., Kay, N. E., Van Dyke, D. L., & Chronic Lymphocytic Leukemia Research, C.
(2010). Stimulation of chronic lymphocytic leukemia cells with CpG
oligodeoxynucleotide gives consistent karyotypic results among laboratories: a
CLL Research Consortium (CRC) Study. Cancer genetics and cytogenetics,
203(2), 134-140. doi:10.1016/j.cancergencyto.2010.07.128 [doi]
Houldsworth, J., Guttapalli, A., Thodima, V., Yan, X. J., Mendiratta, G., Zielonka, T.,
Nanjangud, G., Chen, W., Patil, S., Mato, A., Brown, J. R., Rai, K., Chiorazzi, N.,
& Chaganti, R. S. (2014). Genomic imbalance defines three prognostic groups
for risk stratification of patients with chronic lymphocytic leukemia. Leuk
Lymphoma, 55(4), 920-928. doi:10.3109/10428194.2013.845882
Hu, F., Zhou, Y., Wang, Q., Yang, Z., Shi, Y., & Chi, Q. (2019). Gene expression
classification of lung adenocarcinoma into molecular subtypes. IEEE/ACM Trans
Comput Biol Bioinform. doi:10.1109/tcbb.2019.2905553
Huang, M., Zheng, J., Ren, Y., Zhu, J., Kou, L., & Nie, J. (2020). LINC00221 suppresses
the malignancy of children acute lymphoblastic leukemia. Biosci Rep, 40(5).
doi:10.1042/bsr20194070
Ibbotson, R., Athanasiadou, A., Sutton, L. A., Davis, Z., Gardiner, A., Baliakas, P.,
Gunnarsson, R., Anagnostopoulos, A., Juliusson, G., Rosenquist, R., Oscier, D.,
& Stamatopoulos, K. (2012). Coexistence of trisomies of chromosomes 12 and
19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG-positive
variant. Leukemia, 26(1), 170-172. doi:10.1038/leu.2011.186
Improgo, M. R., & Brown, J. R. (2013). Genomic approaches to chronic lymphocytic
leukemia. Hematol Oncol Clin North Am, 27(2), 157-171.
doi:10.1016/j.hoc.2013.01.001
An International System for Human Cytogenomic Nomenclature (ISCN). (2016). (J.
McGowan-Jordan, A. Simons, & M. Schmid Eds.). Unionville, CT, USA: Karger.
Jing, Z., Gao, L., Wang, H., Chen, J., Nie, B., & Hong, Q. (2019). Long non-coding RNA
GAS5 regulates human B lymphocytic leukaemia tumourigenesis and metastasis
by sponging miR-222. Cancer Biomark, 26(3), 385-392. doi:10.3233/cbm-190246
Kalpadakis, C., Pangalis, G. A., Sachanas, S., Vassilakopoulos, T. P., Kyriakaki, S.,
Korkolopoulou, P., Koulieris, E., Moschogiannis, M., Yiakoumis, X., Tsirkinidis,
P., Kyrtsonis, M.-C., Levidou, G., Papadaki, H. A., Panayiotidis, P., &
Angelopoulou, M. K. (2014). New insights into monoclonal B-cell lymphocytosis.
BioMed research international, 2014, 258917-258917. doi:10.1155/2014/258917
Kawamata, N., Moreilhon, C., Saitoh, T., Karasawa, M., Bernstein, B. K., Sato-Otsubo,
A., Ogawa, S., Raynaud, S., & Koeffler, H. P. (2013). Genetic differences
between Asian and Caucasian chronic lymphocytic leukemia. Int J Oncol, 43(2),
561-565. doi:10.3892/ijo.2013.1966
Kern, W., Bacher, U., Haferlach, C., Dicker, F., Alpermann, T., Schnittger, S., &
Haferlach, T. (2012). Monoclonal B-cell lymphocytosis is closely related to

220

chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
Br J Haematol, 157(1), 86-96. doi:10.1111/j.1365-2141.2011.09010.x
Khan, M., Saif, A., Sandler, S., & Mirrakhimov, A. E. (2014). Idelalisib for the treatment
of chronic lymphocytic leukemia. ISRN Oncol, 2014, 931858.
doi:10.1155/2014/931858
Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G.,
O'Brien, S., Gribben, J., & Rai, K. (2017). Chronic lymphocytic leukaemia. Nat
Rev Dis Primers, 3, 16096. doi:10.1038/nrdp.2016.96
Kolquist, K. A., Schultz, R. A., Slovak, M. L., McDaniel, L. D., Brown, T. C., Tubbs, R. R.,
Cook, J. R., Theil, K. S., Cawich, V., & Valentin, C. (2011). Evaluation of chronic
lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers
novel aberrations not detected by FISH or cytogenetic analysis. Molecular
cytogenetics, 4(1), 1-14.
Landau, D. A., Tausch, E., Taylor-Weiner, A. N., Stewart, C., Reiter, J. G., Bahlo, J.,
Kluth, S., Bozic, I., Lawrence, M., Bottcher, S., Carter, S. L., Cibulskis, K.,
Mertens, D., Sougnez, C. L., Rosenberg, M., Hess, J. M., Edelmann, J., Kless,
S., Kneba, M., Ritgen, M., et al. (2015). Mutations driving CLL and their evolution
in progression and relapse. Nature, 526(7574), 525-530.
doi:10.1038/nature15395
Lu, G., Kong, Y., & Yue, C. (2010). Genetic and immunophenotypic profile of IGH@
rearrangement detected by fluorescence in situ hybridization in 149 cases of Bcell chronic lymphocytic leukemia. Cancer Genet Cytogenet, 196(1), 56-63.
doi:10.1016/j.cancergencyto.2009.08.021
Malek, S. N. (2013). The biology and clinical significance of acquired genomic copy
number aberrations and recurrent gene mutations in chronic lymphocytic
leukemia. Oncogene, 32(23), 2805-2817. doi:10.1038/onc.2012.411 [doi]
Mato, A. R., Thompson, M. C., Nabhan, C., Svoboda, J., & Schuster, S. J. (2017).
Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A
Narrative Review. Clin Lymphoma Myeloma Leuk, 17(12), 852-856.
doi:10.1016/j.clml.2017.07.007
Mayr, C., Speicher, M. R., Kofler, D. M., Buhmann, R., Strehl, J., Busch, R., Hallek, M.,
& Wendtner, C. M. (2006). Chromosomal translocations are associated with poor
prognosis in chronic lymphocytic leukemia. Blood, 107(2), 742-751.
doi:10.1182/blood-2005-05-2093
Mehes, G. (2005). Chromosome abnormalities with prognostic impact in B-cell chronic
lymphocytic leukemia. Pathology oncology research : POR, 11(4), 205-210.
doi:PAOR.2005.11.4.0205 [doi]
Mian, M., Rinaldi, A., Mensah, A. A., Rossi, D., Ladetto, M., Forconi, F., Marasca, R.,
Uhr, M., Stussi, G., Kwee, I., Cavalli, F., Gaidano, G., Zucca, E., & Bertoni, F.
(2013). Large genomic aberrations detected by SNP array are independent
prognosticators of a shorter time to first treatment in chronic lymphocytic
leukemia patients with normal FISH. Ann Oncol, 24(5), 1378-1384.
doi:10.1093/annonc/mds646
Mikhail, F. M., Biegel, J. A., Cooley, L. D., Dubuc, A. M., Hirsch, B., Horner, V. L.,
Newman, S., Shao, L., Wolff, D. J., & Raca, G. (2019). Technical laboratory
standards for interpretation and reporting of acquired copy-number abnormalities
and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus
recommendation from the American College of Medical Genetics and Genomics
(ACMG) and the Cancer Genomics Consortium (CGC). Genet Med, 21(9), 19031916. doi:10.1038/s41436-019-0545-7

221

Mikhail, F. M., Heerema, N. A., Rao, K. W., Burnside, R. D., Cherry, A. M., & Cooley, L.
D. (2016). Section E6.1-6.4 of the ACMG technical standards and guidelines:
chromosome studies of neoplastic blood and bone marrow-acquired
chromosomal abnormalities. Genet Med, 18(6), 635-642.
doi:10.1038/gim.2016.50
Minot, G. B., & Isaacs, R. (1924). Lymphatic leukemia; age incidence, duration, and
benefit derived from irradiation. The Boston Medical and Surgical Journal,
191(1), 1-9.
Montserrat, E., Bauman, T., & Delgado, J. (2016). Present and future of personalized
medicine in CLL. Best Pract Res Clin Haematol, 29(1), 100-110.
doi:10.1016/j.beha.2016.08.009
Mosca, L., Fabris, S., Lionetti, M., Todoerti, K., Agnelli, L., Morabito, F., Cutrona, G.,
Andronache, A., Matis, S., Ferrari, F., Gentile, M., Spriano, M., Callea, V.,
Festini, G., Molica, S., Deliliers, G. L., Bicciato, S., Ferrarini, M., & Neri, A.
(2010). Integrative genomics analyses reveal molecularly distinct subgroups of Bcell chronic lymphocytic leukemia patients with 13q14 deletion. Clin Cancer Res,
16(23), 5641-5653. doi:10.1158/1078-0432.Ccr-10-0151
Mraz, M., Dolezalova, D., Plevova, K., Stano Kozubik, K., Mayerova, V., Cerna, K.,
Musilova, K., Tichy, B., Pavlova, S., Borsky, M., Verner, J., Doubek, M.,
Brychtova, Y., Trbusek, M., Hampl, A., Mayer, J., & Pospisilova, S. (2012).
MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement
and affects the biology of chronic lymphocytic leukemia. Blood, 119(9), 21102113. doi:10.1182/blood-2011-11-394874
Muthusamy, N., Breidenbach, H., Andritsos, L., Flynn, J., Jones, J., Ramanunni, A., Mo,
X., Jarjoura, D., Byrd, J. C., & Heerema, N. A. (2011). Enhanced detection of
chromosomal abnormalities in chronic lymphocytic leukemia by conventional
cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen
and phorbol myristate acetate. Cancer Genet, 204(2), 77-83.
doi:10.1016/j.cancergen.2010.12.006
Naeim, F., Rao, P. N., & Grody, W. W. (2009). Mature B-Cell neoplasms.
Hematopathology: morphology, immunophenotype, cytogenetics and molecular
approaches, 297-372.
Nishida, Y., Takeuchi, K., Tsuda, K., Ugai, T., Sugihara, H., Yamakura, M., Takeuchi,
M., & Matsue, K. (2013). Acquisition of t(11;14) in a patient with chronic
lymphocytic leukemia carrying both t(14;19)(q32;q13.1) and +12. Eur J
Haematol, 91(2), 179-182. doi:10.1111/ejh.12119
O'Malley, D. P., Giudice, C., Chang, A. S., Chang, D., Barry, T. S., Hibbard, M. K., Chen,
R., & Chen, S. T. (2011). Comparison of array comparative genomic
hybridization (aCGH) to FISH and cytogenetics in prognostic evaluation of
chronic lymphocytic leukemia. International Journal Of Laboratory Hematology,
33(3), 238-244. doi:10.1111/j.1751-553X.2010.01284.x
Oscier, D., Dearden, C., Erem, E., Fegan, C., Follows, G., Hillmen, P., Illidge, T.,
Matutes, E., Milligan, D. W., & Pettitt, A. (2012). Guidelines on the diagnosis,
investigation and management of chronic lymphocytic leukaemia. British journal
of haematology, 159(5), 541-564.
Ouillette, P., Collins, R., Shakhan, S., Li, J., Li, C., Shedden, K., & Malek, S. N. (2011).
The prognostic significance of various 13q14 deletions in chronic lymphocytic
leukemia. Clin Cancer Res, 17(21), 6778-6790. doi:10.1158/1078-0432.Ccr-110785

222

Ouillette, P., Collins, R., Shakhan, S., Li, J., Peres, E., Kujawski, L., Talpaz, M.,
Kaminski, M., Li, C., Shedden, K., & Malek, S. N. (2011). Acquired genomic copy
number aberrations and survival in chronic lymphocytic leukemia. Blood,
118(11), 3051-3061. doi:10.1182/blood-2010-12-327858
Ouillette, P., & Malek, S. (2013). Acquired genomic copy number aberrations in CLL.
Adv Exp Med Biol, 792, 47-86. doi:10.1007/978-1-4614-8051-8_3
Parikh, S. A., & Shanafelt, T. D. (2016). Prognostic factors and risk stratification in
chronic lymphocytic leukemia. Semin Oncol, 43(2), 233-240.
doi:10.1053/j.seminoncol.2016.02.009
Parikh, S. A., Strati, P., Tsang, M., West, C. P., & Shanafelt, T. D. (2016). Should IGHV
status and FISH testing be performed in all CLL patients at diagnosis? A
systematic review and meta-analysis. Blood, 127(14), 1752-1760.
doi:10.1182/blood-2015-10-620864
Parker, H., Rose-Zerilli, M. J., Parker, A., Chaplin, T., Wade, R., Gardiner, A., Griffiths,
M., Collins, A., Young, B. D., Oscier, D. G., & Strefford, J. C. (2011). 13q deletion
anatomy and disease progression in patients with chronic lymphocytic leukemia.
Leukemia, 25(3), 489-497. doi:10.1038/leu.2010.288
Pei, J., Robu, V., Feder, M., Cheung, M., Neumann-Domer, E., Talarchek, J., Dulaimi,
E., Millenson, M. M., & Testa, J. R. (2014). Copy neutral loss of heterozygosity in
20q in chronic lymphocytic leukemia/small lymphocytic lymphoma. Cancer
genetics, 207(3), 98-102. doi:10.1016/j.cancergen.2014.02.005 [doi]
Pekarsky, Y., & Croce, C. M. (2015). Role of miR-15/16 in CLL. Cell Death Differ, 22(1),
6-11. doi:10.1038/cdd.2014.87
Pepper, C., Majid, A., Lin, T. T., Hewamana, S., Pratt, G., Walewska, R., Gesk, S.,
Siebert, R., Wagner, S., & Kennedy, B. (2012). Defining the prognosis of early
stage chronic lymphocytic leukaemia patients. British journal of haematology,
156(4), 499-507.
Pfeifer, D., Pantic, M., Skatulla, I., Rawluk, J., Kreutz, C., Martens, U. M., Fisch, P.,
Timmer, J., & Veelken, H. (2007). Genome-wide analysis of DNA copy number
changes and LOH in CLL using high-density SNP arrays. Blood, 109(3), 12021210. doi:10.1182/blood-2006-07-034256
Pospisilova, H., Baens, M., Michaux, L., Stul, M., Van Hummelen, P., Van Loo, P.,
Vermeesch, J., Jarosova, M., Zemanova, Z., Michalova, K., Van den Berghe, I.,
Alexander, H. D., Hagemeijer, A., Vandenberghe, P., Cools, J., De Wolf-Peeters,
C., Marynen, P., & Wlodarska, I. (2007). Interstitial del(14)(q) involving IGH: a
novel recurrent aberration in B-NHL. Leukemia, 21(9), 2079-2083.
doi:10.1038/sj.leu.2404739
Puiggros, A., Blanco, G., & Espinet, B. (2014). Genetic abnormalities in chronic
lymphocytic leukemia: where we are and where we go. BioMed research
international, 2014, 1-13. doi:10.1155/2014/435983 [doi]
Puiggros, A., Collado, R., Calasanz, M. J., Ortega, M., Ruiz-Xiville, N., Rivas-Delgado,
A., Luno, E., Gonzalez, T., Navarro, B., Garcia-Malo, M., Valiente, A.,
Hernandez, J. A., Ardanaz, M. T., Pinan, M. A., Blanco, M. L., HernandezSanchez, M., Batlle-Lopez, A., Salgado, R., Salido, M., Ferrer, A., et al. (2017).
Patients with chronic lymphocytic leukemia and complex karyotype show an
adverse outcome even in absence of TP53/ATM FISH deletions. Oncotarget,
8(33), 54297-54303. doi:10.18632/oncotarget.17350
Puiggros, A., Delgado, J., Rodriguez-Vicente, A., Collado, R., Aventin, A., Luno, E.,
Grau, J., Hernandez, J. A., Marugan, I., Ardanaz, M., Gonzalez, T., Valiente, A.,
Osma, M., Calasanz, M. J., Sanzo, C., Carrio, A., Ortega, M., Santacruz, R.,

223

Abrisqueta, P., Abella, E., et al. (2013). Biallelic losses of 13q do not confer a
poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with
isolated 13q deletion. Br J Haematol, 163(1), 47-54. doi:10.1111/bjh.12479
Puiggros, A., Puigdecanet, E., Salido, M., Ferrer, A., Abella, E., Gimeno, E., Nonell, L.,
Herranz, M. J., Galvan, A. B., Rodriguez-Rivera, M., Melero, C., Pairet, S.,
Bellosillo, B., Serrano, S., Florensa, L., Sole, F., & Espinet, B. (2013). Genomic
arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to
substitute conventional cytogenetics and fluorescence in situ hybridization
techniques? Leuk Lymphoma, 54(5), 986-995.
doi:10.3109/10428194.2012.731598
Quintero-Rivera, F., Nooraie, F., & Rao, P. N. (2009). Frequency of 5'IGH deletions in Bcell chronic lymphocytic leukemia. Cancer genetics and cytogenetics, 190(1), 3339. doi:10.1016/j.cancergencyto.2008.12.004
Rai, K. R., & Jain, P. (2016). Chronic lymphocytic leukemia (CLL)-Then and now. Am J
Hematol, 91(3), 330-340. doi:10.1002/ajh.24282
Rai, K. R., & Keating, M. J. (2003). Historical Perspective. In D. W. Kufe, R. E. Pollock,
R. R. Weichselbaum, R. C. Bast Jr, T. S. Gansler, J. F. Holland, & E. Frei Iii
(Eds.), Holland-Frei Cancer Medicine (6th Edition ed.). Hamilton ON: BC Decker.
Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N., & Pasternack, B.
S. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46(2), 219234.
Ransohoff, J. D., Wei, Y., & Khavari, P. A. (2018). The functions and unique features of
long intergenic non-coding RNA. Nature reviews. Molecular cell biology, 19(3),
143-157. doi:10.1038/nrm.2017.104
Reindl, L., Bacher, U., Dicker, F., Alpermann, T., Kern, W., Schnittger, S., Haferlach, T.,
& Haferlach, C. (2010). Biological and clinical characterization of recurrent 14q
deletions in CLL and other mature B-cell neoplasms. British journal of
haematology, 151(1), 25-36. doi:10.1111/j.1365-2141.2010.08299.x
Rigolin, G. M., Cavallari, M., Quaglia, F. M., Formigaro, L., Lista, E., Urso, A.,
Guardalben, E., Liberatore, C., Faraci, D., Saccenti, E., Bassi, C., Lupini, L.,
Bardi, M. A., Volta, E., Tammiso, E., Melandri, A., Negrini, M., Cavazzini, F., &
Cuneo, A. (2017). In CLL, comorbidities and the complex karyotype are
associated with an inferior outcome independently of CLL-IPI. Blood, 129(26),
3495-3498. doi:10.1182/blood-2017-03-772285
Schliemann, I., Oschlies, I., Nagel, I., Maria Murga Penas, E., Siebert, R., & Sander, B.
(2016). The t(11;14)(q13;q32)/CCND1-IGH translocation is a recurrent secondary
genetic aberration in relapsed chronic lymphocytic leukemia. Leuk Lymphoma,
57(11), 2672-2676. doi:10.3109/10428194.2016.1153085
Schnaiter, A., Mertens, D., & Stilgenbauer, S. (2011). Genetics of Chronic Lymphocytic
Leukemia. Clinics in laboratory medicine, 31(4), 649-658.
doi:10.1016/j.cll.2011.07.006
Seifert, M., Sellmann, L., Bloehdorn, J., Wein, F., Stilgenbauer, S., Durig, J., & Kuppers,
R. (2012). Cellular origin and pathophysiology of chronic lymphocytic leukemia.
The Journal of experimental medicine, 209(12), 2183-2198.
doi:10.1084/jem.20120833 [doi]
Shahjahani, M., Mohammadiasl, J., Noroozi, F., Seghatoleslami, M., Shahrabi, S., Saba,
F., & Saki, N. (2015). Molecular basis of chronic lymphocytic leukemia diagnosis
and prognosis. Cell Oncol (Dordr), 38(2), 93-109. doi:10.1007/s13402-014-02153

224

Shanafelt, T. D., Geyer, S. M., & Kay, N. E. (2004). Prognosis at diagnosis: integrating
molecular biologic insights into clinical practice for patients with CLL. Blood,
103(4), 1202-1210. doi:10.1182/blood-2003-07-2281
Shanshal, M., & Haddad, R. Y. (2012). Chronic lymphocytic leukemia. Dis Mon, 58(4),
153-167. doi:10.1016/j.disamonth.2012.01.009
Shi, M., Cipollini, M. J., Crowley-Bish, P. A., Higgins, A. W., Yu, H., & Miron, P. M.
(2013). Improved detection rate of cytogenetic abnormalities in chronic
lymphocytic leukemia and other mature B-cell neoplasms with use of CpGoligonucleotide DSP30 and interleukin 2 stimulation. American Journal of Clinical
Pathology, 139(5), 662-669. doi:10.1309/AJCP7G4VMYZJQVFI [doi]
Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA Cancer J Clin,
69(1), 7-34. doi:10.3322/caac.21551
Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA Cancer J Clin,
70(1), 7-30. doi:10.3322/caac.21590
Slager, S. L., Caporaso, N. E., de Sanjose, S., & Goldin, L. R. (2013). Genetic
susceptibility to chronic lymphocytic leukemia. Semin Hematol, 50(4), 296-302.
doi:10.1053/j.seminhematol.2013.09.007
Speedy, H. E., Kinnersley, B., Chubb, D., Broderick, P., Law, P. J., Litchfield, K., Jayne,
S., Dyer, M. J. S., Dearden, C., Follows, G. A., Catovsky, D., & Houlston, R. S.
(2016). Germ line mutations in shelterin complex genes are associated with
familial chronic lymphocytic leukemia. Blood, 128(19), 2319-2326.
doi:10.1182/blood-2016-01-695692
Stevens-Kroef, M. J., van den Berg, E., Olde Weghuis, D., Geurts van Kessel, A.,
Pfundt, R., Linssen-Wiersma, M., Benjamins, M., Dijkhuizen, T., Groenen, P. J.,
& Simons, A. (2014). Identification of prognostic relevant chromosomal
abnormalities in chronic lymphocytic leukemia using microarray-based genomic
profiling. Mol Cytogenet, 7(1), 3. doi:10.1186/1755-8166-7-3
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Hillmen, P., Seymour, J. F., Coutre, S.,
Jurczak, W., Mulligan, S. P., Schuh, A., Assouline, S., Wendtner, C. M., Roberts,
A. W., Davids, M. S., Bloehdorn, J., Munir, T., Bottcher, S., Zhou, L., Salem, A.
H., Desai, M., Chyla, B., et al. (2018). Venetoclax for Patients With Chronic
Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a
Phase II Pivotal Trial. J Clin Oncol, 36(19), 1973-1980.
doi:10.1200/jco.2017.76.6840
Stockero, K. J., Fink, S. R., Smoley, S. A., Paternoster, S. F., Shanafelt, T. D., Call, T.
G., Zent, C. S., Van Dyke, D. L., Kay, N. E., & Dewald, G. W. (2006). Metaphase
cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable
by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.
Cancer Genet Cytogenet, 166(2), 152-156.
doi:10.1016/j.cancergencyto.2005.10.011
Swerdlow, S. H., Campo, E., Seto, M., & Müller-Hermelink, H. K. (2017). Mantle cell
lymphoma. In S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri, H.
Stein, & J. Thiele (Eds.), WHO Classification of Tumors of Haematopoietic and
Lymphoid Tissues (4th ed., pp. 285-290). Lyon, France: International Agency for
Research on Cancer (IARC).
Tam, C. S., Shanafelt, T. D., Wierda, W. G., Abruzzo, L. V., Van Dyke, D. L., O'Brien, S.,
Ferrajoli, A., Lerner, S. A., Lynn, A., Kay, N. E., & Keating, M. J. (2009). De novo
deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical
heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood, 114(5),
957-964. doi:10.1182/blood-2009-03-210591

225

Tang, H., Han, X., Li, M., Li, T., & Hao, Y. (2019). Linc00221 modulates cisplatin
resistance in non-small-cell lung cancer via sponging miR-519a. Biochimie, 162,
134-143. doi:10.1016/j.biochi.2019.04.019
Ten Hacken, E., Gounari, M., Ghia, P., & Burger, J. A. (2019). The importance of B cell
receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia,
33(2), 287-298. doi:10.1038/s41375-018-0303-x
Tsai, M. C., Spitale, R. C., & Chang, H. Y. (2011). Long intergenic noncoding RNAs: new
links in cancer progression. Cancer Res, 71(1), 3-7. doi:10.1158/0008-5472.Can10-2483
Turk, W. (1903). Ein system der lymphomatosen. Wien Klin Wochenschr, 16(1073), 1.
Urbankova, H., Baens, M., Michaux, L., Tousseyn, T., Rack, K., Katrincsakova, B.,
Ferreiro, J. F., van Loo, P., de Kelver, W., Dierickx, D., Demuynck, H., Delannoy,
A., Verschuere, J., Jarosova, M., de Wolf-Peeters, C., Vandenberghe, P., &
Wlodarska, I. (2012). Recurrent breakpoints in 14q32.13/TCL1A region in mature
B-cell neoplasms with villous lymphocytes. Leuk Lymphoma, 53(12), 2449-2455.
doi:10.3109/10428194.2012.690098
Urbankova, H., Papajik, T., Plachy, R., Holzerova, M., Balcarkova, J., Divoka, M.,
Prochazka, V., Pikalova, Z., Indrak, K., & Jarosova, M. (2014). Array-based
karyotyping in chronic lymphocytic leukemia (CLL) detects new unbalanced
abnormalities that escape conventional cytogenetics and CLL FISH panel.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 158(1), 56-64.
doi:10.5507/bp.2012.031
Van Dyke, D. L., Shanafelt, T. D., Call, T. G., Zent, C. S., Smoley, S. A., Rabe, K. G.,
Schwager, S. M., Sonbert, J. C., Slager, S. L., & Kay, N. E. (2010). A
comprehensive evaluation of the prognostic significance of 13q deletions in
patients with B-chronic lymphocytic leukaemia. Br J Haematol, 148(4), 544-550.
doi:10.1111/j.1365-2141.2009.07982.x
van Goor, H., Melenhorst, W. B., Turner, A. J., & Holgate, S. T. (2009). Adamalysins in
biology and disease. J Pathol, 219(3), 277-286. doi:10.1002/path.2594
Wang, D. M., Miao, K. R., Fan, L., Qiu, H. R., Fang, C., Zhu, D. X., Qiu, H. X., Xu, W., &
Li, J. Y. (2011). Intermediate prognosis of 6q deletion in chronic lymphocytic
leukemia. Leuk Lymphoma, 52(2), 230-237. doi:10.3109/10428194.2010.542599
Wang, H., Niu, L., Jiang, S., Zhai, J., Wang, P., Kong, F., & Jin, X. (2016).
Comprehensive analysis of aberrantly expressed profiles of lncRNAs and
miRNAs with associated ceRNA network in muscle-invasive bladder cancer.
Oncotarget, 7(52), 86174-86185. doi:10.18632/oncotarget.13363
Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D.,
Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S.,
Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps,
T. J., Lim, M. S., Ma, S., et al. (2020). Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in
Oncology. J Natl Compr Canc Netw, 18(2), 185-217.
doi:10.6004/jnccn.2020.0006
Wiktor, A., Rybicki, B. A., Piao, Z. S., Shurafa, M., Barthel, B., Maeda, K., & Van Dyke,
D. L. (2000). Clinical significance of Y chromosome loss in hematologic disease.
Genes Chromosomes Cancer, 27(1), 11-16.
Wlodarska, I., Matthews, C., Veyt, E., Pospisilova, H., Catherwood, M. A., Poulsen, T.
S., Vanhentenrijk, V., Ibbotson, R., Vandenberghe, P., Morris, T. C., &
Alexander, H. D. (2007). Telomeric IGH losses detectable by fluorescence in situ

226

hybridization in chronic lymphocytic leukemia reflect somatic VH recombination
events. J Mol Diagn, 9(1), 47-54. doi:10.2353/jmoldx.2007.060088
Wu, D., Zhou, P., Cao, F., Lin, Z., Liang, D., & Zhou, X. (2020). Expression Profiling and
Cell Type Classification Analysis in Periodontitis Reveal Dysregulation of Multiple
lncRNAs in Plasma Cells. Front Genet, 11, 382. doi:10.3389/fgene.2020.00382
Xu, X., Johnson, E. B., Leverton, L., Arthur, A., Watson, Q., Chang, F. L., Raca, G., &
Laffin, J. J. (2013). The advantage of using SNP array in clinical testing for
hematological malignancies--a comparative study of three genetic testing
methods. Cancer Genet, 206(9-10), 317-326.
doi:10.1016/j.cancergen.2013.09.001
Yang, G., Lu, X., & Yuan, L. (2014). LncRNA: a link between RNA and cancer. Biochim
Biophys Acta, 1839(11), 1097-1109. doi:10.1016/j.bbagrm.2014.08.012
Yang, S. M., Li, J. Y., Gale, R. P., & Huang, X. J. (2015). The mystery of chronic
lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us
about etiology, pathogenesis and biology? Blood Rev, 29(3), 205-213.
doi:10.1016/j.blre.2014.12.001
Yi, S., Li, H., Li, Z., Xiong, W., Liu, H., Liu, W., Lv, R., Yu, Z., Zou, D., Xu, Y., An, G., &
Qiu, L. (2017). The prognostic significance of 13q deletions of different sizes in
patients with B-cell chronic lymphoproliferative disorders: a retrospective study.
Int J Hematol, 106(3), 418-425. doi:10.1007/s12185-017-2240-2
Yu, X., Lin, Y., Sui, W., Zou, Y., & Lv, Z. (2017). Analysis of distinct long noncoding RNA
transcriptional fingerprints in pancreatic ductal adenocarcinoma. Cancer Med,
6(3), 673-680. doi:10.1002/cam4.1027
Zhang, S., & Kipps, T. J. (2014). The pathogenesis of chronic lymphocytic leukemia.
Annual review of pathology, 9, 103-118. doi:10.1146/annurev-pathol-020712163955 [doi]

